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ABSTRACT
The role of nitric oxide (NO) in brain physiology and pathology is governed by 
its concentration, a function of the balance between synthesis and breakdown. 
Following cerebral ischaemia NO may play a protective or destructive role, 
and the literature is plagued by contradictory findings. Contributing to the 
confusion is a lack of knowledge as to what constitutes a toxic concentration 
of NO, how NO is inactivated in vivo, and a large number of potential pitfalls.
Measured using an NO-sensitive electrode, most of the NO delivered 
using a NONOate donor was removed by reaction with tissue culture medium. 
The main constituent responsible was Hepes buffer, which consumed NO in a 
superoxide dismutase-sensitive manner, indicating formation of peroxynitrite 
from superoxide and NO. Given the widespread use of Hepes, the reaction 
may contribute artifactually to multiple effects of NO observed in vitro.
The hypothesis that NO mediates neurodegeneration arising from 
NMDA receptor activity was then re-examined using organotypic slice cultures 
of rat hippocampus. The NO-cGMP signaling pathway was well preserved in 
such cultures but no component of NMDA-induced cell death was attributable 
to NO. At the same time, the tissue was remarkably resistant to exogenous 
NO at up to 1000-fold higher concentrations. Together, these results seriously 
question the proposed role of NO in NMDA receptor-mediated excitotoxicity.
An avid NO consumption mechanism in rat cerebellar cells and brain 
homogenate had been previously described. A combination of transition 
metals and ascorbate was shown to be responsible for a component of this 
consumption. When this mechanism of consumption was inhibited dispersed 
rat brain preparations continued to consume NO by another powerful, as yet 
undetermined, mechanism.
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CHAPTER 1: INTRODUCTION
1.1 THE DISCOVERY OF NO
Nitric oxide (nitrogen monoxide radical; NO) had a colourful beginning when, 
as a contaminant of the laughing gas nitrous oxide, it proved almost fatal 
when inhaled by Sir Humphrey Davy, whose pioneering work concerned the 
administration of medicinal airs (Smith, 1967). Since these early days, and 
from its reputation as an environmental pollutant in smog and cigarette 
smoke, this unique signalling molecule has come far, being named “molecule 
of the year” by the journal Science in 1992 (Culotta & Koshland, Jr., 1992), 
and earning the Nobel Prize for Physiology or Medicine for a trio of American 
researchers in 1998. NO is freely diffusible, a property unique for a signalling 
molecule. The neurotransmitter glutamate, for example, is typically stored in, 
and released from vesicles into the synapse, from where specific uptake 
mechanisms are in place to control its concentration. In contrast NO is 
synthesised when needed, and to date there are no clear-cut routes 
established for its degradation. Furthermore, NO is very unstable in biological 
systems, which, in addition to its reputation as a toxic molecule, contributed 
to the difficulties inherent in its identification and isolation. It took evidence 
from several lines of biological enquiry for researchers to begin to understand 
the incredibly diverse role NO plays in both physiological signalling and 
cytotoxicity.
The vasodilating properties of nitroglycerin had been used for many 
decades in the treatment of hypertension before it was realised that its 
actions were mediated through the liberation of NO. Release of NO from this, 
and other nitrovasodilators (including sodium nitroprusside and sodium 
azide), stimulates the enzyme guanylate cyclase (GC) to produce cyclic 
guanosine 3’-5’ monophosphate (cGMP) from 5’ guanosine triphosphate 
(GTP) (Arnold etal., 1977; Katsuki etal., 1977). Several years later, an 
investigation into the cGMP-dependent vasodilating actions of acetylcholine 
(ACh) in vitro, observed that unintentional rubbing of the intimal surface of 
rabbit thoracic aorta removed the endothelial cells, thereby rendering the 
vessels unresponsive (Furchgott & Zawadzki, 1980). In response to ACh
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then, a diffusible endothelium-derived relaxing factor (EDRF) was produced 
that could permeate the smooth muscle leading to relaxation. Notably the 
nitrovasodilators could elicit muscle relaxation in the absence of endothelial 
cells. The identity of EDRF proved difficult to pin down, until, following 
suggestions during a meeting in 1986 by Robert Furchgott, and then Louis 
Ignarro, that EDRF was NO, it was demonstrated that vascular endothelial 
cells could synthesize NO in quantities sufficient to relax smooth muscle 
(Palmer etal., 1987).
Meanwhile, experiments in the CNS examined the response of 
cerebellar tissue to stimulation with the excitatory neurotransmitter glutamate, 
or the GC activator sodium nitroprusside. Using selective lesioning of the 
tissue, this work concluded that the subsequent cGMP increases did not 
occur in the same cells stimulated by glutamate, but in other cell types. It was 
suggested that an unstable factor might be diffusing intercellularly 
(Garthwaite & Garthwaite, 1987). Subsequently this factor was shown to 
behave identically to EDRF. It caused aortic smooth muscle relaxation and 
like EDRF its release was Ca2+-dependent. Moreover responses could be 
increased in the presence of superoxide dismutase (SOD), an enzyme 
known to prolong the life of EDRF (Garthwaite etal., 1988). Subsequently, as 
had already been shown in macrophages (see below), and endothelial cells 
(Palmer et al., 1988), the precursor required for this novel activity was 
reported to be L-arginine. The diffusible factor was, of course, NO 
(Garthwaite etal., 1989).
Whilst the novel field of NO signalling was bom, a third area of 
research had connected NO to cellular toxicity. Measurement of urinary 
nitrate (NO3") had revealed that more N03- was excreted than was consumed 
in the diet by both rats and humans (Green et al., 1981a; Green et al.,
1981b). Synthesis of NO3' could be increased remarkably following injection 
of rats with the inflammatory stimulator lipopolysaccharide (LPS) (Wagner et 
al., 1983). Further investigation found that the major source of NO3' (and 
NO2') in LPS treated mice was from macrophages (Stuehr & Marietta, 1985). 
The cytotoxic properties of the activated macrophages were found to be 
dependent upon L-arginine (Hibbs, Jr. et al., 1987), and finally the effector 
molecule reported to be NO (Hibbs, Jr. etal., 1988).
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1.2 NITRIC OXIDE PRODUCTION
Nitric oxide synthase, catalytic mechanism
In the space of a year, three diverse cell types (endothelial cells, cerebellar 
granule cells and macrophages) had been recognised to synthesise NO from 
L-arginine, so the subsequent identification and molecular characterisation of 
three distinct genes for differing NO synthase (NOS) isoforms was perhaps 
not surprising. Termed endothelial NOS (eNOS), neuronal NOS (nNOS) and 
inducible NOS (iNOS), the active enzymes exist as a homodimer composed 
of subunits of between 130-160 kDa. eNOS and nNOS are constitutively 
expressed and calcium-dependent, while iNOS expression is induced by a 
number of cytokines and is calcium-independent. The enzymes contain 
relatively tightly bound cofactors (6R)-5,6,7,8-tetrahydrobiopterin (BH4), flavin 
adenine dinucleotide (FAD), flavin mononucleotide (FMN), haem and 
calmodulin (CaM). The overall reaction is depicted below (figure 1.1) and, 
though not yet fully understood, it involves donation of electrons by NADPH 
to the reductase domain, which proceed via FAD and FMN to the oxygenase 
domain.
Arginine
o2
Citrulline 
NO
Figure 1.1 Overall reaction catalysed by NOS (from Alderton etal., 2001)
There they interact with the haem iron and BH4 at the active site to catalyse 
the reaction of oxygen with L-arginine, forming NG-Hydroxy-L-arginine as an 
intermediate, and finally generating citrulline and NO as products (Alderton et 
al., 2001). In elucidating the mechanism by which NOS generates NO, 
comparisons have been made with cytochrome P450 reductase, which
Oxygenase
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donates electrons to the cytochrome P450 enzyme family involved in fatty 
acid oxidation in the endoplasmic reticulum. This reductase shares close 
homology to the reductase domain of NOS (Bredt et al., 1991).
The possible existence of a further NOS isoform has been discussed 
in the literature since immunocytochemical techniques localized eNOS 
staining to (non-synaptosomal) rat brain and liver mitochondria (Bates etal.,
1995). Afunctional enzyme (mitochondrial NOS; mtNOS) was then reported 
in intact liver mitochondria, where activity was associated with the inner 
membrane (Ghafourifar & Richter, 1997). Recent studies indicate that 
mtNOS is a splice variant of nNOS (Elfering etal., 2002; Giulivi, 2003), 
though its identity, and relevance, continues to be debated (Lacza et al., 
2003).
The regulation of NOS by CaM was first noted when nNOS was 
purified from the cerebellum (Bredt & Snyder, 1990). The Ca2+ sensitivity of 
both nNOS and eNOS (EC50 ~250-350 nM) is now understood to require the 
presence of a 45 amino acid long ‘autoinhibitory loop’ inserted into the middle 
of the FMN binding domain. At resting Ca2+ levels in the cell (< 100 nM) CaM 
does not bind to NOS. However when Ca2+ levels rise Ca2+/CaM binds and 
the loop is displaced from its docking site elsewhere on the protein, causing a 
conformational change, and relieving the inhibitory effect (probably impeded 
electron transfer) (Lane & Gross, 2000). The lack of such a sequence in 
iNOS renders it Ca2+-independent. However iNOS binds CaM tightly, so is 
active irrespective of changes in Ca2+ concentration. The consequence of 
such regulation is that nNOS can respond to Ca2+ transients with a ‘pufP of 
NO, while iNOS derived NO may reach higher concentrations since the 
enzyme is persistently activated for longer durations. The role of BH4 in NOS 
activity is complicated in contrast to that of CaM. Many different mechanisms 
of action have been suggested including a role in dimerisation, or redox 
activity during catalysis (see Alderton et al, 2001).
nNOS Localization
On a regional scale the brain contains vastly differing NOS activities, with the 
highest being found in the cerebellum (Salter et al., 1995). NADPH 
diaphorase staining has proved a useful tool for NOS localization, though it
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does not discriminate between isoforms. After paraformaldehyde fixation, and 
in the presence of NADPH, NOS reduces the dye nitroblue tetrazolium into a 
dark blue formazan product. The staining co-localizes remarkably well with 
nNOS immunohistochemistry and, in combination, these techniques have 
localized nNOS to discrete, but widespread, neuronal populations, though 
they do not match any neurotransmitter exactly (Dawson et al., 1991a; 
Southam & Garthwaite, 1993). Staining is densest in the cerebellar molecular 
layer and granule cell layers. High immunoreactivity is also found in the 
olfactory bulb, inferior and superior colliculi and dentate gyrus of the 
hippocampus. eNOS is also found in the CNS, where it is located exclusively 
in endothelial cells (Topel etal., 1998).
nNOS is localized to synaptic membranes via a PDZ domain on its N- 
terminal, which interacts with the postsynaptic density proteins PSD-95 and 
PSD-93 (Brenman etal., 1996). This discovery is significant because NR2 
subunits of the NMDA-type glutamate receptor also interact with PSD-95 
(Kornau et al., 1995). A ternary complex is thus formed with NMDA 
receptors, PSD-95 and nNOS (Christopherson etal., 1999). In this way 
nNOS is conveniently placed close to Ca2+ influx during glutamate 
stimulation, thus enhancing the potential of NO to act in a spatially discrete 
manner. Additional regulation may occur through interaction of the PDZ 
domain of nNOS with the recently identified protein CAPON. Overexpression 
of CAPON results in the loss of PSD-95/nNOS complexes in transfected cells 
(Jaffrey et al., 1998). CAPON has recently also been reported to form a 
complex with nNOS and synapsin, which is enriched in presynaptic terminals 
(Jaffrey et al., 2002). Several studies have confirmed the synaptic co­
localization of nNOS and PSD-95 using detailed immunohistochemical 
methods (Aoki etal., 1998; Burette etal., 2002; Martinelli etal., 2002).
Splice variants of the full-length nNOS gene (nNOSa) have been 
detected. nNOSp and nNOSy are found in the brains of nNOSa knockout 
mice where they are responsible for residual activity, probably explaining why 
the knockouts do not have serious pathology. nNOSp has a similar activity to 
nNOSa in vitro, though nNOSy is considerably less active (Brenman etal., 
1996). In agreement with a more prominent role for nNOSp, this variant
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undergoes 2-3 fold upregulation in the cortex and striatum of knockouts while 
nNOSy mRNA is not detected (Eliasson et al., 1997a). Notably nNOSp lacks 
the PDZ domain of nNOSa and does not bind PSD-95. Though despite being 
separated from NMDA receptors it remains catalytically active.
1.3 NO INACTIVATION
The principle means by which NO is broken down in aqueous solution is 
through reaction with O2 (autoxidation, see chapter 3.1). Autoxidation of NO 
is slow, however, and cannot account for NO breakdown in biological 
systems. Surprisingly little is known about NO inactivation in the brain, 
though several potential NO inactivation mechanisms have been proposed, 
these are discussed in chapter 6 .1.
1.4 NO SIGNAL TRANSDUCTION 
Guanylyl cyclase coupled receptors
It is widely recognised that NO exerts most of its physiological effects by 
activation of guanylyl cyclase (GC)-coupled receptors (NOgcR), which 
catalyse the generation of cGMP from GTP (Denninger & Marietta, 1999; 
Hobbs, 1997). The active enzyme usually exists as an obligate heterodimer 
composed of one of two a  and one of two p  subunits, though a fifth subunit, 
variant p i  (v/52), has recently been identified which may be active as a 
homodimer (Gibb et al., 2003; Koglin et al., 2001). Of the four subunit 
combinations possible; a1 p i , oQp\, al p i  and oQ.pi, only two have been 
shown to exist at the protein level. a \p \ is widely expressed and was first 
isolated from bovine lung, and oQp\ was originally identified in the human 
placenta. Notably these isoforms have by far the greater catalytic activity 
upon transfection into COS-7 cells (Gibb etal., 2003). NOgcRs are typically 
around 150 kDa in mass, require Mg2+or Mn2+ for activation, and bind NO by 
virtue of a prosthetic haem in the N-terminal region. The haem moiety is 
associated with the /? subunit of NOgcR via an axial ligand provided by a 
histidine residue, His105 (Wedel etal., 1994). The catalytic domain is at the
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C-terminal region, with a dimerization domain, thought to mediate the subunit 
association, sandwiched in-between (Figure 1.2).
HOOC
Haem Binding 
Domain
*=His105
Dimerization
Domain
Catalytic
Domain
COOH
GTP cGMP
Figure 1.2 Schematic representation of a N O Gc R  (*P  
heterodimer (after Hobbs, 1997)
The mechanism of NOgcR activation is unclear, and indeed the number of 
NO binding sites has been a matter of some debate (Bellamy et al., 2002b; 
Zhao etal., 1999). It is thought that upon NO binding the His105 bond 
breaks, triggering a conformational change and exposing the catalytic site 
(Sharma & Magde, 1999). Recent methodological advances have allowed 
the generation of steady-state NO concentrations in vitro, a requisite for 
ascertaining the potency of NO at its receptor targets. Using such methods it 
was found that NO activates NOgcRs with EC50 values of <2 nM in intact 
cells (Gibb etal., 2003; Griffiths et al., 2003), a value substantially lower than 
earlier estimates of 250-300 nM (Russwurm etal., 1998; Stone & Marietta,
1996).
An important characteristic underlying the actions of NO as a 
neurotransmitter is the ability of native NOgcRs (compared to purified 
enzyme) to desensitize within seconds upon sustained activation (Bellamy et 
al., 2000; Bellamy & Garthwaite, 2001b; Wykes etal., 2002). This
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mechanism (in combination with phosphodiesterase activity, see below) may 
underlie the diversity of cellular cGMP responses. Although the mechanism 
of desensitization is as yet unknown, it appears to be regulated by cGMP 
(Wykes etal., 2002).
Previously localization studies have concentrated upon the expression 
of either the a1 or the p\ subunit, and it was not until recently that expression 
of all four subunits was compared in the rat brain by in situ hybridisation 
(Gibb & Garthwaite, 2001). Broadly speaking the results of this study found 
that in some areas, e.g. caudate-putamen and nucleus accumbens, NOgcRs 
exist mainly as the a\ p\ heterodimer. In other areas such as the 
hippocampus and olfactory bulb cQ.p\ is dominant. Interesting recent 
developments have now altered the long held perception of GC as a soluble 
enzyme. The oQ.p\ isoform was demonstrated, by co-precipitation from brain 
homogenates, to interact with PSD-95. Similarly to NOS this interaction 
occurs at a PDZ domain, thus forming a signalling microdomain composed of 
Ca2+ permeable NMDA receptors, Ca2+-dependent nNOS and oQ.p\ NOgcR 
(Russwurm et al., 2001). Other work has confirmed this membrane 
localization in various cell types and further found that it may be Ca2+- 
sensitive (Zabel etal., 2002).
Regulating cGMP
Cyclic nucleotide phosphodiesterase (PDE) enzymes catalyse the hydrolysis 
of cyclic nucleotides (cAMP or cGMP) to 5’ monophosphates (5’AMP or 
5’GMP). Their major function is often thought to be simple termination of the 
cyclic nucleotide second messenger signal, though since NOgcR activity 
does not vary between the two major heterodimers (see above) it may be left 
to PDEs to modulate both the amplitude and duration of the signal. A large 
variety of PDE gene families (totalling 11) have now been classified 
according to their primary sequence and regulation (see table 1.1 Beavo, 
1995; Fawcett etal., 2000; Soderling & Beavo, 2000). Nearly all the PDEs 
are homodimers with monomer molecular weights of 50-135 kDa. Most 
families have been shown to have more than one gene product and splice 
variants have been found in many cases. All PDEs contain a core of -270
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amino acids that are highly conserved and form the C-terminal catalytic 
domain. The N-terminal region contains the regulatory segment such as a 
CaM binding (PDE1) or cGMP binding domain (PDE2, 5, 6, 10 and 11).
Family Preference Tissue distribution Comments
1 cGMP + cAMP Widespread Ca2l7CaM-activated
2 cAMP + cGMP Adrenal cortex, brain, platelets, heart cGMP-activated
3 CAMP Smooth muscle, platelets, heart, liver, 
lymphocytes
cGMP-inhibited
4 CAMP Widespread 'cAMP-specific'
5 CGMP Smooth muscle, platelets, brain, kidney cGMP-binding, ‘cGMP-specific’
6 CGMP Retina, pineal gland Retinal rod photoreceptor PDE
7 CAMP Lymphocytes (PDE7A), widespread (7B) 'cAMP-specific'
8 CAMP Testis, eye, liver, kidney, skeletal muscle PAS domain (protein and 
ligand interactions)
9 CGMP Widespread High affinity cGMP hydrolysis
10 cAMP + cGMP Heart, brain, placenta, kidney cGMP-binding
11 cAMP + cGMP Widespread cAMP-inhibited?
cGMP-binding?
Table 1.1 Properties of the phosphodiesterase fami 
1995; Fawcett et al., 2000; Soderling & Beavo, 2000).
ies. From (Beavo,
The localization of PDEs families in the brain has been well characterised 
(Cherry & Davis, 1999; Kotera et al., 2000; Repaske etal., 1993; van 
Staveren et al., 2001), although much of this work relies on in situ 
hybridisation, which does not provide evidence of protein function. An 
example is PDE1B1, whose mRNA is high in the striatum (Polli & Kincaid,
1994) whereas, in contradiction, activity in this area was found to be mainly 
related to PDE2 (Wykes et al., 2002). The distinct expression profiles (and 
activities) of different families, highlighted recently by a study on PDEs 2, 5 
and 9 (van Staveren etal., 2003), is likely to have a strong bearing on the 
resultant cGMP profiles in the respective cells. In the cerebellum, for 
example, cGMP accumulates to a steady plateau over two minutes under the 
influence of PDE5 and, surprisingly, some PDE4 activity (Bellamy & 
Garthwaite, 2001a). In contrast striatal cells (containing PDE2) exhibit a more 
transient cGMP profile within the same time scale (Wykes etal., 2002).
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Downstream of cGMP
There are three main classes of effector proteins mediated by cGMP: PDEs, 
cGMP-dependent protein kinases (cGKs) and cyclic nucleotide gated (CNG) 
ion channels.
As seen in table 1.1, PDEs 2 and 3 are both regulated by cGMP, 
which either activates or inhibits the enzyme. Taking PDE3 first, cGMP 
binding inhibits the degradation of cAMP (thus raising cAMP levels) simply 
due to the less efficient hydrolysis of cGMP at the catalytic site (Degerman et 
al., 1997). In contrast PDE2 (and indeed PDEs 5 and 6 ,10 and 11) contains 
two modulatory binding sites for cGMP known as GAF domains A and B 
(Martinez et al., 2002). When cGMP binds the GAFB domain of PDE2 the 
enzymes rate and affinity of the catalytic site for both cAMP and cGMP is 
increased by allosteric interactions. Similarly, cGMP binding to the GAFA 
domain on PDE5 increases cGMP hydrolysis at the catalytic site (Rybalkin et 
al., 2003). Subsequent phosphorylation of the enzyme by cGMP-dependent 
protein kinase I (cGKI) further enhances its activity (Mullershausen et al., 
2003). In summary then, cGMP can influence not only its own hydrolysis but 
also that of cAMP, providing potential for PDE-dependent ‘crosstalk’ between 
the two second messenger molecules.
Two genes for cGKs have been identified in mammals, cGKI (which 
has a and p splice variants) and cGKII. The translated proteins are 
homodimers with the 76 kDa cGKI located primarily in the cytosol and the 86  
kDa cGKII membrane bound, by virtue of a myristoylation site on its N- 
terminal. cGKs also contain N-terminal dimerization domains, 
autophosphorylation sites, an autoinhibitory region (cGKI), two cGMP binding 
sites (high and low affinity) and a C-terminal catalytic domain with ATP and 
peptide binding regions (Lohmann etal., 1997; Lucas etal., 2000). In the 
CNS cGKI appears to be located almost exclusively in the Purkinje cells of 
the cerebellum while cGKII is more widespread (de Vente et al., 2001; El 
Husseini et al., 1999). Despite the fact that over 40 distinct CNS proteins may 
be phosphorylated by cGKs (Wang & Robinson, 1995) relatively few have 
been thoroughly characterised. Best understood is G-substrate, which (like 
cGKI) is mainly localized in Purkinje cells (Detre etal., 1984). Upon
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phosphorylation, G-substrate (and a similar protein DARPP-32) inhibits 
protein phosphotase-1 activity (Hall etal., 1999). cGMP signalling via this 
pathway has been proposed to mediate cerebellar long-term depression 
(LTD) (Feil etal., 2003), and hippocampal long-term potentiation (Kleppisch 
etal., 2003).
Cyclic nucleotide gated (CNG) channels were first discovered in the 
visual and olfactory systems. Upon binding of intracellular cAMP or cGMP a 
conformational change in the C-terminal region is coupled to the opening of 
the channel pore which is preferentially permeable to Ca2+ ions (Flynn et al.,
2001). The nomenclature for these channels has been somewhat confusing, 
but recently a consensus has been reached. There are 6 members of the 
gene family grouped into two subtypes, A and B. The channels form as 
tetramers of A and B subunits (each containing six transmembrane domains) 
surrounding the central pore. The prototypical rod channel consists of 
CNGA1 and CNGB1, while the cone channel consists of CNGA3 and 
CNGB3, finally the olfactory channel is made up from CNGA2, CNGA4 and a 
splice variant, CNGBIb (Kaupp & Seifert, 2002; Matulef & Zagotta, 2003). 
CNG channels are known to be expressed in a range of non-sensory tissues 
and have been identified in the brain mainly by mRNA detection. Both 
CNGA1 and CNGA2 have been described in the CNS where they are 
localised to discrete neuronal types (El Husseini etal., 1995; Kingston etal., 
1996; Kingston etal., 1999; Strijbos etal., 1999). Functional channels have 
been described in the hippocampus where activation and Ca2+ influx may be 
involved in synaptic plasticity (Bradley etal., 1997).
1.5 THE PHYSIOLOGICAL ROLE OF NO
In vitro NO is well known to reversibly inhibit the terminal enzyme of the 
mitochondrial respiratory chain, cytochrome c oxidase, in competition with 
oxygen (Brown & Cooper, 1994; Koivisto etal., 1997). O2 binding occurs at 
the haem a3 of the binuclear haem a3/CuB centre when the enzyme is 
reduced (a32+ and Cu+). NO can bind to either metal, but when the complex is 
under high electron flux (more reduced) NO binds the ferrous haem (a32+), 
and at low electron flux (when the binuclear centre is oxidised), NO binds to
21
the Cu2+ and is rapidly converted to NO2', see (Cooper, 2002). Respiratory 
inhibition by NO in this manner has been suggested to regulate mitochondrial 
respiration by increasing the Km of cytochrome c oxidase for oxygen (Brown,
1995), a consequence of which might be to increase O2 supply to 
surrounding tissues (Thomas etal., 2001). Several lines of evidence have 
found that endogenously produced NO can decrease O2 consumption in vitro 
(Brown etal., 1998; Clementi etal., 1999; Loke etal., 1999; Poderoso etal., 
1998; Shen etal., 1995) and in vivo (Shen etal., 1994; Shen etal., 1995), 
though it remains possible that cGMP may mediate some of these effects 
(Balligand etal., 1993; Gong etal., 1998; Shen etal., 1995). In addition the 
sensitivity of NOgcR to NO is at least two orders of magnitude higher than 
that of cytochrome c oxidase (Bellamy et al., 2002a). The important question 
of whether NO regulates cellular respiration in vivo thus remains unresolved 
(Brown, 2001; Moncada & Erusalimsky, 2002).
Perhaps the most widely researched correlate of NO physiology in the 
brain is its role in synaptic plasticity, a process involved in memory formation. 
Following brief, high frequency synaptic stimulation, LTP (usually studied in 
slices of the hippocampus) is a resultant long-lasting (hours or days) increase 
in the efficacy of synaptic transmission. Long-term depression (LTD) in 
contrast is a decrease (hours) in synaptic strength. As befits the NO field, the 
evidence for its role in LTP is conflicting. Some studies find LTP is completely 
blocked by NOS inhibitors (Bohme etal., 1991; O'Dell etal., 1991), while 
others show only partial (Haley et al., 1993; Holscher, 1999), or no effect 
(Cummings et al., 1994). Much of this controversy may stem from the 
variations in the stimulation intensities applied by different labs, with stronger 
stimulations being NO-independent (Haley etal., 1993), while temperature 
may also be an issue. When evidence is positive for a role of NO, 
experiments point to the involvement of cGMP in this pathway (Boulton et al., 
1995; Kleppisch etal., 2003).
1.6 NO AND NEUROPATHOLOGY
NO continues to be of great interest in the pathogenesis of chronic disease 
states including Parkinson’s (Hirsch & Hunot, 2000; Liberatore etal., 1999),
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Alzheimer’s (Dorheim etal., 1994; Gahtan & Overmier, 1999) and multiple 
sclerosis (Smith & Lassmann, 2002), though its role in the acute death 
associated with cerebral ischaemia has received the most attention to date. 
The remainder of this chapter concerns the role of NO in ischaemic brain 
injury. Much of the literature is contradictory, but remains fascinating since 
NO may play either a destructive or protective role. There are many good 
reviews of NO in ischaemia (ladecola, 1997; Samdani etal., 1997a; Strijbos, 
1998) which together with the exhaustive ‘Ischaemic Cell Death In Brain 
Neurones’ (Lipton, 1999) and other selected reviews concerning NO induced 
cell death (Brown & Borutaite, 2002; Murphy, 1999; Virag etal., 2003) 
provide an excellent background to the field.
Global ischaemia (for example caused by cardiac arrest) and focal 
ischaemia (following thrombosis of a specific artery) are characterised by 
diminished blood flow, the concomitant O2 and nutrient deprivation initiating 
the cascade of events leading to neuronal death. Germane to the hypothesis 
that NO contributes to cell death following an ischaemic episode is the post- 
ischaemic release of ‘excitotoxic’ glutamate which causes sustained 
activation of the NMDA type of glutamate receptor. Since NMDA receptors 
are physically linked to nNOS via PSD-95 (Brenman et al., 1996) it has been 
suggested that NO mediates cell death following NMDA receptor activity 
(Dawson et al., 1991b; Sattler et al., 1999). Much of the impetus for this 
hypothesis has stemmed from experiments using a brief NMDA stimulation to 
activate this pathway in dispersed neuronal cultures. Remarkable protection 
was found following inhibition of NOS (Dawson etal., 1991b; Izumi etal., 
1992; Strijbos etal., 1996) or disruption of the nNOS gene (Dawson etal.,
1996). Characteristically for this field, however, other reports showed no 
protection by NOS inhibition (Demerle-Pallardy etal., 1991; Hewett etal., 
1993; Pauwels & Leysen, 1992).
Further evidence that NO is damaging in ischaemia has been 
accumulated from various models in vitro and in vivo utilising NOS inhibitors 
and knockout mice, microsensor detection of NO, or measurement of end 
products such as nitrite and nitrate (NOx") or nitrotyrosine. However, results 
have again been conflicting, and are subject to many pitfalls as detailed 
below. The current dogma is that nNOS-generated NO may reach toxic
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levels (low pM) in focal ischaemia, and particularly during the reperfusion 
following global ischaemia, thereby contributing to a neuronal death that 
starts to manifest 6-12 hrs post-insult. iNOS is also upregulated following 
global or focal ischaemia (probably in glia or invading leukocytes 
respectively) peaking at 24 -  48 hrs after the initial insult. Therefore NO also 
impacts upon the later stages of a progressive degeneration that may 
continue for up to a week, see (ladecola, 1997; Lipton, 1999; Samdani etal., 
1997a; Strijbos, 1998).
Of the mechanisms put forward to explain NO-dependent cell death, 
there are two leading candidates. NO alone is relatively unreactive, though it 
can bind in competition with O2 to cytochrome c oxidase, thereby directly 
inhibiting respiration, at least in vitro (Bal-Price & Brown, 2001; Brorson et al., 
1999; Brown & Borutaite, 2002). Perhaps more attractive is the diffusion- 
limited reaction of NO with superoxide (O2*"), which is increased during and 
after ischaemia, to form the highly toxic species peroxynitrite (ONOO'), a 
strong oxidant (Beckman & Koppenol, 1996).
Paradoxically, NO generation may also be neuroprotective, either via 
cGMP-mediated mechanisms such as increased vasodilation and platlet 
disaggregation (ladecola, 1997; Samdani etal., 1997a; Strijbos, 1998), 
inhibition of apoptosis (Fiscus, 2002), stimulation of angiogenesis (Ando et 
al., 2002; Maulik & Das, 2002; Zhang etal., 2003), or more directly by 
inhibition of lipid peroxidation (Hogg & Kalyanaraman, 1999; O'Donnell & 
Freeman, 2001). Evidence, particularly from studies with NOS inhibitors, 
suggests that post-ischaemic NO generated by eNOS may indeed be 
protective. Furthermore recent evidence has implicated NO as a protective 
factor in ischaemic pre-conditioning, and also in the neurogenic response 
that follows several days after the insult. These proposed destructive and 
protective roles of NO in cerebral ischaemia are summarised in figure 1.3.
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Figure 1.3 Summary diagram of the possible degenerative and 
protective roles of NO in cerebral ischaemia (see text for details).
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1.7 IDENTIFYING POTENTIAL ARTIFACTS
Tissue culture experiments
Many of the discrepancies in the literature concerning NO pathology may 
have arisen from problems associated with culturing cells. It has long been 
observed that the numbers of nNOS-positive neurones may change when 
culture conditions are altered. For example plating neurones on glial feeder 
layers compared with a polyornithine matrix has been associated with an 
impoverishment of nNOS containing neurones (Samdani etal., 1997b). 
Equally important may be the developmental age of the culture, and the 
timing and intensity of the insult (Aizenman etal., 1998).
It is often overlooked that cultured cells may be abnormally vulnerable 
to oxidative and nitrosative stress. Media are frequently deficient in 
antioxidants (vitamin E is insoluble and vitamin C unstable) and are actually 
pro-oxidant unless trace metals are deliberately scavenged. Furthermore in 
air-equilibrated media (about 200 pM 02, compared to 25 pM in vivo) 
cultured cells may generate more reactive oxygen species (ROS; such as 
O2*") because the O2 concentration is not limiting, for discussion see 
(Halliwell, 2003).
A good alternative to primary dissociated cultures may be organotypic 
slice cultures. Such slices survive for longer in culture (up to a month) and 
they retain their complex cellular organization and normal 
electrophysiological properties (Gahwiler, 1981; Stoppini etal., 1991). 
Hippocampal slice cultures are regularly used for the study of ischaemic and 
excitotoxic insults and show a similar regional vulnerability to that found in 
vivo (Pringle etal., 1997; Strasser & Fischer, 1995; Vornov etal., 1994; 
Vornov et a!., 1991). Surprisingly there have been no reports of the effects of 
NO following such stimulations.
NOS inhibition
Initial experiments in vivo using competitive inhibitors such as nitro-L-arginine 
(L-NNA) and its pro-drug NG-nitro-L-arginine methyl ester (L-NAME) gave 
conflicting results. These compounds are non-selective and the resulting
26
eNOS inhibition is likely to have led to unwanted effects such as reduction of 
cerebral blood flow and constriction of pial arterioles, leading to increases in 
infarct volume, reviewed in (ladecola, 1997). L-NAME may also have non­
specific effects, such as muscarinic antagonism (Buxton etal., 1993).
More recently the compound 7-nitroindazole (7-NI) has been used as 
a selective nNOS inhibitor (Adachi etal., 2000; Lei etal., 1999) though this 
may be misguided as, at the level of isolated enzyme, no selectivity is seen 
(Alderton et a!., 2001). 7-NI can indeed reduce focal infarct volume without 
increasing blood pressure (Yoshida etal., 1994), but this may have other 
explanations, such as a selectivity for neuronal vs. endothelial cells (Alderton 
et al., 2001). Recently, 7-NI was reported to protect gerbils from 5-min global 
ischaemia by an unknown mechanism distinct from nNOS inhibition (Lei et 
al., 1999). Besides its NOS inhibitory actions, 7-NI may act as a monoamine 
oxidase (MAO) inhibitor /n vivo (Desvignes etal., 1999). Following global 
ischaemia in rats, accumulated catecholamines may produce H2O2 via MAO, 
although the use of MAO inhibitors or knockout animals offered no protection 
(Holschneider et al., 1999; Simonson etal., 1993). Nevertheless, a protective 
combination of NOS/MAO inhibition by 7-NI cannot be ruled out as the 
mechanism of action for this compound. Data obtained with another partially 
selective nNOS inhibitor ARL 17477 (23-fold selective vs. eNOS) have 
shown protection against transient ischaemia in vivo (O'Neill et al., 2000; 
Zhang et al., 1996b), but this compound is only five-fold selective vs. iNOS, 
the inhibition of which was not monitored.
Similar problems with selectivity have occurred with studies using the 
iNOS selective inhibitor aminoguanidine. This compound has approximately 
10-fold selectivity vs. eNOS, but very little vs. nNOS (Alderton etal., 2001). 
Although protective in some studies (ladecola etal., 1995; ladecola etal., 
1996; Zhang et al., 1996a) such effects could be caused by nNOS inhibition 
or be related to the inhibition of polyamine oxidase activity (Ivanova et al., 
1998). Furthermore, aminoguanidine may have other effects, such as 
catalase inhibition (Ou & Wolff, 1993) and antioxidant properties (Giardino et 
al., 1998; Yildiz etal., 1998).
The only inhibitors to exhibit high selectivity are against iNOS: N-(3- 
(aminomethyl)benzyl)acetamidine (1400W), GW273629 and GW274150 are
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greater than 50-fold selective over both the constitutive NOS isoforms 
(Alderton etal., 2001). Importantly, 1400Whas recently been successful in 
reducing infarct volume in focal ischaemia (Parmentier etal., 1999). 
Unfortunately, the development of highly selective inhibitors of nNOS and 
eNOS remains elusive; they would be very useful in addressing ambiguities 
plaguing the literature.
Exogenous NO
Cell death due to the application of exogenous NO to neurones is one of the 
key criteria used to support the hypothesis that endogenous NO is toxic. 
Although there is little knowledge of what constitutes a pathological NO 
concentration, various NO-releasing chemicals have been applied in many 
models (Bonfoco etal., 1995; Brorson etal., 1999; Dawson etal., 1996;
Izumi etal., 1993). Historically the most commonly used donors, sodium 
nitroprusside (SNP), S-nitroso-N-acetylpenicillamine (SNAP) and 3- 
morpholinosydnonimine (SIN-1) are now recognised not to produce NO as 
their primary species (Feelisch etal., 1989; Lipton & Stamler, 1994). The 
advent of the NONOates, which release authentic NO with predictable 
kinetics, has simplified matters (Keefer et al., 1996) and the resulting NO 
concentrations in biological buffers can be predicted (Schmidt etal., 1997), 
see section 3.1. Unfortunately errors are still made, such as comparing NO 
levels released from NONOates at room temperature with neuronal toxicity of 
these compounds at 37°C (Brorson etal., 1999). Importantly the rates of NO 
release from NONOates may also be influenced by metal ions and have a 
striking dependence upon pH (Davies et al., 2001), and so they should be 
used with a degree of caution.
Measuring NO
Changes in NO following ischaemic insults have been monitored by several 
methods, including electron paramagnetic resonance (Tominaga etal., 1993; 
Wei etal., 1999), or microdialysis (Adachi etal., 2000; Fassbenderetal., 
2000; Lei et al., 1999); unfortunately these methods give readings that are 
difficult to translate into brain NO concentrations. Monitoring NO directly with 
time using a microsensor should be a good solution, but results using this
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technique have been variable. In one often quoted study (Malinski et al.,
1993) NO rose from undetectable levels to a 1-4 |iM peak in the time 
immediately following middle cerebral artery occlusion. Alternatively, a much 
lower peak concentration (< 20 nM) has been recorded (Lin et al., 1996). 
Microsensor data may well be compromised since the electrodes are 
susceptible to interference from various compounds including tyrosine and 
ascorbate (Lin etal., 1996; Stingele etal., 1998). Perhaps the most sensitive 
method of measuring NO in the brain is to use NOgcRs as a biosensor and 
follow the production of cGMP. Recent data obtained in this manner from 
striatal slices agrees with the lowest microsensor estimates of post-ischaemic 
NO, in that NO concentrations were less than 1 nM and rose only modestly 
(2-fold) following simulated ischaemia (Griffiths et al., 2002a).
Formation of ONOO' is thought to be one of the major routes by which 
NO may elicit neuronal death. In vitro, ONOO'may nitrate tyrosine residues 
at physiological pH (Beckman & Koppenol, 1996; Reiter etal., 2000) and the 
presence of 3-nitrotyrosine (3-NT) staining post-ischaemia is often taken as 
strong evidence of the formation of ONOO'in toxic quantities (Forman et al., 
1998; Tanaka et al., 1997). However such data should be treated with 
caution, firstly because tyrosine nitration may be indicative of a number of 
reactive nitrogen species (RNS) in vivo and secondly, because the assays 
used to detect 3-NT appear unreliable (Halliwell etal., 1999).
The recent development of a series of fluorescent NO indicators 
(Kojima etal., 1998a) has culminated in an increasing use of the compound
4,5-diaminofluorescein (DAF-2). In the presence of O2, NO and NO-related 
RNS nitrosate DAF-2 to yield the highly fluorescent DAF-2 triazole. DAF-2 
and its cell permeable analogue DAF-2 DA have been used to image NO 
following NMDA stimulation in the CA1 region of acute hippocampal slices 
(Kojima etal., 1998b), and in organotypic hippocampal slices subjected to 
ischaemia (Morrison etal., 2002). However, the specificity of these 
compounds has been questioned following a report that their fluorescence 
may be enhanced by Ca2+, Mg2+ or incident light (Broillet et al., 2001). 
Although further investigation blamed these effects upon increased NO 
release from the donor S-nitrosocysteine, other donors used in the original
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study (DETA/NO and SNP) have no such reactivity (Suzuki et al., 2002). 
Other groups have since highlighted DAF-2 reactivity with ascorbic acid 
(Zhang et al., 2002b) or ONOO‘ (Roychowdhury et al., 2002). Use of these 
fluorescent compounds should therefore only be undertaken with stringent 
controls, and in the knowledge that results are unlikely to be quantitative for 
NO.
1.8 DOES NO CONTRIBUTE TO ISCHAEMIC DAMAGE?
The initial evidence of a role for NO in ischaemic damage has been reviewed 
many times, the focus here is on recently published data investigating the 
role of endogenously produced NO.
In vitro 
NO from nNOS
Data from dissociated cultures are conflicting. Further evidence for NO- 
dependent cell death includes an interesting set of experiments in which 
NMDA-stimulated NO formation (measured by EPR spin trapping) was 
correlated with cerebellar granule cell death. When levels of methylarginines 
(thought to be endogenous competitive inhibitors of NOS) were raised, NO- 
mediated excitotoxicity was suppressed (Cardounel & Zweier, 2002). 
Confirming previous findings, several groups have also been able to evoke 
NO release and subsequent death (blocked by the addition of L-NAME) by 
stimulating cortical cultures with glutamate (Almeida & Bolanos, 2001; Ruiz et 
al., 2000). Conversely, NOS inhibition failed to protect neurones from 
hypoxia-induced cell death (Demerle-Pallardy etal., 2000) and, in agreement 
with earlier findings that NO is not toxic (Hewett et al., 1993), nitrotyrosine 
staining was not detected in NMDA stimulated cortical neurones (Trackey et 
al., 2001). No attempt was made to quantify NO levels in these studies.
Interestingly there are no new reports of NO contributing to damage in 
intact brain slice models. However, recent studies have monitored the 
production of NO following hypoxia (Meini et al., 2003) and stimulated 
ischaemia (Oxygen glucose deprivation: OGD) in the striatum (Griffiths etal.,
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2002a) and have confirmed previous findings in vivo (Toung etal., 1999) 
indicating that NO rises only very modestly (2-fold) following such insults, 
perhaps by as little as 35 %, from 0.6 to 0.8 nM (Griffiths et al., 2002a).
NO from iNOS
Several groups have investigated the toxicity of NO generated from iNOS in 
vitro. Expression of functional iNOS may be induced by stimulating glia with a 
combination of a bacterial endotoxin (lipopolysaccharide, LPS) and a 
cytokine (interferon^, IFN^y). Astrocytic (Stewart etal., 2000; Stewart etal.,
2002) microglial (Golde etal., 2002) or mixed glial (Bal-Price & Brown, 2001) 
cultures stimulated in this way have all been shown able to cause death of 
co-cultured neurones through NO release. Unfortunately the relevance of 
these findings is difficult to gauge since glia proliferate in culture while 
neuronal numbers remain relatively constant. The numbers of iNOS positive 
cells (and NO level generated) may therefore be markedly enhanced 
compared to in vivo.
In addition to glia, iNOS expression in the ischaemic brain has also 
been detected in cerebral endothelial cells (ladecola et al., 1996) which in 
vitro can produce NO after treatment with proinflammatory cytokines 
(Bonmann etal., 1997). Following ischaemia, cerebral endothelial cell death 
may contribute to secondary injuries, such as breakdown of the blood brain 
barrier. Recent work has shown that OGD induces iNOS in cultured 
endothelial cells, leading to an NO-dependent cell death (Xu etal., 2000). 
However, the relevance of NO toxicity in such an unphysiological scenario is 
unclear.
Compared with dissociated cultures, organotypic slices of 
hippocampus appear a better model in which to examine iNOS generated 
NO toxicity. Neuronal/glia ratios are akin to those seen in vivo, and the 
progression of cell death may be followed for many days. In agreement with 
a recent study in glial cultures (Sola etal., 2002) it has been confirmed in our 
lab that iNOS activation is confined to microglia in LPS/IFN^y stimulated 
hippocampal slice cultures. However, in contrast to another study (Lee etal.,
2003), when NO levels (measured by monitoring accumulated NOx“) were
31
significantly increased compared to control, no neuronal cell death was seen 
up to six days post-stimulation [Dr S. Duport, personal communication].
In vivo
Further experiments using 7-NI treated rats or nNOS deficient mice have 
confirmed that NO generated from nNOS increases post-ischaemic infarct 
volumes (Goyagi etal., 2001). However the picture remains complicated as 
7-NI did not protect neurones when administered during reperfusion following 
focal ischaemia, leading to the suggestion that eNOS generated NO may 
contribute to cellular demise at that time (Gursoy-Ozdemir et al., 2000). A 
recent study also indicates that changes in intracellular pH during ischaemia 
may have a strong bearing on the variable results previously seen with 7-NI, 
and other inhibitors (Coert etal., 2003).
Concerning the role of iNOS in vivo, microdialysis studies in rat 
striatum did not detect a major generation of NO during acute cerebral 
ischaemia whereas, 2 days following the insult, nitrite levels doubled. This 
delayed NO generation was inhibited by aminoguanidine, indicating iNOS 
dependence (Fassbender ef a/., 2000). In agreement, the iNOS selective 
inhibitor 1400W reduced infarct size by 36 %, ameliorated the neurological 
score, and attenuated the weight loss of rats normally seen 3 days following 
transient focal ischaemia (Parmentier etal., 1999). Antisense 
oligodeoxynucleotides against iNOS have also decreased lesion volume and 
nitrotyrosine staining following transient focal ischaemia in rats (Parmentier- 
Batteur etal., 2001). Furthermore, aminoguanidine-treated mice displayed 
reduced infarct volumes similar to those seen in iNOS knockout mice 
(Sugimoto & ladecola, 2002), whilst L-arginine exacerbated the infarct size in 
wild-type but not iNOS knockout mice, supporting a deleterious effect of NO 
(Zhao etal., 2003). Expression of iNOS perse, however, may not be 
damaging because local or systemic LPS injection caused the expression of 
iNOS in microglia in vivo, but no neuronal degeneration (Han et al., 2002; 
Morimoto etal., 2002). Perhaps, in ischaemia, iNOS-derived NO is damaging 
because it adds on to other ongoing pathological mechanisms (see below).
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1.9 HOW DOES NO CONTRIBUTE TO ISCHAEMIC DAMAGE?
Respiratory inhibition
The inhibition of mitochondrial respiration by NO has been the subject of 
some excellent recent reviews (Brown & Borutaite, 2002; Moncada & 
Erusalimsky, 2002; Stewart & Heales, 2003). Briefly, NO may inhibit 
respiration reversibly at cytochrome c oxidase (see above), or irreversibly, 
after prolonged exposure, at multiple sites including complex I (Clementi et 
al., 1998), possibly after the conversion of NO to other RNS such as ONOO" 
(Riobo et al., 2001). Alternatively NO may shift the mitochondrial electron 
transport chain into a more reduced state, enhancing 02*' formation 
(Poderoso et al., 1996). At lower NO levels this O2*' increase will result in 
H2O2 production while higher NO levels are likely to scavenge the O2*' 
resulting in ONOO" production. Several different pathways to cell death can 
occur. Apoptosis or necrosis may ensue dependent upon the glycolytic 
capacity of the cell (Bal-Price & Brown, 2000). ATP depletion may also lead 
to further excitotoxicity in neurones (Bal-Price & Brown, 2001; Stewart et al.,
2002). Alternatively NO, or more likely RNS, can cause induction of the MPT 
and apoptosis (Borutaite etal., 2000).
It is important to note that inhibition of respiration by NO is in 
competition with O2. At the hyperoxic O2 concentrations (approximately 200 
liM) in which air equilibrated in vitro experiments are undertaken, the IC50 of 
NO for cytochrome c oxidase may be up to 450 nM (Koivisto et al., 1997) 
compared with an IC50 of 120 nM at physiological tissue O2 (Bellamy et al., 
2002a). This difference in potency highlights the need to conduct in vitro 
experiments at more physiological O2 concentrations.
Elegant studies in dissociated neuronal cultures have recently 
implicated both reversible (Bal-Price & Brown, 2001) and irreversible 
(Stewart etal., 2000) respiratory inhibition, and subsequent excitotoxicity 
(Bal-Price & Brown, 2001; Stewart etal., 2002), dependent upon neuronal 
maturation state (Golde et al., 2002), as the cause of death following 
expression of iNOS in co-cultured glia. Similarly, glutamate receptor- 
mediated activation of nNOS in cultured cortical neurones may trigger either
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apoptosis (by transient inhibition of ATP synthesis and MPT pore opening) or 
necrosis (by oxidative stress and persistent inhibition of ATP synthesis) 
(Almeida & Bolanos, 2001).
Although direct inhibition of respiration by NO is an appealing 
hypothesis, the only study to address this possibility in vivo gave evidence to 
the contrary (De Visscher etal., 2002). In addition, although NO production 
following expression of iNOS in organotypic hippocampal slices may be toxic 
(Lee etal., 2003), this is not always the case (Dr S.Duport, personal 
communication). In agreement, LPS injection was only seen to be toxic in 
vivo when paired with an excitotoxic stimulus, in this case injection of 
ibotenate (Morimoto etal., 2002).
ONOO'formation
ONOO'is a powerful oxidant, more toxic than NO and O2*" individually, that is 
formed when the rate of NO generation is sufficient to out-compete 
superoxide dismutase (SOD) for O2*' (Beckman & Koppenol, 1996). Under 
ischaemic conditions the O2*' required for this reaction may be generated by 
leakage from the mitochondrial electron transport chain, particularly during 
reperfusion (Piantadosi & Zhang, 1996). Amongst other mechanisms, 
enzymatic O2*' generation may occur by the xanthine/xanthine oxidase 
pathway or from plasma membrane NADPH oxidase in microglia and other 
cells (see chapter 6.1). The reactions of ONOO'are affected by intracellular 
pH and antioxidant status, and death may be initiated by many mechanisms, 
including lipid peroxidation, protein nitration, DNA damage, or the irreversible 
inhibition of respiration (recently reviewed in Szabo, 2003; Virag et al., 2003).
Unfortunately the production of ONOO' is difficult to detect 
unequivocally. As before, recent studies have monitored 3-nitrotyrosine 
increases in both focal (Han et al., 2002; Parmentier-Batteur et al., 2001; 
Gursoy-Ozdemir et al., 2000) and global (Alonso et al., 2002) ischaemia, 
though the specific mechanism of death was not investigated. Recent work 
has demonstrated that ONOO' may be generated in vitro by microglia 
activated with LPS/IFN^y (to stimulate iNOS) and phorbol 12-myristate 13- 
acetate (to generate O2”) though the quantities involved were not enough to
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cause neuronal death over the short timecourse of these experiments (Bal- 
Price etal., 2002).
ONOO'-dependent DNA damage and subsequent activation of the 
nuclear enzyme poly(ADP-ribose) polymerase (PARP-1) has been well 
studied in ischaemia. PARP-1 uses NAD (an important co-enzyme in energy 
metabolism) as its substrate. Excessive PARP-1 activation leads to 
decreased NAD levels and thus subsequent ATP depletion (Pieper et al.,
1999). Both inhibition of PARP-1 (Plaschke etal., 2000) or knockout of the 
PARP-1 gene (Eliasson etal., 1997b) have shown significant protection in 
experimental ischaemia. Consistent with the theory that NO and ONOO' are 
involved in PARP-1 activation, PARP-1 was not activated after NMDA 
administration in mice lacking the nNOS gene (Mandir et al., 2000).
Other mechanisms
One means by which low NO levels may cause damage is through enhanced 
synaptic transmission. In vivo, most hippocampal CA1 neurones destined to 
die following ischaemic reperfusion were found to exhibit potentiated synaptic 
transmission (Gao etal., 1999) and, following inhibition of mitochondrial 
respiration in vitro, endogenous NO (acting via cGMP) potentiates 
hippocampal synaptic transmission during low frequency stimulation (Bon & 
Garthwaite, 2001). It may be proposed, therefore, that NO aids synaptic 
potentiation and, hence, delayed excitotoxicity by operating through 
physiological cGMP-dependent pathways. Consistent with this hypothesis, 
transient anoxia can elicit a long term potentiation-like phenomenon that can 
be blocked by NO synthase inhibition in the CA1 hippocampus in vitro 
(Huang & Hsu, 1997). Other ways in which low (nanomolar) concentrations of 
NO could contribute to damage include a cGMP-dependent enhancement of 
neurotransmitter release (Trabace & Kendrick, 2000) or activation of ion 
channels (Kaupp & Seifert, 2002).
Alternative mechanisms include matrix metalloproteinases (MMPs), a 
class of endopeptidase whose levels are increased in experimental 
ischaemia and which may be deleterious. Recent findings suggest that 
activation of extracellular soluble or membrane bound MMPs may occur by 
S-nitrosation reactions following ischaemia (Gu et al., 2002). Another
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interesting possibility is that NO may induce intracellular Ca2+ mobilisation 
from the endoplasmic reticulum following hypoxia (Meini et al., 2003).
Summary I (NO-dependent death)
The conflicting data generated in dissociated cultures continues to muddy the 
issue of whether endogenous NO generated from nNOS causes cell death 
post-ischaemia. There has been no confirmation that nNOS generates the 
high (nM) levels of NO measured previously (Malinski etal., 1993). Indeed, 
NO levels appear to rise so modestly that it is difficult to understand how they 
could become directly toxic (Griffiths etal., 2002a). While blocking nNOS in 
vivo with 7-NI appears protective there remain several unresolved issues 
concerning this compound (see artifacts section above). The possibility 
remains however, that low NO levels generated by nNOS can contribute to 
damage by enhancing synaptic transmission, or through formation of ONOO'.
Although dissociated cultures exposed to LPS/IFN^y can die in 
response to iNOS-generated NO, a similar activation of endogenous 
microglia is not always sufficient to cause neuronal death in more complex 
tissue models. Meanwhile, data generated in vivo with selective inhibitors 
and knockout mice does strengthen the case for iNOS-dependent death that 
is delayed several days post-insult. The most likely cause of iNOS-dependent 
cell death in ischaemia is through formation of ONOO'. It shall be interesting 
to see if direct targeting of this oxidant using the novel ONOO' decomposition 
catalyst recently described (Szabo et al., 2002) offers therapeutic benefit.
1.10 IS NO PROTECTIVE IN ISCHAEMIA?
In vitro
Historically, in vitro experiments have been used to examine the toxic role of 
NO in cerebral ischaemia. However the subsequent use of NOS inhibitors in 
vivo quickly uncovered evidence that NO could be protective through 
mechanisms such as vasodilation and the inhibition of platelet aggregation or 
leukocyte adhesion (ladecola, 1997; Samdani etal., 1997a; Strijbos, 1998).
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Although other mechanisms of NO protection have been suggested (see 
below), only a few groups have addressed them in excitotoxic or ischaemic 
models in vitro. Recently NO donors were reported to reduce NMDA-induced 
neuronal injury in mixed cortical cultures (Vidwans etal., 1999), and in 
oligodendrocytes undergoing oxidative stress (Rosenberg etal., 1999). NO 
is also involved in ischaemic preconditioning in dissociated cultures 
subjected to OGD (Gonzalez-Zulueta etal., 2000), hippocampal slices 
undergoing anoxic preconditioning (Centeno etal., 1999), and a 
macrophage-like cell line (RAW264) preconditioned against an NO induced 
death (Yoshioka et al., 2003).
In vivo
A selection of studies has continued to address eNOS expression in 
ischaemia. eNOS protein expression starts to increase in all striatal 
microvessels between 6 and 24 hrs following transient focal ischaemia, and 
continues for at least a week (Veltkamp et al., 2002). Similarly eNOS staining 
increased during the week following permanent focal ischaemia and, 
interestingly, appeared in both neuronal and non-neuronal cell types, 
particularly in the penumbra (Leker etal., 2001). Furthermore, during the 
early phase of global ischaemia NO release appears to derive prominently 
from eNOS, although this isoform contributes to only a fraction of total brain 
NOS activity (Wei etal., 1999).
NO is protective following transient ischaemia in gerbil striatum, since 
damage is aggravated by L-NNA; the similar effect of 7-NI implies that nNOS 
may be responsible for protection rather than eNOS (Adachi et al., 2000). 
Non-transcriptional activation of eNOS in response to corticosteroid 
treatment augments cerebral blood flow and reduces infarct size in a mouse 
model of transient cerebral ischaemia (Limbourg etal., 2002). In contrast, 
other experiments using 7-NI and L-NNA have concluded that eNOS- 
generated NO may be damaging during reperfusion (Gursoy-Ozdemir etal.,
2000). In agreement with the hypothesis that NO is protective, NO donors 
reduced infarct volume in a rat models of global (Mason et al., 2000) and 
transient focal (Pluta etal., 2001) ischaemia. Finally, other recent evidence
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indicates that NO is involved in ischaemic preconditioning (Atochin etal.,
2003), angiogenesis (Zhang etal., 2003) and neurogenesis (Zhang etal., 
2001; Zhu etal., 2003) (see below).
1.11 HOW IS NO PROTECTIVE IN ISCHAEMIA?
NO as an antioxidant
Although much of the literature has focused on the reaction of NO with O2*' 
(and formation of deleterious ONOO") NO is extremely reactive with other 
species such as peroxyl (RO2*) and hydroxyl (OH*) radicals. By these 
reactions, or chelation of redox active metal ions such as iron to form iron 
nitrosyl complexes, NO may achieve antioxidant effects (Halliwell etal.,
1999; Kagan et al., 2001; Wink et al., 2001). There is extensive evidence that 
ROS formation and consequently lipid peroxyl radicals (LOO*) are 
deleterious in stroke, and a good degree of neuroprotection is seen upon 
application of lipid peroxidation inhibitors (Hall et al., 1997; Huh et al., 2000). 
NO reacts potently with LOO* and, by acting as a chain-breaking antioxidant, 
prevents the propagation of lipid peroxides with a greater efficacy than the 
endogenous antioxidant a-tocopherol (vitamin E) (O'Donnell etal., 1997).
The inhibition of lipid peroxidation by NO has been well reviewed recently 
(Hogg & Kalyanaraman, 1999; O'Donnell & Freeman, 2001) and, though 
there is no direct evidence that NO is protective by this manner in ischaemia, 
the protective effects of NO release from donors post-ischaemia correlate 
with a decrease in levels of reactive O2 species (Mason et al., 2000; Pluta et 
al., 2001). Finally, it is important to remember that NO is not solely an 
antioxidant: its actions will greatly depend upon the redox environment of the 
cell and the levels of other endogenous antioxidants, such as glutathione, 
SOD, catalase and vitamin E.
Increase in cerebral blood flow
Perhaps the clearest mechanism by which NO exerts protective effects in 
ischaemic tissue is through the maintenance of cerebral blood flow (ladecola, 
1997; Samdani etal., 1997a; Strijbos, 1998). Recently, NOS inhibitors have
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been used to assess the relative contributions of the different NOS isoforms 
to blood flow during forebrain ischaemia and the results indicate that the 
contribution of nNOS to vasodilation in hippocampus, striatum and cortex is 
greater than that of eNOS (Santizo et al., 2000). However, this phenomenon 
may be model-dependent since earlier studies with knockout mice implicated 
eNOS in improved perfusion following focal ischaemia (Lo etal., 1S96). More 
recent work in eNOS knockout mice supports the idea that eNOS activity is 
critical for augmenting blood flow during acute L-arginine infusion (Yamada et 
al., 2000).
Stimulation of angiogenesis
Angiogenesis, the process by which new blood vessels are formed from pre­
existing ones, may be regulated by several growth factors, including vascular 
endothelial growth factor (VEGF), which aids the recruitment and proliferation 
of endothelial cells. VEGF promotes NO production and induces eNOS and 
iNOS expression in vascular endothelial cells in vitro (Hood etal., 1998; Kroll 
& Waltenberger, 1998). NO may also act upstream of VEGF and enhance its 
synthesis by stabilising the activity of hypoxia-inducible factor (HIF-1) (Dulak 
& Jozkowicz, 2003). NO is known to stimulate angiogenesis in both 
ischaemic cardiac tissue (Maulik & Das, 2002) and ischaemic retina in vivo 
(Ando etal., 2002), and principally exerts its actions through cGMP- 
dependent pathways (Donnini & Ziche, 2002). Cerebral eNOS may play a 
predominant role in VEGF-induced angiogenesis and vascular permeability in 
vivo (Fukumura etal., 2001) and, in the ischaemic penumbra, eNOS 
expression appears to temporally and anatomically co-localise with VEGF 
expression (Leker et al., 2001). Though few groups have directly examined 
NO-induced angiogenesis in ischaemic brain, recent experiments using 
DETA/NO support the conclusion that the NO/cGMP pathway is involved 
(Zhang etal., 2003).
Inhibition of apoptosis
Apoptosis, or programmed cell death, is directly associated with the 
activation of caspase proteases and mitochondrial cytochrome c release, and 
is one of the end stage mechanisms by which delayed neuronal death
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manifests following ischaemia (Lipton, 1999; Nicotera etal., 1999). Using 
antagonists of the NOgsRs, NO donors, or synthetic cGMP analogues, it has 
been found that NO, at low non-toxic concentrations, potently inhibits 
apoptosis in a cGMP/cGK-dependent manner in many cell types (reviewed in 
Fiscus, 2002). Indeed, basal cGMP appears to be requisite for survival of 
cerebellar granule cells in culture (Ciani etal., 2002c). This, and other studies 
using a PC12 cell line (Ha etal., 2003) have indicated a role for the PI3K/Akt 
pathway in NO-mediated protection from apoptosis, possibly by 
phosphorylation and inhibition of the pro-apoptotic protein BAD. Alternatively 
cGK-dependent phosphorylation of another transcription factor, cAMP 
response element binding protein (CREB) may be involved (Ciani et al., 
2002a; Ciani et al., 2002b).
Ischaemic preconditioning
Ischaemic preconditioning is the ability of brief (sublethal) insults to protect 
the tissue from a subsequent severe ischaemia. Preconditioning may be 
rapid (min to hrs between insults) or delayed, with hrs to days between 
insults and requiring new protein synthesis. Though the molecular 
mechanisms are not fully understood a growing body of literature supports 
the role of NO in cerebral ischaemic preconditioning (Centeno etal., 1999; 
Gonzalez-Zulueta etal., 2000). This includes a reported lack of rapid cerebral 
preconditioning in nNOS and eNOS knockout mice compared to wildtype 
(Atochin etal., 2003). The NO-dependent signalling cascades responsible for 
neuronal ischaemic preconditioning were recently reviewed (Nandagopal et 
al., 2001), and are thought to involve NMDA receptor-dependent NOS 
activation, the Ras/Erk signalling cascade and ultimately the activation of 
CREB, leading to increased production of neuroprotective molecules.
Stimulation of neurogenesis
Neurogenesis is now known to occur in the adult rat dentate gyrus after 
simulated stroke (Jin etal., 2001; Liu etal., 1998) suggesting it may be a 
critical element of brain repair. Recently it was reported that NO released 
from DETA/NO may induce neurogenesis and reduce functional deficits in 
post-ischaemic rat dentate gyrus (Zhang etal., 2001). In agreement, another
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group attributed a 3-fold increase in new post-ischaemic granule neurones in 
rat dentate gyrus to NO release since neither iNOS knockout mice nor 
aminoguanidine-treated rats showed such increases (Zhu etal., 2003). 
Similar neurogenic effects, and reduced neurological deficits, are seen when 
cGMP levels were increased following application of sildenafil (an inhibitor of 
cGMP breakdown by the phosphodiesterase PDE5) to post-ischaemic rats 
(Zhang et al., 2002a).
NMDA receptor modulation
An often-quoted mechanism by which NO may have protective actions is 
through direct action at a redox modulatory site on the NMDA receptor 
(Lipton etal., 1993; Lipton & Stamler, 1994). However this theory is 
controversial (Aizenman etal., 1998) and to date there is no convincing 
evidence that it occurs in vivo.
Summary II (NO protection)
A good deal of evidence supports a protective role for NO in cerebral 
ischaemia, and our knowledge of the mechanisms by which NO can be 
protective has advanced substantially. There appears to be little debate that 
eNOS-generated NO is protective through blood flow augmentation. Both 
nNOS and eNOS may be involved in the process of preconditioning, while 
iNOS looks to be important in subsequent repair. A substantial literature has 
continued to highlight the potential for NO to act as a direct antioxidant or, 
through cGMP, to inhibit apoptosis or stimulate angiogenesis. These 
mechanisms remain to be examined thoroughly in cerebral ischaemia models 
in vivo.
1.12 CONCLUSIONS
The flood of conflicting evidence concerning the involvement of NO in post- 
ischaemic neurodegeneration or protection may now be evaluated in light of 
the many pitfalls to have beset the field. With this in mind, the last few years 
have seen little evidence that, following cerebral ischaemia in vivo,
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endogenous nNOS produces concentrations of NO sufficient to have direct 
cytotoxic effects. That nNOS knockout mice show less ischaemia-evoked 
damage may reflect alternative (possibly physiological) mechanisms 
engaged by NO. The use of a new generation of selective inhibitors has 
confirmed that iNOS-generated NO can contribute to ischaemic damage; 
although the mechanism remains to be established, direct respiratory 
inhibition appears unlikely. In general the tide is turning towards a better 
appreciation of the protective and restorative actions of NO and, with regard 
to cerebral ischaemia, we are only beginning to understand the many ways 
by which such protection may be mediated. Elucidating the molecular 
mechanisms by which NO exerts protection may help identify new potential 
therapeutic targets.
1.13 GENERAL AIMS
Many doubts remain as to the validity of studies designed to examine NO 
toxicity. Particularly lacking is a consensus as to the toxic NO concentration 
generated following pathological insult, meaning that experiments using 
exogenous donor compounds are difficult to understand in context. This NO 
concentration is ultimately a balance between production and breakdown, 
though surprisingly little is known about the latter. The following chapters 
explore the reactivity and toxicity of NO in a complex tissue culture model 
(organotypic slices). In later chapters a recently described mechanism by 
which NO is consumed in brain preparations (Griffiths & Garthwaite, 2001) 
has been further characterised.
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CHAPTER 2: MATERIALS AND METHODS
2.1 MATERIALS
Compound Abbreviation Source
D(-)-2-Amino-5-phosphonoperitanoic acid D-AP5 Tocris
Ascorbate - Sigma
Ascorbate Oxidase AO Sigma
B27 supplement (without antioxidants) B27 Life-Tech
Bovine serum albumin (fraction V) BSA Sigma
Cuprizone - Sigma
Guanosine 3’,5’-cyclic monophosphate cGMP Sigma
Guanosine triphosphate GTP Sigma
Deferoxamine-mesylate - Sigma
Deoxyribonuclease DNase Sigma
Diaminobenzadine DAB Vector
Diethylamine NONOate DEA/NO Alexis
Diethylenetriamine NONOate DETA/NO Alexis
Diethylenetriaminepentaacetic acid DTPA Sigma
Dimethyl sulfoxide DMSO Sigma
Dithiothreitol DTT Sigma
Dizocilpine maleate MK-801 Tocris
Deoxyribonuclease DNase Sigma
Dulbecco’s modified eagle medium DMEM; 41965 Life-Tech
Ethylenediaminetetraacetic acid EDTA Sigma
Ethylene glyco-bis(p-aminoethyl ether)- EGTA Sigma
N,N,N’,N -tetraacetic acid
Hank’s balanced salt solution HBSS Life-Tech
Haemoglobin Hb Sigma
Haemoglobin beads Hb-beads Sigma
Horse serum (heat inactivated) HS Life-Tech
/V-2-Hydroxyethylpiperazine-A/’-2- Hepes Sigma
ethanesulfonic acid
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1-Hydroxy-2-oxo-3-(/V-ethyl-2-ami noethyl)- NOC-12 Alexis
3-ethyl-1-triazene
3-lsobutyl-1 -methylxanthine IBMX Sigma
Minimal essential medium (with Hepes) MEM 10012 Life-Tech
Minimal essential medium (with NaHCOs) MEM 31095 Life-Tech
Minimal essential medium vitamin mix Vits Life-Tech
Myxothiazol - Sigma
Neurobasal medium NBM21103 Life-Tech
L-nitroarginine L-NNA Tocris
7-nitroindazole 7-NI Tocris
Neocuproine - Sigma
N-Methyl-D-aspartic acid NMDA Sigma
Penicillin/streptomycin P/S Life-Tech
Propidium Iodide PI Sigma
Poly-D-Lysine - Sigma
Riboflavin Rib Sigma
RPMI-1640 No. 31870 Life-Tech
Sodium hydroxide NaOH BDH
Sodium nitrite NaN02 BDH
Sodium cyanide NaCN Sigma
Soluble guanylate cyclase (from bovine sGC Alexis
lung)
Soybean trypsin inhibitor - Sigma
Superoxide dismutase SOD Sigma
Triton X-100 - Sigma
T ris(hyroxymethyl)aminomethane Tris Sigma
6-Hydroxy-2,5,7,8-tetramethylchroman-2- Trolox Sigma
carboxylic acid
Trypan blue - Sigma
Trypsin - Sigma
Trypsin/EDTA - Life-Tech
Uric acid - Sigma
Table 2.1 General materials
KEY
BDH: BDH/Merck, Poole, Dorset, UK.
Calbiochem Calbiochem, CN Biosciences UK, Nottingham, UK.
Life-Tech: Life-Technoiogies Ltd (GIBCO-BRL), Paisley, UK.
Sigma: Sigma-Aldrich Company LTD, Poole, Dorset, UK.
Tocris: Tocris: Tocris Cookson Ltd, Avonmouth, Bristol, UK
Vector: Vector Labs, Inc, Burlingame, CA 94010, US.
1st Antibody 1st
Host
Cone. 2nd
Host
Cone. Linked
cGMP (gift from Dr. J. de Vente, 
Maastricht, Netherlands)
Sheep 1:8000 Donkey 1:200 Biotin
GFAP (Dako, Cambridgeshire, 
UK)
Rabbit 1:1000 Donkey 1:200 Rhodamine
nNOS (gift from Dr. P.C. Emson, 
Cambridge, UK.)
Sheep 1:10000 Donkey 1:200 Biotin
eNOS (BD Transduction Labs, Mouse 1:1000 Horse 1:300 Biotin
Kentucky, USA)
Table 2.2 Antibodies for immunohistochemistry
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2.2 GENERAL SOLUTIONS
NO donors
Donor stocks were prepared freshly each day in 10 mM NaOH, and kept on 
ice to prevent decomposition.
Donor Structure Half-life (pH 7 .4 ,37°C)
DEA/NO H, ,
HjC N CH3
2.1 min
DETA/NO
/N-
N
H3N' ‘NhL
20 h
CL
NOC-12
Table 2.3 NO donor compounds
.CHj
100 min
Tissue inactivation buffer
50 mM Tris, 4 mM EDTA at pH 7.4, heated to 90°C 5 min prior to use
Haemoglobin preparation
1 mM Hb (type 1) was incubated with 10 mM Na+ dithionate for 4 hours at 
room temperature. 10 ml of Hb/dithionate solution was dialysed in 1 L of 
water at 4°C overnight (water was changed after 1 hour), and stored in 
aliquots at -20°C until use.
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2.3 GENERAL METHODS
Tissue Inactivation
GC reaction mix or hippocampal slices were inactivated by immersion in an 
Eppendorf tube containing 150-200 pi tissue inactivation buffer, pre-heated to 
90°C for 5 min. Inactivated enzyme or tissue was homogenised and frozen at 
-20°C until use.
cGMP radioimmunoassay
Inactivated tissue was homogenised by sonication, a sample was removed 
for protein determination and the remainder centrifuged at 10,000g for 5 min 
at 4°C. The supernatant was analysed for cGMP content using 
radioimmunoassay (details available from Amersham pic, Buckinghamshire, 
UK) and expressed as pmol cGMP/mg protein.
Protein Determination
Sample protein content was determined using the bicinchoninic acid method. 
Briefly, 10 pi samples or BSA standards (0-1 mg/ml; prepared in inactivation 
buffer) was added to 200 pi of bicinchoninic acid reagent (Pierce 
biotechnology, Rockford, US.). Samples were incubated at 37 °C for 30 min 
and absorbance read at 642 nm. Sample protein content was determined 
against the BSA standard curve.
Measurement of NO and O2.
Continuously stirred samples (1 ml) were measured in tissue culture medium, 
cell incubation buffer, Tris (25 mM), or Hepes (25 mM), at pH 7.4 in a sealed 
chamber maintained at 37°C. In some experiments the chamber remained 
open to the air. The chamber was equipped with a Clark type O2 electrode 
(Rank Brothers, Bottisham, Cambs, U.K.) and an NO sensitive 
electrochemical probe (ISO-NOP, World Precision Instruments, Stevenage, 
U.K., see figure 2.1). The NO probe was calibrated using the chemical 
reduction of NaN02 (0.1-10 pM) in the presence of 0.1 M H2SO4 and 0.1 M 
Kl. The O2 electrode was zeroed by addition of excess Na+ dithionate, and 
O2 content of air-equilibrated solution assumed to be 185 pM. Compounds
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were injected into the chamber through a rubber seal using a Hamilton 
syringe (maximum volume, 10 pi). NO and O2 probe signals were sampled at 
1 Hz using Duo 18 version 1.1™ (World Precision Instruments). At the 
termination of each experiment the probes were baselined by the addition of 
excess Hb or Na+ dithionate as appropriate.
r IS0-N0P electrode
Adjustable
plunger
Rubber 
seal —
•H  Water Jacket
C 1 ml sample
Oxygen electrode
Stir Bar
Figure 2.1 NO and 0 2 electrode setup
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CHAPTER 3: IDENTIFYING A CONFOUNDING
ARTIFACT
3.1 INTRODUCTION
One of the key criteria to be met in order to sustain the hypothesis that NO is 
an endogenous toxin is that exogenous NO, at concentrations relevant to 
those produced endogenously, should be able to elicit cell death. 
Unfortunately, there is little knowledge of what constitutes a pathological 
concentration of NO when it is generated endogenously in vivo. As previously 
mentioned (chapter 2), various NO-releasing chemicals have been used in 
various concentrations to investigate the toxic potential of NO (Bonfoco et al., 
1995; Brorson etal., 1999; Dawson etal., 1996). Historically the most 
commonly used ones include sodium nitroprusside (SNP), S-nitroso-N- 
acetylpenicillamine (SNAP) and 3-morpholinosydnonimine (SIN-1). However, 
the primary species produced by these donors may not be NO. For example, 
SIN-1 decomposition is associated with 02*“ release and ONOO' generation 
(Feelisch etal., 1989). Furthermore reactive nitrogen species that act as 
nitrosonium ion (N0+) donors have been implicated in the actions of SNAP 
and SNP (Butler etal., 1995; Lipton & Stamler, 1994).
The advent of the NONOates, which release authentic NO with 
predictable kinetics, has simplified matters. The rate of NO release from the 
NONOates is a function of pH, temperature and the identity of the 
nucleophile carrier (Keefer et al., 1996). In aqueous, aerobic solutions, NO is 
inactivated by reaction with O2 in a process termed autoxidation (Ford et al., 
1993). Knowing the kinetics of NO release and inactivation, the resulting NO 
concentrations in biological buffers can be predicted (Schmidt etal., 1997).
In aqueous, aerobic solutions, NO reacts with molecular O2 to ultimately 
form NO2' according to the reaction sequence described below.
(1) 2N0 + 0 2 — 2N02
(2) 2N02 + 2N0 — 2N2O3
(3) 2N20 3 + 2H20  -> WO2 + 4/T
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This autoxidation reaction is summarised in equation (4) below, where k is 
the rate constant of inactivation.
(4) ‘M ° } = k [0 2 ][N 0 ]i  
dt
By monitoring the appearance of NO2', disappearance of NO, or formation of 
H+, several groups have studied the kinetics of this reaction and made 
various estimates of k at 22-25°C, pH 7.4 (Goldstein & Czapski, 1995; 
Kharitonov etal., 1994; Lewis & Deen, 1994; Wink eta !., 1993). It is clear 
from these studies, and equation (4) above, that the autoxidation reaction is 
second order with respect to NO and first order with respect to O2 . Thus, 
though relatively stable at low nM concentrations, higher NO concentrations 
are more rapidly inactivated. This is illustrated clearly when following NO 
profiles generated by the NONOates, autoxidation is negligible in the initial 
phase but becomes progressively effective as NO concentrations rise (Figure 
3.1). Using their reported value for k at 37°C (13.6x106 M~2 s'1) the 
mathematical model of Schmidt et a!., has been used to illustrate the differing 
NO profiles derived from donor compounds used in this thesis.
3.01
2.5 Noc-12
2.0
1.5
1.0 DETA/NO
0.6
DEA/NO
0.0
TT T
0 10 20 30 40 50 60
Time (min)
Figure 3.1 Predicted NO profiles for NOC-12 (100 pM), DETA/NO (300 pM) and 
DEA/NO (3 pM) at pH 7.4, 37°C, see Schmidt et al., 1997.
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Aims
In the course of studies originally aimed at determining the toxicity of 
exogenous NO towards brain neurones maintained in primary culture, it was 
decided to use the donor compound diethylenetriamine NONOate 
(DETA/NO), since it has a long half-life (20 h). In simple buffer solutions, the 
NO generated by DETA/NO accumulates to a steady-state concentration 
when the rate of autoxidation is equal to the rate of NO release, making it 
potentially useful for studies of the cytotoxicity of NO at defined 
concentrations and over long time periods in tissue culture. On measuring 
the concentrations attained in the tissue culture media itself, however, a large 
and unexpected difference was found compared with predictions. This 
chapter reports on the origin of the discrepancy and the potentially serious 
implications this has for working with NO in tissue culture media, or even 
simple buffer solutions.
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3.2 METHODS
Measuring NO concentration
NO concentrations were measured in tissue culture medium, Tris (25 mM) or 
Hepes (25 mM), all 1 ml at pH 7.4, 37°C, using the electrochemical probe 
(ISO-NO) placed in a sealed vessel (see chapter 2.3). The tissue culture 
media tested were: minimal essential medium buffered with Hepes or 
NaHC03 , Neurobasal medium, Dulbecco’s modified eagle medium, and 
RPMI-1640. DETA/NO was prepared fresh each day in 10 mM NaOH and 
kept on ice until use. Where indicated, SOD was added to give an activity of 
1000 U/ml (Beckman & Koppenol, 1996). The metal chelators and radical 
scavengers DTPA, neocuproine, cuprizone, uric acid, and deferoxamine 
were added from at least 100-fold concentrated stock solutions to Tris or 
Hepes buffer and, where appropriate, the pH was re-adjusted to 7.4.
Vitamins (100x minimal essential medium vitamin mix), or riboflavin (0.1 -  0.2 
mg/l) were added to Tris or Hepes buffer. Experiments designed to examine 
the effect of laboratory lighting used a lightproof cardboard box covering the 
entire apparatus, whose lid could be opened and closed as desired. Upon 
opening the lid the apparatus was exposed, at a distance of approximately 2 
meters, to standard laboratory lighting conditions (4 fluorescent strip bulbs). 
All experiments were undertaken at least 3 times and statistical differences 
analysed using one-way or multiple comparison ANOVA with Dunnett’s post- 
hoc test; P values of <0.05 were regarded as significant.
Determination of NOgcR activity
Enzyme activity was measured at 37°C in 1.5 ml Eppendorf tubes. Purified 
NOgcR from bovine lung was diluted in buffer (pH 7.4) containing Tris (10 
mM), DTT (1 mM) and BSA (0.05%) to give a stock concentration of 5 pg/ml 
and stored on ice. DETA/NO (3 pM) was pre-equilibrated at 37°C for 3 hours 
in Tris or Hepes (25 mM), MgCb (3 mM), and BSA (0.05%) with or without 
the addition of SOD (1000 U/ml). Substrate (GTP, 1 mM) was added to the 
reaction 10 s before the addition of NOgcR to give a final concentration of 
0.05 pg/ml. Aliquots of the reaction mix were removed after 10 min, 
inactivated by addition to boiling buffer (50 mM Tris, 3 mM EDTA) and cGMP
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levels measured by radioimmunoassay. Results are given as means ± 
S.E.M. and were analysed by one-way ANOVA with Dunnett’s post-hoc test.
53
3.3 RESULTS
Inactivation of NO in tissue culture medium
Addition of the slow releasing NO donor DETA/NO (300 pM) to simple Tris 
buffer (25 mM, pH 7.4) resulted in a build up of NO, which reached a plateau 
of around 1 pM after about 10 min (Figure 3.2A.B) as predicted by the 
kinetics of autoxidation (Schmidt et al., 1997). Subsequent addition of SOD 
(1000 U/ml) had no significant effect. When a similar test was performed in 
MEM (Life Technologies catalogue number 10012), which forms the basis of 
many different cell culture media, the NO plateau was much lower, about 0.2 
pM. Addition of SOD then resulted in an increase in the NO concentration to 
a value (about 0.8 pM) close to, but still significantly less than, that found in 
Tris buffer. These findings suggest that, in Tris, NO is being consumed 
largely by autoxidation whereas, in MEM, reaction with 02*’ is mainly 
responsible. Broadly, MEM contains 4 main ingredients: inorganic salts, 
amino acids, vitamins and other compounds (D-glucose, Hepes, phenol red, 
sodium succinate).
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Figure 3.2 Inactivation of NO by MEM
(A), Representative traces of NO accumulation upon addition of DETA/NO (300 p.M) to Tris 
buffer (filled circles) or MEM (open circles); subsequent additions of SOD (1000 U/ml) are 
marked by arrows. (B) Summary data from 3 independent experiments; * P<0.05 versus the 
control NO concentration in Tris buffer.
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Importance of the buffer
Initially, Hepes and Tris buffers (25 mM) were compared (Figure 3.3A.B). In 
response to 300 pM DETA/NO, the mean steady-state NO concentration 
attained in Hepes was consistently less than in Tris (1.0 ± 0.12 pM vs 1.19 ± 
0.09 pM; n =3). Addition of SOD to Hepes restored NO to the concentration 
found in Tris (1.17 ± 0.09 pM). As the DETA/NO concentration was lowered 
to 100 pM and then to 30 pM, a greater proportion of the NO was consumed 
in the Hepes buffer (reversible by SOD) such that, at 30 pM DETA/NO, the 
NO plateau was reduced by about 75% (Figure 3.3B). The difference in 
absolute NO concentrations at 30 pM DETA/NO, however, was less (0.13 
pM) than at 100 pM (0.2 pM) or 300 pM (0.2 pM). With a fixed DETA/NO 
concentration (300 pM), the consumption of NO increased with increasing 
Hepes concentrations over the range 12.5-200 mM (Figure 3.3C)
The influence of Hepes at DETA/NO concentrations lower than 30 pM 
could not be measured easily because the resulting NO concentration 
approached the detection limit of the electrochemical probe (10 nM). To 
determine if Hepes-dependent NO consumption occurred at NO 
concentrations relevant to physiological signalling, the activity of the NO 
receptor enzyme, NOgcR, was measured. Activation of NOgcR by NO 
catalyses the production of cGMP from GTP, and occurs at low nanomolar 
NO concentrations (Bellamy eta /., 2000; Griffiths & Garthwaite, 2001). In 
Tris-buffered reaction mix, DETA/NO (3 pM) stimulated cGMP accumulation 
from NOgcR at a rate of 10.1 + 1.6 pmol/min/mg and there was no significant 
change in the rate in the presence of SOD (Figure 3.3D). In contrast, in 
Hepes-buffered reaction mix, NOgcR activity was reduced by approximately 
65% compared to that seen in Tris, and the control activity could be restored 
by SOD.
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Figure 3.3 Inactivation of NO by Hepes buffer
(A) Representative traces of NO accumulation upon addition of DETA/NO (30-300 p.M) to 
Tris (filled circles) or Hepes (open circles); subsequent additions of SOD (1000 U/ml) are 
marked by arrows. (B), summary data from 3 independent experiments; *P<0.05 versus the 
control NO concentration in Tris buffer. Key: solid bars, Tris + SOD; open bars, Hepes; 
hatched bars, Hepes + SOD. (C), summary data of steady-state NO concentrations 
generated from DETA/NO (300 |iM) in different Hepes concentrations (12.5 -  200 mM). Data 
are expressed as a percentage of the maximum NO signal (approximately 1 |iM in all cases) 
generated following further addition of SOD (1000 U/ml). (D), sCG was stimulated by 
addition to a reaction mix pre-equilibrated with DETA/NO (3 |j.M) and buffered with either Tris 
or Hepes in the presence or absence of SOD as indicated. Data are means ± S.E.M. from 6 
independent experiments; *P<0.05 versus Tris control, ns = not significant versus Tris 
control.
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The source of O2*"
The inhibition of NO consumption in Hepes buffer by SOD suggests an 
involvement of O2* ', which reacts extremely rapidly with NO to form ONOO' 
(Beckman & Koppenol, 1996). A possible source of O2*' would be the 
autoxidation of contaminating metal ions, particularly iron and copper ions 
(Halliwell, 1992). To examine this possibility, DETA/NO (100 pM) was added 
to Tris or Hepes buffer (25 mM) containing the Cu+ chelator neocuprione 
(100 pM), the Cu2+ chelator cuprizone (100 pM), or the iron chelators DTPA 
(100 pM) or deferoxamine (300 pM). Addition of neocuproine, cuprizone or 
DTPA had no effect on NO levels in Hepes (all remained significantly lower 
than in Tris controls), and subsequent additions of SOD restored NO to the 
concentrations found in Tris (Figure 3.4). In the presence of deferoxamine, 
however, NO levels attained in Hepes buffer were the same as those formed 
in Tris buffer, and subsequent additions of SOD had no further effect. A 
similar result was obtained in the presence of the ONOO' scavenger uric acid 
(300 pM; Figure 3.4).
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Figure 3.4 Effect of metal chelators and uric acid on NO concentrations
DETA/NO (100 (j.M) was added to Tris or Hepes (25 mM) in the presence of DTPA, 
neocuproine or cuprizone (all at 100 p.M), deferoxamine (300 jiM) or uric acid (100 p.M). 
Once a steady-state NO concentration was achieved, SOD (1000 units/ml) was added and 
the recording continued until the NO concentration was again steady. Data are from 3-6 
independent experiments and show the test NO concentrations expressed as a percentage 
of the control NO concentration found in Tris buffer (approximately 300 nM). *P<0.05 versus 
control.
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Effect of vitamins
The consumption of NO in Hepes buffer alone cannot explain the extent of 
NO inactivation observed when 300 pM DETA/NO was added to MEM. In 
pursuit of the other ingredients responsible, the mix of vitamins present in 
MEM was examined (Figure 3.5A). In Tris buffer, the vitamins decreased the 
maximum level of NO achieved by 300 pM DETA/NO by about 0.2 pM and 
NO levels were restored by the addition of SOD (Figure 3.5A,B). With the 
vitamins in Hepes buffer, however, the NO signal was almost abolished. SOD 
restored the NO concentration under these conditions to about 80% of 
control.
Of the components of the vitamin mix present (D-Ca pantothenate, 
choline chloride, folic acid, i-inositol, nicotinamide, pyroxidal HCI, riboflavin, 
thiamine HCI), riboflavin was considered a likely candidate because it is 
capable of generating O2*' (Joshi, 1985). When DETA/NO (300 pM) was 
added to Tris in the presence of riboflavin at the concentration found in MEM 
(0.1 mg/l; Figure 3.5C) the maximum concentration of NO was reduced by 
0.18 + 0.03 pM (n = 3). SOD restored NO to the control level (1.1 + 0.1 pM). 
Increasing the riboflavin concentration led to an approximately proportional 
increase in NO consumption that was, in all cases, inhibited by SOD (Figure 
3.5D). When examined in Hepes buffer, the NO concentration reached in the 
presence of riboflavin was below detection levels, consistent with the very 
low concentration found in the vitamin mix. Again, SOD restored the NO 
concentration to approximately 80% of the control.
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Figure 3.5 Inactivation of NO by vitamins
(A) Representative traces of NO accumulation upon addition of D ETA /N O  (300 pM) to Tris 
(filled circles) or Hepes (hollow circles) in the presence of vitamins (+Vits). SO D  (1000 U/ml) 
was added as indicated by the arrow or, with Hepes, was present throughout. The control 
trace (labelled “control”) contained no additions. (B), summary data from 3 independent 
experiments; *P<0.05 versus Tris control. (C), summary data from similar experiments (n = 
3-4) using riboflavin (Rib, 0.1 mg/l) instead of the mixture of vitamins; *P<0.05 vs Tris 
control. (D), Steady-state NO concentrations generated from D ETA /N O  (300 pM) in different 
riboflavin concentrations (0.1 - 0.2 mg/L) in Tris buffer. Data (n = 3 - 4) are expressed as a 
percentage of the maximum NO signal (approximately 1 pM in all cases) generated following 
a further addition of SO D  (1000 U/ml).
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Influence of light
Riboflavin is photosensitive and its presence in culture media has been 
reported to contribute to phototoxic effects (Zigler, Jr. etal., 1985). To 
investigate whether the consumption of NO was due to photosensitisation of 
riboflavin the apparatus was enclosed in a light-proof box, the lid of which 
could be opened or closed as desired. As before, in the light (Figure 3.6A,D), 
the presence of riboflavin reduced the maximum NO concentration achieved 
with DETA/NO (300 pM) in Tris buffer by about 20%. In the dark, no effect of 
riboflavin in Tris buffer was observed (Figure 3.6B,D). In Hepes buffer in the 
dark, riboflavin did not decrease the NO concentration further (Figure 
3.6C,D). On opening the box, however, the NO concentration fell by about 
0.5 pM within 10 min and then continued to fall more gradually (Figure 
3.6C,D). On closing the box, NO abruptly increased and, within 20 min, 
regained the concentration previously achieved. In Hepes buffer without 
riboflavin light did not alter the NO concentration (Figure 3.6C).
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Figure 3.6 Effects of light on the consumption of NO in Tris or Hepes in the presence 
or absence of riboflavin
(A) and (B) show representative traces of NO accumulation upon addition of DETA/NO (300 
p.M) to Tris buffer (filled circles) or Tris + riboflavin (Rib, 0.1 mg/l, open circles) in the light (A) 
or dark (B). (C), trace showing the accumulation of NO in Tris buffer alone (filled circles) or 
Hepes buffer (open circles) in the absence or presence of riboflavin (Rib), as indicated. The 
apparatus was initially kept in the dark but was exposed to light during the interval indicated. 
(D), summary data from 3-6 experiments; *P<0.05 versus Tris control.
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NO consumption by different tissue culture media
Several commonly used tissue culture media containing various Hepes and 
riboflavin concentrations (MEM 11012 and 31095, Neurobasal medium, 
DMEM and RPMI-1640) were tested for their ability to consume NO released 
by DETA/NO (100 pM) in the light or dark. In the dark, only MEM 11012 
(which contains 25 mM Hepes) was effective whereas in the light, NO 
concentrations attained in all the media tested were below the detection limit 
(Table 3.1).
Media Life-Tech
Catalogue
Number
Hepes
(mM)
Riboflavin
(mg/L)
NO in dark 
(pM)
NO in light 
(pM)
MEM 11012 25 0.1 0.14 ±0.01 * <0.01 *
MEM 31095 — 0.1 0.29 ±0.03 0.01 ± 0.005 *
RPMI-1640 31870 — 0.2 0.25 ± 0.03 <0.01 *
DMEM 41965 — 0.4 0.24 ± 0.02 <0.01 *
Neurobasal 21103 10 0.4 0.24 ± 0.02 <0.01 *
Table 3.1 Steady-state NO concentrations in different tissue culture media
The data (n = 3 -1 0 ) represent the mean steady-state NO concentration formed following 
addition of 100 pM DETA/NO to various tissue culture media in the light or dark.
*P<0.05 vs Tris control (0.28 ± 0.01 jiM).
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3.4 DISCUSSION
The study in this chapter shows that, over a range of concentrations covering 
those encountered in vitro following constitutive or inducible NO synthase 
activity (Bal-Price & Brown, 2001; Clementi etal., 1999; Lewis eta!., 1995), 
NO can be consumed as a result of the presence of two common 
constituents of cell culture media: riboflavin and Hepes buffer. The 
combination of the two ingredients under normal laboratory lighting 
conditions leads to a greatly amplified quench of the NO signal. Moreover, 
the sensitivity of the quench to SOD in all cases implies the participation of 
02*’ and subsequent generation of ONOO', which can be a powerful oxidant 
and cytotoxin (Beckman & Koppenol, 1996).
Hepes is a very commonly-used biological buffer and the finding that NO 
was consumed by this buffer in a SOD-sensitive manner, implies a 
continuous formation of O2*" that interacts with NO. Moreover, the effect 
remained marked down at the NO concentrations relevant to NOgcR 
activation, which lie in the low nanomolar range (Bellamy ef a/., 2000;
Griffiths & Garthwaite, 2001). Consequently, Hepes buffer could introduce 
artifacts associated with O2*' formation over a wide range of biologically- 
relevant NO concentrations.
As no such effect was observed in Tris buffer, the O2*' generation is not 
simply due to contaminants, such as metal ions. A likely mechanism comes 
from a study (Kirsch eta !., 1998) showing that 02“ was generated upon 
addition of ONOO'to Hepes. It was suggested that ONOO' (or any strong 
oxidant derived from it) oxidises the piperazine ring of Hepes. Following 
deprotonation, reaction with O2 leads to the formation of 02“ which then goes 
on to form hydrogen peroxide via dismutation. In our experiments, the 
inhibition of the Hepes-dependent NO consumption by SOD and by the 
ONOO' scavenger uric acid would be consistent with this reaction being 
responsible.
For such a scheme to explain the results, there would need to be a 
source of 02*" to initiate ONOO' formation. One possible source considered 
was the autoxidation of trace metals (for more detail see chapter 6), the most 
likely candidates being iron and copper. Neither of the copper chelators had
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a significant effect on the Hepes-dependent NO quench, which could indicate 
a lack of involvement of copper ions. However, Cu2+ can form an active 
complex with Hepes (Hegetschweiler & Saltman, 1986; Simpson etal., 1988) 
which could render the ion unavailable for chelation. The iron chelators DTPA 
and deferoxamine gave differing results, with only deferoxamine inhibiting 
NO consumption. Again these results are difficult to interpret clearly. A lack of 
effect of DTPA could be explained by the iron-DTPA complex continuing to 
catalyse oxygen radical generation (Egan etal., 1992). Conversely, the effect 
of deferoxamine may be explained by the ability of this compound to 
scavenge free radicals, including 02*’ (Davies etal., 1987), rather than 
sequester iron. Thus, whilst metal contaminants are still good candidates, 
unambiguous evidence for their involvement is difficult to obtain.
Nevertheless, it is likely that there is a background formation of O2*' that 
would react with NO at a diffusion-controlled rate (Koppenol, 1998) to form 
ONOO' which, by oxidising Hepes, would lead to more 02*', more ONOO', 
and so on (Figure 3.7). Adding further complications, the reaction of ONOO' 
with Hepes buffer may also result in the formation of NO donors with 
unknown additional reactivity (Schmidt etal., 1998). Obviously, it would have 
been desirable to have measured the rates of formation of O2*' and/or 
ONOO' directly but the usual methods for doing so result in the consumption 
of these species, which would have the effect of inhibiting the reaction (c.f. 
effect of SOD or uric acid).
The other ingredient found to be responsible for NO consumption was 
riboflavin, when exposed to laboratory lighting. The generation of O2*' by 
illuminated riboflavin is well documented (Joshi, 1985; Naseem etal., 1988). 
Indeed, riboflavin is used to produce 02*'for determining the efficiency of O2*' 
scavengers (Roubaud et al., 1997). However O2*' may not be the only 
species involved in riboflavin photosensitisation. Reactions involving 
riboflavin are complex, and light-sensitised riboflavin may also produce 
singlet oxygen (102 ), which may further react with organic compounds 
(Spikes, 1989). Deleterious effects of riboflavin on mammalian cells in culture 
have been known for many years and have been ascribed to various 
mechanisms. Work by Griffin et al suggested that just 3 h exposure of
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riboflavin-containing medium to bench top levels of cold white fluorescent 
light could produce significant toxicity to a leukemic cell line (Griffin et al.,
1981). The principal mechanism of phototoxicity is thought to involve the 
generation o f102  and probable subsequent oxidation of the amino acids 
tryptophan and tyrosine (Griffin etal., 1981; Stoien & Wang, 1974). It has 
since been demonstrated that fluorescent light may cause build up of toxic 
H2O2 levels in Dulbecco’s modified Eagle’s medium or RPM11640 medium, 
both of which contain riboflavin (Wang & Nixon, 1978; Zigler, Jr. etal., 1985).
In the present experiments, the SOD-sensitive quench of the NO signal 
produced by riboflavin alone (in the light) in Tris buffer increased in 
proportion with riboflavin concentration, as expected from a simple 
generation of O2*'. At the concentrations found in MEM (11012) the NO 
quench exerted by riboflavin (0.1 mg/L) was similar to that produced by 
Hepes (25 mM) implying similar rates of NO consumption (about 20% of the 
rate of release from the donor) under these two conditions. The quench of 
NO down to undetectable levels observed with the combination of Hepes and 
riboflavin (in the light) implies a much greater than additive effect. This may 
be explained by there being disproportionately more O2*' ultimately available 
as a result of its additional formation following Hepes oxidation (Figure 3.7).
In comparison with the simple combination of Hepes and riboflavin in the 
light, the complete MEM containing the same concentrations of these 
ingredients quenched NO less (80% versus 100% with 300 |iM DETA/NO), 
suggesting that other components of MEM may act as radical scavengers or 
suppress radical generation. A likely contributor here is the pH indicator 
phenol red, which quenches photoexcited riboflavin (Grzelak etal., 2001). At 
a lower DETA/NO concentration normally generating about 300 nM NO, 
however, light exposure effectively eliminated the NO signal in Hepes- 
containing MEM (Table 3.1). Under the same conditions, other common 
media (lacking Hepes) behaved similarly, suggesting that, in the light, the 
riboflavin content alone is sufficient to consume all the available NO, when 
released at this rate (approximately 100 nM/min; Griffiths & Garthwaite, 
2001).
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Figure 3.7 Possible interactions between NO, Hepes, riboflavin and light
0 2* \ initially generated by riboflavin and/or from the presence of metal contaminants, reacts 
with NO to form O N O O , which then oxidises Hepes buffer forming the Hepes radical. This 
radical fuels further 0 2*‘ generation from molecular 0 2. By this means Hepes sustains 0 2*' 
generation and the subsequent consumption of NO. The products H20 2 and/or O N O O  
formed artifactually in this way could exert biological actions, including cytotoxicity.
Overall, the results point to potential sources of artifact that may have 
unwittingly complicated many in vitro studies. Since the inclusion of Hepes 
buffer is an option in most standard media formulations (MEM, RPMI-1640, 
DMEM) and is inherent in others (Neurobasal Medium) its presence is not 
always published. Likewise, as the frequency and intensity of light exposure 
is rarely mentioned, it must be assumed that the potential problems 
associated with NO being present with either Hepes buffer or light-exposed 
riboflavin, despite being deducible from information in the literature, are not 
generally appreciated. The exaggerated effect of the two together multiplies 
the potential problems. The findings with Hepes are likely to apply to other 
“Good” buffers equipped with a piperazine ring, such as MOPS, PIPES and 
EPPS (Grady etal., 1988; Kirsch etal., 1998), and they should therefore be 
only used with caution, particularly in experiments with NO.
0 2
autoxidation of metal 
ions ?
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3.5 CONCLUSION
In the absence of the requisite information, the extent to which media factors 
might have generated spurious results in published studies cannot be 
evaluated. Blockade of cell death by NO synthase inhibitors and SOD is 
typically taken to indicate mediation by endogenously-generated ONOO'. It 
now becomes plausible that inadvertent reactions between NO and 
constituents of the bathing medium are responsible. Interestingly, the 
cytotoxicity of dopamine has recently been attributed to artifactual oxidative 
reactions occurring in tissue culture media (Clement et al.f 2002) although 
the ingredients responsible were not identified. Alternatively, the consumption 
of NO by the medium may render NO non-toxic, depending on its fate 
therein. Whether NO appears to participate in a toxic (or other) process in 
cultured cells or not may depend on a simple experimental variable, such as 
the choice of buffer or the degree of exposure to light.
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CHAPTER 4: HIPPOCAMPAL SLICE CULTURES AND DAMAGE BY
ENDOGENOUS NO
4.1 INTRODUCTION
Following ischaemic episodes central neurones degenerate, often with a 
delayed time-course of up to several days. A contributor to the damage is 
glutamate release, leading to a sustained activation of NMDA receptors 
(Choi, 1992; Meldrum & Garthwaite, 1990; Strijbos etal., 1996). NMDA 
receptors are physically linked to the Ca2+-dependent neuronal NO synthase 
nNOS (Brenman etal., 1996), and NO produced following prolonged NMDA 
receptor activation may act as a toxin that contributes to neuronal death 
(Dawson etal., 1991; Sattler etal., 1999). The mechanisms usually invoked 
include inhibition of mitochondrial respiration, and combination with 02*’ to 
form the oxidant species, ONOO'. Evidence that endogenous NO contributes 
directly to damage through these or other mechanisms, however, remains 
controversial (for discussion see chapter 1).
Glutamate is an excitotoxin
Glutamate is the major fast excitatory neurotransmitter in the mammalian 
brain. Over three decades ago it was discovered that application of glutamic 
acid was toxic to neurones of the mouse retina (Lucas & Newhouse, 1957) 
and may result in cell death of different brain regions (Olney, 1969). The term 
excitotoxicity was later christened to describe the phenomenon that 
“glutamate toxicity is a direct effect of its excitatory actions on neurones”.
For neurones to transmit information at a high rate, and to prevent 
possible toxicity, it is necessary for glutamate’s postsynaptic actions to be 
terminated rapidly. To this end a family of high-affinity excitatory amino acid 
transporters have evolved with both glial (EAAT1-2) and neuronal (EAAT3-5) 
subtypes. The most widespread are EAAT2 and 3, with other subtypes being 
more tissue specific (Gegelashvili & Schousboe, 1998). The uptake of 
glutamate into astrocytes is quantitatively superior to that into neurones, 
hence it is a combination of astrocytic uptake, and diffusion away from the
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synaptic cleft that enables glutamate concentrations to return to ambient 
levels within milliseconds (Bergles et al., 1999). Glutamate is transported 
against a steep concentration gradient by the co-transport of three Na+ and 
one H+ ions into the cell, while one K* is transported out (Levy et al., 1998). 
The maintenance of glutamate concentrations is therefore much at the mercy 
of ion pumps such as the NaVK* ATPase.
Glutamate release in ischaemia
The initial consequence of a block in cerebral blood flow (CBF) is a decrease 
in tissue O2 and therefore cessation of aerobic respiration. As ATP falls in the 
affected tissue ATP-dependent processes (including the Na+/IC  ATPase) 
cease functioning. The following rise in extracellular K* and intracellular Na+ 
triggers an ‘anoxic depolarization’ (Szatkowski & Attwell, 1994), that is 
enhanced by glutamate transporters reversing, pumping glutamate out of 
cells (Rossi etal., 2000; Szatkowski etal., 1990). Glutamate release has 
been detected following in vitro ischaemia (Mitani etal., 1991; Roettger & 
Lipton, 1996) and excitotoxicity (Strijbos etal., 1996), or in vivo (Benveniste 
etal., 1984; Obrenovitch etal., 1993), where it can accumulate to high levels 
(~100 pM) sufficient to trigger neurodegeneration. Although other 
mechanisms for glutamate release have been proposed (Ca2+-dependent 
vesicular release, and release through swelling activated anion channels), 
‘reversed uptake’, occurring mainly via the neuronal transporters, appears to 
be the major mechanism by which glutamate is released during ischaemia 
(Jabaudon etal., 2000; Rossi etal., 2000).
A vicious cycle leads to delayed neuronal death
Surprisingly, despite intensive research, the mechanisms underlying 
glutamate induced neuronal death are not fully understood. Such death may 
be either acute, or delayed, depending upon the duration and intensity of 
glutamate exposure. Moreover, the different classes of glutamate receptor 
(NMDA, AMPA and metabotropic) do not participate equally in the ensuing 
death, hence the receptor profile of the affected tissue is critical (Meldrum & 
Garthwaite, 1990). Following ischaemic glutamate release, NMDA receptor 
activation is of central importance, and its pharmacological blockade is
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neuroprotective in various models (Fujisawa etal., 1993; Kaku et al., 1993). 
Blockade of AMPA receptors can be equally protective (Fujisawa et al., 1993) 
though it does not protect all regions (Gill et al., 1992), and the protective 
actions of the AMPA antagonist NBQX may simply have been mediated 
through lowering of core temperature in vivo (Nurse & Corbett, 1996). Less 
comprehensive research into metabotropic receptor antagonism has been 
undertaken. The available evidence therefore points towards ionotropic 
glutamate receptors, particularly the NMDA receptor, as primarily responsible 
for excitotoxicity. Following sustained NMDA receptor activation the 
consequent rises in intracellular Ca2+ may trigger events such as calpain and 
lipase activation as well as free radical generation and activation of Ca2+- 
ATPase, which will further deplete energy (Meldrum & Garthwaite, 1990).
In models of excitotoxicity, prolonged exposure to NMDA elicits 
neuronal death rapidly, whereas brief exposure produces a delayed death 
more akin to that seen following ischaemia (Dawson et al., 1991; Strijbos et 
al., 1996). Mechanistically it has been proposed that a cycle may be set in 
motion linking initial (non-toxic) NMDA receptor stimulation, with Na+- 
channel activation, further glutamate release, and eventually cell death as a 
consequence of persistent NO production see Fig 4.1.
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Figure 4.1 A vicious cycle to neuronal death, from Strijbos etal, 1996
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This cycle was first proposed to occur in cultured striatal neurones 
which were found to release glutamate for about 8 h following a transient (5 
min) NMDA stimulation (Strijbos et al., 1996). The glutamate increase was 
prevented either by blocking NMDA receptors, or voltage-gated Na+ 
channels. The voltage-gated Na+ channel generates action potentials in 
excitable cells, but its blockade by compounds such as lamotrigine or 
tetrodotoxin confers neuroprotection in many models of ischaemia (Probert et 
al., 1997; Smith & Meldrum, 1995; Weber & Taylor, 1994; Wiard et al., 1995). 
Limiting Na+ influx in this way may have several beneficial effects including; a 
reduction in cellular energy expenditure, an increase in the voltage-sensitive 
block of the NMDA-operated channels by Mg2+, or preventing reversal of the 
glutamate transporter as outlined above. Cell death in the striatal model was 
delayed, becoming maximal only after 16 h, and could be inhibited by post­
insult application of the voltage-gated Na+ channel inhibitor tetradotoxin 
(TTX), NMDA receptor blockade with MK801, or NOS inhibition with L-NNA 
(Strijbos etal., 1996).
The role of NO in excitotoxicity
As described above, excitotoxicity is most commonly investigated by 
challenging dispersed neuronal cultures briefly with glutamate or NMDA and 
then monitoring cell survival over the next day (Taylor & Meldrum, 1995). 
Some studies showed clear neuroprotection by NOS inhibition (Dawson et 
al., 1991; Izumi etal., 1992b; Strijbos etal., 1996) or knockout of the nNOS 
gene (Dawson etal., 1996), but others found no causal relationship between 
NO and cell death (Demerle-Pallardy etal., 1991; Hewett etal., 1993; 
Pauwels & Leysen, 1992). The potential causes of such discrepancies have 
been discussed previously (see chapter 1).
More limited experiments have used freshly-prepared brain slices, 
which should be more representative of the intact brain, but the results have 
been similarly discordant. One study on hippocampal slices found NOS 
inhibition to be protective (Izumi etal., 1992a), while another, using 
seemingly identical methods, found no protection (Garthwaite & Garthwaite, 
1994). An obvious limitation here is the short recovery period allowed 
(typically 90 min), which may not allow time for a more delayed NO-
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dependent death to become manifest. Unfortunately, experiments 
undertaken in vivo do not clarify matters, (see Moncada et al., 1992;
Fujisawa etal., 1993; Lemer-Natoli etal., 1992; Globus etal., 1995). A 
complication here is the non-selectivity of the NOS inhibitors influencing 
blood flow through inhibition of the endothelial NOS (eNOS).
Aims
In view of the unresolved contradictions and the potential problems with 
experimental models used beforehand, this study has re-examined the role of 
NO in NMDA-induced neurodegeneration using organotypic hippocampal 
slice cultures as the model. Such cultures are increasingly used because 
they retain their complex cellular organization and electrophysiological 
properties, and can survive for weeks to months (Gahwiler, 1981; Stoppini et 
al., 1991). Moreover, hippocampal slice cultures show a similar regional 
vulnerability to that found in vivo in response to ischaemic and excitotoxic 
insults (Pringle etal., 1997; Strasser & Fischer, 1995; Vornov etal., 1991). 
Consequently, provided that the endogenous NO signalling pathway remains 
intact in such preparations, they should represent good experimental material 
with which to test the hypothesis that NO contributes to excitotoxic damage.
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4.2 METHODS
Hippocampal slice culture preparation
Slice cultures were prepared according to the method of (Stoppini et al., 
1991). Sprague-Dawley rats (7-8 days old, from Charles River, UK Limited) 
were killed by decapitation and associated exsanguination as approved by 
the British Home Office and local ethics committee. The brains were 
immersed in ice-cold minimal essential medium supplemented with 10 mM 
Tris, and penicillin/streptomycin (100 U/ml and 100 pg/ml respectively). 
Hippocampi were rapidly dissected out and 400 pm transverse sections 
prepared on a Mcllwain tissue chopper (Mickle Laboratory Engineering Ltd, 
Surrey, UK). Slices were separated mechanically and randomised before 
being placed onto culture inserts (Millicell-CM: Millipore, Watford, UK, 4 
slices per insert). Culture inserts were incubated in 6-well plates with 1 ml 
media consisting of minimal essential medium (50%), heat-inactivated horse 
serum (25%), Hank’s balanced salt solution (25%), and 
penicillin/streptomycin (as above), buffered to pH 7.3 with Tris (5 mM) and 
NaHC03  (0.35 g/100 ml). Cultures were incubated at 37°C in 5% CO2 for 4 
days and subsequently at 33°C in 5% CO2 until use at 12-14 days in vitro. 
Inserts were transferred to fresh media after 1, 4, 7, and 10 days.
General protocols
Serum may protect against glutamate excitotoxicity in cortical neurones and 
cerebellar cultures (Dux et al., 1992; Wood etal., 1997) while HEPES buffer 
contributes to O2*" -dependent NO consumption, presumably forming ONOO' 
(see chapter 3), experiments were therefore performed on cultures pre­
incubated for 1 h in serum-free/HEPES-free medium (SFM) consisting of: 
minimal essential medium without HEPES (74 %), Hank’s balanced salt 
solution (24 %), B27 supplement without antioxidants (2 %) 
penicillin/streptomycin (as above) and glucose (0.5 g/l). O2*' -dependent NO 
consumption is also brought about by the action of laboratory lighting on 
riboflavin (see chapter 3) a universal constituent of culture media. Care was 
therefore taken at all times to keep exposure of the slices to light to a
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minimum by performing all media changes with the laboratory lighting 
switched-off and limiting microscopic observation to the beginning and end of 
the experiments; separate cultures were therefore used for each time point.
NMDA stimulations
Cultures were transferred to SFM containing NMDA (0.1-1 mM) for 15 min. 
After a brief wash in fresh SFM, cultures were replaced in the same SFM 
used for preincubation and recovered for 0-72 h. The NOS inhibitors L- 
nitroarginine (L-NNA) and 7-nitroindazole (7-NI) were present 15 min prior to 
addition of NMDA and throughout the stimulation and recovery. MK801 (10 
pM) was added during the recovery period only.
cGMP accumulation
Cultures were exposed to the NO donor DEA/NO and/or NMDA for 2-15 min 
in the presence of the general phosphodiesterase inhibitor IBMX, 1 mM, (10 
min preincubation). When used, the NOS inhibitors L-NNA or 7-NI were pre­
incubated with the slices for 15 min, and remained present during NMDA 
stimulation. Individual slices were inactivated by immersion in boiling buffer 
(Tris 50 mM, EDTA 4 mM, pH 7.5, 150 pl/slice). Protein was determined by 
the bicinchoninic acid method and cGMP quantified by radioimmunoassay. 
Alternatively slices were fixed for immunohistochemistry (see below). 
Statistical differences were analysed using one-way ANOVA with Dunnett’s 
post hoc test; P values of < 0.05 were regarded as significant.
Immunohistochemistry
Slices were fixed (4% paraformaldehyde in 0.1 M phosphate buffer) for at 
least 30 min (overnight for cGMP staining) before being permeabilized with 
0.1% Triton X-100 in Tris-buffered saline for 20 min. Non-specific binding 
was reduced by incubation (1 h) in 5-10% serum of the secondary antibody 
host (see Table 2.2). Primary antibodies were applied for 48 h at appropriate 
concentrations (Table 2.2). Slices were further washed in Tris-buffered saline 
before being incubated overnight in the appropriate biotinylated or 
fluorescent secondary antibody (Chemicon International Ltd, Harrow, UK or
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Vector Labs, Peterborough, UK). Biotin staining was developed using a 
standard avidin-peroxidase complex (Vectastain Elite ABC kit; Vector Labs), 
with diaminobenzidine as the substrate. For cGMP co-localisation studies, 
biotin staining was visualised with avidin/fluoroscein (Vector Labs). Slices 
were mounted on gelatin-coated slides and images captured on a PC running 
KS300 Imaging System (Imaging Associates, Thame, UK) using a JVC KY- 
F55B colour video camera (JVC Professional Products; London, UK) 
attached to a Leica DMRD microscope (Leica, Cambridge, UK). Slices 
double-labelled with cGMP/GFAP were imaged using a Leica TCS SP 
confocal microscope.
Assessment of neuronal damage
Propidium iodide (PI) is a highly polar fluorescent dye that can enter dying or 
injured cells and intercalate with their DNA and RNA to produce a red/yellow 
fluorescence at excitation 493 nm and emission 630 nm (Newell et a/., 1995). 
Cultures were placed into SFM containing PI (5 pg/ml) 1 h prior to stimulation 
and viability was assessed after 30 minutes. Any cultures in which neuronal 
damage was observed were discarded (< 5 % of slices). PI remained in the 
medium throughout the experimental and recovery period. At the termination 
of experiments fluorescence images (focussed through the brightest plane of 
the slice) were captured using a Leica DM IRB inverted microscope. Analysis 
was undertaken using Scion Image Version 4.0.2. (written by Wayne 
Rasband at the U.S. National Institutes of Health and available as free 
download from www.scioncorp.com). To aid identification of the areas of 
CA1, CA3 and the dentate gyrus all slices underwent a further overnight 
incubation at 4°C and images were re-captured. Maximal fluorescent signal 
(100 % death) was determined from those slices that had undergone 
treatment giving close to maximal death (1 mM NMDA or 3 pM myxothiazol). 
The area of PI fluorescence above background in each region was 
determined using the ‘density slice’ function contained in Scion Image. To 
ensure areas of PI correlated with areas of neuronal death, cultures were 
fixed overnight in 4 % paraformaldehyde and stained with the Nissl stain 
thionin (data not shown; Pringle eta !., 1997; Strasser & Fischer, 1995;
Vornov etal., 1991). Statistical differences were analysed using one-way
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ANOVA with Bonferroni correction for multiple comparisons; P values of < 
0.05 were regarded as significant.
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RESULTS
Despite the increasing use of organotypic hippocampal slice cultures, the 
extent to which the NO signalling pathway is preserved in these preparations 
is unknown; accordingly, the first objective was to address this question.
Immunohistochemical characterisation
In good agreement with findings in vivo (Valtschanoff eta !., 1993) 
immunohistochemistry revealed nNOS-positive staining in all regions of the 
hippocampal slice cultures after 12-14 days in vitro (Fig. 4.2A-C). The 
majority of this staining was concentrated in the dentate gyrus (DG) and 
subiculum where a proportion of cells may form back projections to CA1 in 
vivo (Seress et al., 2002). The pyramidal layers (CA1-3) contained only a 
small proportion of the total nNOS positive cell bodies. nNOS positive cells 
appeared mainly rounded in shape, consistent with their primary 
colocalization with GABA in intemeurones (Valtschanoff ef a/., 1993), 
although occasional bipolar neurones were stained in the CA3 area (Fig. 
4.2A, arrow). Notably there was no appreciable staining in the CA1 pyramidal 
cells themselves, consistent with a majority of studies (Lin & Totterdell,
1998). A network of nNOS positive fibres was evident throughout the slice, 
however, particularly in CA2 (not shown).
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Figure 4.2 Distribution of nNOS
Photomicrographs of nNOS staining in hippocampal slice cultures. (A) positive neurones can 
be found in all layers of CA3; stratum oriens (so), stratum pyramidale (sp) and stratum 
radiatum (sr). Positive cells in the sp are clearly bipolar in shape (arrow) and not pyramidal.
(B) A clear demarcation may be seen between CA1 (little staining) and the subiculum (many 
nNOS positive cells). (C) Small nNO S positive neurones are evenly distributed throughout 
the dentate gyrus. Scale bars = 50 pm.
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In vivo, eNOS staining is found in endothelial cells at all stages of rat 
brain development (Topel etal., 1998). Accordingly, eNOS labelling in the 
slices was evident in capillaries, which remained as a network at 12 days in 
vitro (Figs 4.3A, B) but degenerated after a month in culture to leave only a 
few isolated eNOS positive cells (not shown). Although eNOS staining has 
been reported in CA1 pyramidal neurones, this has now been considered an 
artifact (Demas etal., 1999); in agreement, we detected no eNOS staining in 
CA1 pyramidal neurones.
Figure 4.3 Distribution of eNOS (A) Low power (scale bar = 100 fim) and (B) high power 
(scale bar = 50 fj.m) photomicrographs of eNOS-positive endothelial cell networks in 
hippocampal slice cultures.
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We next sought to determine the existence of the downstream components 
of the endogenous NO signalling pathway. Upon binding NO, the guanylyl 
cyclase (GC)-coupled NO receptors synthesise cGMP from GTP (Ignarro, 
1991; Waldman & Murad, 1987). In control slices (incubated with IBMX to 
inhibit phosphodiesterase activity) the unstimulated level of cGMP amounted 
to about 20 pmol/mg protein. Following a 5 min stimulation of slices with 
increasing concentrations of the NO donor DEA/NO (1-100 |iM), cGMP 
accumulation increased to reach a maximum of about 90 pmol/mg protein 
(Fig. 4.4A). Immunohistochemistry following this maximum DEA/NO 
stimulation revealed a large, but non-uniform, increase of cGMP staining 
throughout the slice in comparison to IBMX controls (Figs 4.4B, C). This 
staining was evident in neuronal-like cell bodies throughout CA3 and the DG 
(arrows, Fig. 4.4C), but was more diffuse in the region of CA1 (Fig. 4.4C). In 
other regions (CA3, Fig. 4.4D) a network of cGMP-positive fibres was 
evident, the origin of which appeared neuronal because in some cases they 
could be traced back to neurone-like cell bodies. The findings are in good 
agreement with the pattern of cGMP staining observed in acute hippocampal 
preparations (Teunissen etal., 2001; van Staveren etal., 2001). To identify 
the cell type responsible for cGMP staining in CA1 we undertook dual 
labelling with antibodies against GFAP (which stains astrocytes) and cGMP. 
Co-localisation (yellow/orange, Figs 4.5E, F) of cGMP (green, Figs 4.5A, B) 
and GFAP (red, Figs 4.5C, D) staining was seen in CA1, while occasional 
large neurone-like cell bodies were cGMP- but not GFAP-positive (arrows 
Fig. 4.5F).
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Figure 4.4 cGMP distribution and accumulation
(A) cGMP accumulation was measured 5 min following stimulation with the NO donor 
DEA/NO in a range of concentrations (n = 10-15 slices). (B) Photomicrograph of cGMP 
staining in a hippocampal slice culture following exposure to IBMX alone. (C) After a 5 min 
maximal (100 pM) DEA/NO stimulation, cGMP staining is evident in neuronal-like cells in 
CA3 and the dentate gyrus (DG, arrows) while a more diffuse staining is seen in CA1. (D) A 
clear network of cGMP positive fibers is evident throughout the slice. Scale bars = 100 pm 
(B,C) or 10 pm (D).
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Figure 4.5 cGMP co-localises with GFAP in CA1
Following a maximal DEA/NO stimulation (100 jiM, 5 min) confocal microscopy at low 
(A,C,E) and high (B,D,F) magnifications reveals that the staining for cGMP (green; A,B) and 
GFAP (red; C,D) partially co-localises in the CA1 region (yellow; E,F). Occasional neurone­
like cells were cGMP-positive but GFAP-negative (arrows, F). Scale bars = 100 |j.m (A.C.E) 
or 25 pm (B,D,F).
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NMDA-evoked neuronal degeneration
Hippocampal slice cultures exposed to a brief (15 min) NMDA stimulation of 
graded intensity (100 pM-1 mM) were recovered for up to 24 h. Neuronal 
viability was assessed in the separate regions of the hippocampus by PI 
staining. Following exposure to 100 and 300 pM NMDA, there was a regional 
susceptibility to damage in the order CA1>CA3>DG whereas, with 1 mM 
NMDA, the cell death was relatively non-selective (90% in both CA1 and 
CA3). Damage intensity was NMDA concentration-dependent (Figs 4.6A,B) 
and, at 300 pM, was delayed in onset by up to 6 h and maximal by 16 h (Fig. 
4.6C). In the same experiments, addition of the non-competitive NMDA 
receptor antagonist MK801 (10 pM) during the 24 h recovery from NMDA 
afforded almost complete protection (Fig 4.6D).
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NMDA (300 pM)
Figure 4.6 NMDA stimulations
(A) Representative photomicrographs of slices stained with PI 24 h following brief (15 min) 
stimulation with NMDA at concentrations of 100 pM (1), 300 pM (2) and 1 mM (3). (B) 
Summary data (means ± SEM; n = 12 slices) is expressed as percentage death in the three 
major hippocampal regions (CA1, CA3 and DG). (C) Time course of cell death in the 
subfields (mean ± SEM; n =12 slices) following stimulation with NMDA (300 pM, 15 min). (D) 
Summary data (mean ± SEM, n = 11-16 slices) showing percentage death in slice regions 24 
h following brief (15 min) NMDA stimulation (100 or 300 pM), and protection by the NMDA 
antagonist MK801 (10 pM), which was added directly following NMDA stimulation.*P<0.05 
versus corresponding NMDA stimulation. Insets are representative photomicrographs of 
slices stimulated with NMDA (300 pM) without (1) or with (2) MK801 (10 pM).
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Coupling of NMDA receptors to NO formation: role in NMDA toxicity
In the hippocampus and elsewhere, NMDA receptor activation leads to NO 
synthesis and subsequent cGMP accumulation (East & Garthwaite, 1991; 
Garthwaite et al., 1989). In agreement with findings using acute slices (East 
& Garthwaite, 1991) exposure of the slice cultures to NMDA generated a 
cGMP response that was maximal at 100-300 pM (Fig. A ik ). The NOS 
inhibitor 7-NI (30-300 pM) concentration-dependently decreased the 
response back to basal levels, an effect that was replicated by another 
inhibitor, L-NNA (300 pM).
To examine the possible protective effect of NOS inhibition on NMDA- 
induced damage, L-NNA or 7-NI (both at 300 pM) was added 15 min prior to, 
during, and after exposure to NMDA (100 and 300 pM). No protection was 
seen following a 24 h recovery (Figs 4.7B, C). Surprisingly while L-NNA 
treated slices retained the same degree of damage as NMDA-treated 
controls, those treated with 7-NI exhibited a 3-fold increase in cell death in 
the CA3 region (to about 70%) following exposure to 300 pM NMDA. As, 
under the same conditions, the DMSO vehicle for 7-NI had no effect on 
tissue viability (data not shown) the additional toxicity of 7-NI may arise from 
another activity of the compound, such as monoamine oxidase inhibition 
(Desvign esetal., 1999).
Because neuronal death in vivo may take several days to complete, 
we checked the progress of damage in the slice cultures over a recovery 
period longer than 24 h. With 72 h recovery, cell death induced by NMDA 
(100 pM) was not significantly higher than that seen at 24 h. With 300 pM 
NMDA, however, there was a slight increase in damage in CA1. Addition of 
L-NNA (300 pM) for the duration of the 72 h recovery had no effect upon the 
cell death induced by either 100 pM or 300 pM NMDA (Fig. 4.7D).
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Figure 4.7 Effect of NOS inhibition
(A) The effects of NOS inhibitors L-NNA (300 pM) or 7-NI (30-300 pM) on cGMP 
accumulation following 15 min stimulation with NMDA (100 or 300 pM) were determined by 
radioimmunoassay. Results from 7-8 slices are expressed as mean ± SEM, ns = no 
significant difference versus IBMX control. (B) Summary data (mean ± SEM, n = 12 slices) 
showing percentage death of hippocampal regions 24 h following 15 min NMDA stimulation. 
L-NNA (300 pM) and 7-NI (300 pM) were added 15 min before the NMDA and remained 
present throughout the stimulation and recovery. (C) Representative photomicrographs of PI 
stained slices at 24 h. Treatments were as follows: (1) control slice, (2) NMDA 300 pM, (3) 
NMDA + L-NNA, (4) NMDA + 7-NI. (D) Summary data (mean ± SEM, n = 12 slices) showing 
the percentage death in hippocampal slice regions following recovery for 1 or 3 days after a 
15 min NMDA stimulation (100 or 300 pM) in the absence or presence of L-NNA (300 pM). 
*P<0.05 versus corresponding NMDA stimulation with 24 h recovery.
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To gauge the intensity of NO accumulation following NMDA receptor 
activation, comparison was made of the ensuing cGMP response relative to 
that produced by exogenous NO, delivered from DEA/NO. With NMDA (100 
pM), the cGMP response was stable between 2 and 15 min exposure, 
indicating a steady-state (Fig. 4.8A). With DEA/NO at a maximal 
concentration (100 pM) cGMP accumulated to 2.5-fold higher levels than 
observed with NMDA, though the amplitude gradually declined after 2 min 
(Fig. 4.8B). The lower response with NMDA may be because, by increasing 
intracellular Ca2+, NMDA receptor activation diminishes the enzymatic activity 
of the NOgcR (Kazerounian etal., 2002) or, alternatively, NMDA-evoked 02*' 
formation (Lafon-Cazal et al., 1993) may reduce the effective NO 
concentration by forming ONOO'. To test these and other possibilities, 
DEA/NO and NMDA were co-administered for 2 min (Fig. 4.8C). Although the 
response to DEA/NO was reduced, cGMP levels were still twice those 
obtained with NMDA alone at maximal concentrations, suggesting that the 
peak NMDA-stimulated NO accumulation was lower than that required to 
maximally-activate the NOgcR.
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Figure 4.8 Accumulation of cGMP in response to NMDA or DEA/NO
All data are means ± SEM (n = 8-12 slices). (A) Time course of cGMP accumulation 
following stimulation of hippocampal slice cultures with NMDA (100 pM). (B) Time course of 
cGMP accumulation following exposure to DEA/NO (100 pM). (C) cGMP accumulation 
measured 2 min following stimulation with NMDA (100 and 300 pM) compared with maximal 
stimulation by DEA/NO (100 and 300 pM) or DEA/NO + NMDA; *P<0.05 versus respective 
DEA/NO concentrations alone.
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4.4 DISCUSSION
The NO signalling pathway in hippocampal slice cultures
The essential first step was to characterise the preservation of the relevant 
pathway in organotypic hippocampal slice cultures. This had not previously 
been carried out despite such cultures being routinely used in physiological 
and pathological investigations of phenomena in which NO has been 
suggested to participate, such as long term potentiation (Muller et al., 1993), 
glutamate excitotoxicity and oxygen glucose deprivation (OGD) (Lahtinen et 
a i, 2001; Pringle etal., 1997), or neuronal development (Stoppini etal., 
1993). The results showed that the distributions of nNOS, eNOS and cGMP 
in slice cultures correspond well with those reported for the hippocampus in 
vivo or in acute slice preparations. This, together with functional evidence for 
effective coupling of NMDA receptor activation to NO formation and 
subsequent cGMP accumulation, commends the slice cultures for research 
on the NO signalling pathway.
Role of NO in NMDA neurotoxicity
In keeping with previous results using slice cultures (Adamchik & Baskys, 
2000; Vornov et ai, 1991) brief (15 min) exposure to NMDA elicited delayed 
neuronal cell death (preferentially of CA1 pyramidal neurones) that could be 
prevented by post-application of MK801, indicating that the death involves a 
secondary exposure of the neurones to glutamate. The preferential 
susceptibility of CA1 neurones may be a function of differential receptor 
expression (higher NMDA receptors density), and other selective cellular 
changes, such as increased expression of protective genes in other cells 
(Lipton, 1999).
Exhaustive tests using different NO synthase inhibitors, stimuli of 
differing intensity, and differing recovery periods, however, failed to provide 
any indication that NO contributes to the ensuing damage, by respiratory 
inhibition or otherwise, despite clear evidence from cGMP measurements 
that activation of NMDA receptors couples to NO generation. Estimation of 
the ambient NO concentrations existing within the stimulated slice tissue 
provides a simple explanation for the negative results. Using the GC-coupled
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NO receptor as a biosensor, the degree of receptor activation obtained 
following exposure to maximal concentrations of NMDA (measured as cGMP 
accumulation) could be augmented about 2-fold by addition of exogenous 
NO, suggesting that the endogenous levels were sufficient to give only half- 
maximal receptor stimulation. Whether based on cGMP responses to NO at 
steady-state in brain cells (Griffiths & Garthwaite, 2001), or on measurements 
of NO-evoked GC activity in cell-free preparations (Bellamy et al., 2002), the 
half-maximally effective concentration of NO on GC-coupled receptors is 
about 2 nM. Hence, physiological concentrations of NO appear all that NMDA 
receptor stimulation is able to generate within the slices at steady-state. In an 
analogous approach used to explore the pathological role of NO in acute 
striatal slices, the peak NO concentration occurring following a period of 
metabolic stress (oxygen and glucose deprivation) was found to be similar, 
about 1 nM (Griffiths et al., 2002a), indicating that the low apparent NO levels 
in the hippocampal slice cultures exposed to NMDA do not represent an 
oddity.
It should be noted that using NOgcR activity to estimate the NMDA 
stimulated rise in NO concentration in brain slices assumes that both NO and 
cGMP levels increase evenly across the slice. This would depend upon the 
distribution of both the NMDA receptors and NOgcR in the tissue. However, 
without the requisite detailed immunohistochemistry the possibility of 
localized microdomains of high NO concentration cannot be ruled out.
The notion that NO rises to much higher (toxic) levels in pathological 
conditions appears to stem from the initial measurement of NO in cerebral 
ischaemia/reperfusion in vivo, where concentrations in the low micromolar 
range were recorded using an electrochemical probe (Malinski etal., 1993). 
However, it has since become evident that such probes are prone to 
interference from other substances such as ascorbate and tyrosine (Lin et al., 
1996; Stingele et al., 1998). More recent measurements give the much lower 
value of 20 nM NO in the ischaemic penumbra in vivo (Lin etal., 1996), and 
16 nM or less following local stimulation with NMDA in vivo (Lin etal., 1996; 
Wu etal., 2001). Consequently, although much lower than previously 
assumed, the estimated maximal NMDA-induced NO concentration in the 
hippocampal slice cultures is compatible with recent direct measurements
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made in vivo. Likewise, in dispersed cultures or brain slices in vitro, estimates 
for the prevailing NO concentration on exposure to NMDA or following 
repetitive electrical stimulation have yielded values in the low nanomolar 
range or below (Liu etal., 1997; Shibuki & Kimura, 1997).
There is no evidence that NO in low nanomolar concentrations can be 
directly toxic to neurones or other cells. Nevertheless, there is evidence that 
nNOS can contribute to damage following both excitotoxic stimulation and 
cerebral ischaemia (Ayata etal., 1997; ladecola, 1997), and see chapter 1. 
Rather than serve as a toxin in this situation, NO might act through 
physiological cGMP-dependent mechanisms to potentiate synaptic 
transmission (Bon & Garthwaite, 2001; Huang & Hsu, 1997; Nikonenko etal., 
2003), thereby contributing to cell death by eliciting an additional excitotoxic 
load on the neurones at risk (Gao etal., 1999; Miyazaki etal., 1993).
Other calcium-dependent effectors
The absence of evidence that NO causes toxicity in hippocampal slice 
cultures suggests that other, probably Ca2+-dependent, enzymes may be 
involved, including phospholipases, protein kinases, endonucleases and 
calpains. Of these, calpain is a Ca2+-activated neutral cysteine protease 
whose activation appears very important in both focal and global ischaemia. 
Two calpain enzymes p- and M-calpain are activated by micromolar and 
millimolar Ca2+ respectively. Activated caplain attacks many cytoskeletal 
proteins including spectrin and tubulin (Saido etal., 1994), it leads to 
loosening of the post-synaptic density (Dosemeci & Reese, 1995) and can 
break down microtubules. Following global ischaemia most calpain activation 
can be prevented by treatment with MK801, and calpain inhibitors have 
attenuated cell death in both focal (Bartus et al., 1994) and global models 
(Lee etal., 1991) or in ischaemic cerebrocortical cell cultures (Wang et al.,
1996). Furthermore, calpain inhibition can reduce toxicity following NMDA 
stimulation of cultured hippocampal cells (Brorson etal., 1995), and improves 
recovery of synaptic responses in hippocampal slice cultures (Bednarski et 
al., 1995).
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4.5 CONCLUSION
The results in this study corroborate recent in vivo findings that cytochrome c 
oxidase is not inhibited by nitric oxide, either in physiologic conditions or 
during reoxygenation after a brief anoxic period in adult rats (De Visscher et 
al., 2002). Taken together, these studies question the concept of NO rising to 
toxic concentrations as a result of NMDA receptor activation.
CHAPTER 5: HIPPOCAMPAL SLICE CULTURES AND DAMAGE BY 
EXOGENOUS NO
5.1 INTRODUCTION
To complement the study in chapter 4, the toxicity of exogenous NO to 
hippocampal slice cultures was examined. The principal mechanisms by 
which NO may cause neuronal death, and the problems of working with older 
generations of NO donors, have been discussed previously in chapters 2 and 
3.
Using exogenously applied NO, recent work has confirmed that NO 
donors may kill neurones by inhibiting respiration. One study (Brorson etal.,
1999) applied older NO donors (SNAP, SIN-1, SNOC) or NONOates 
(DEA/NO, Spermine/NO) to cultured hippocampal neurones, and found that 
NO concentrations of ~2 pM caused substantial ATP depletion, which 
correlated with up to 40% cell death. Later, experiments using PC-12 cells 
(Bal-Price & Brown, 2000) used steady-state levels of 1-3 pM NO released 
from DETA/NO or SNAP causing mitochondrial membrane potential to fall, 
ATP depletion and necrosis (in the absence of glucose) or, when glucose 
was present, apoptosis. Since these results were replicated over a similar 
timecourse by application of the respiratory inhibitors myxothiazol, rotenone 
and azide, respiratory inhibition was deemed responsible. Finally, similar 
methods were applied in a subsequent study. Cerebellar granule cells were 
susceptible to respiratory inhibition by concentrations of ~1-2 pM NO 
released from NO donors or NO saturated water (Bal-Price & Brown, 2001).
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Aims
The principle aim of this study was to determine the concentration of 
exogenous NO required for substantial neuronal death in hippocampal slice 
cultures by means of respiratory inhibition.
5.2 METHODS
Hippocampal slice culture preparation and assessment of neuronal 
damage
See chapter 4.2
Exposure to NO and respiratory inhibitors
To assess the effect of a continuous application of exogenous NO on 
hippocampal slice viability, cultures were exposed to increasing 
concentrations of DETA/NO. Cultures were exposed to freshly prepared 
DETA/NO (3 mM) in SFM (replenished every 24 h) and viability was 
assessed following 24, 48 or 72 h. Control cultures were exposed in the 
same way to 1.2 mM DETA/NO previously left to decompose at 37°C in SFM 
for at least 8 half-lives (1.2 mM being the maximum concentration of 
decomposed DETA/NO that would be present after 24 h). Alternatively, 
cultures were exposed to a faster-releasing donor, NOC-12, or the 
appropriate concentration of decomposed donor. For comparison, cultures 
were exposed to the respiratory inhibitors myxothiazol (3 pM) or sodium 
cyanide (NaCN, 3 mM) for up to 24 h. NO release from donor compounds 
was measured by electrochemical probe (ISO-NOP, see chapter 2.3).
ATP measurement
Following exposure to NO from donor compounds or respiratory inhibitors as 
above, slices were sonicated in ice-cold trichloroacetic acid (0.5 M; 200 
pl/slice). Protein was separated by centrifugation (15,000 g for 15 min), 
resuspended in 0.1 M KOH and quantified by the bicinchoninic acid method. 
ATP levels in the supernatant were determined by a D-luciferin/luciferase 
ATPLite™-M assay kit (Packard Bioscience, Reading, UK). Statistical
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differences were analysed using one-way ANOVA with Dunnett’s post hoc 
test; P values of < 0.05 were regarded as significant.
Measurement of NO consumption
Homogenates from acutely prepared hippocampus (8 and 19 day old rats), or 
hippocampal slice cultures (12 and 19 days old) were centrifuged at 10,000g 
for 5 min and resuspended at a final concentration of 0.1 mg protein/ml in tris 
buffer, supplemented with whole rat brain supernatant (10 %, see chapter 
6.2) and further sonicated before use. NO consumption was measured in 1 
ml samples following addition of DETA/NO (200 pM), using an NO electrode 
(ISO-NOP, see chapter 2.3).
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5.3 RESULTS
Toxicity of exogenous NO
Given the apparent lack of participation of endogenous NO in NMDA toxicity, 
further tests were carried out to evaluate the sensitivity of the tissue to 
exogenous NO. To determine the concentration of NO required to elicit 
damage in hippocampal slice cultures, the slow-releasing NO donor 
DETA/NO was applied for up to 3 days. When measured using an 
electrochemical probe, DETA/NO (3 mM) generated a steady plateau of 4.5 ± 
0.2 pM NO (n = 3) at 33°C after 3 h pre-incubation (needed to allow an 
equilibrium to be formed between the rate of NO release and the rate of NO 
consumption by autoxidation). Application of this DETA/NO concentration to 
the slice cultures for a prolonged interval (2 days) caused only a relatively 
minor degree of death (10 % or less) that was preferentially located in CA3 
(Fig. 5.1 A, B). After an additional day’s exposure, the damage in all regions 
was increased with, again, that in CA3 predominating somewhat (Figs 5.1 A, 
B). A small lowering of the DETA/NO concentration (to 2 mM) greatly 
reduced the damage observed after 3 days exposure (Fig. 5.1 B, inset). 
Decomposed donor had no effect on slice viability at either of the 
concentrations tested (data not shown).
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Figure 5.1 Toxicity of DETA/NO in hippocampal slice cultures
(A) Representative photomicrographs of slices continuously exposed to DETA/NO (3 mM) 
for 1, 2 or 3 days (labelled 1-3 respectively) and stained using PI. (B) Summary data (mean 
± SEM; n = 12-16 slices) expressed as percentage death in the three major hippocampal 
regions. The effect of a lower DETA/NO concentration (2 mM) at 3 days is also shown for 
comparison in the inset.
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Recent evidence in dispersed cultures, found that NO may elicit neuronal 
death by respiratory inhibition and subsequent ATP depletion (Bal-Price & 
Brown, 2001; Brorson et al., 1999). To determine the vulnerability of the slice 
cultures to this intervention, they were exposed to the mitochondrial complex 
III inhibitor, myxothiazol (3 pM). Complete neuronal death ensued within 24 h 
(Figs 5.2A.B).
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Figure 5.2 Toxicity of myxothiazol in hippocampal slice cultures
(A) Representative cell death following continuous exposure to myxothiazol (3 |aM) for 6, 10, 
18 and 24 h (labelled 1-4 respectively). (B) Summary data (mean ± SEM; n = 12) expressed 
as percentage death in the three major hippocampal regions.
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In addition, when measured 6 h following treatment, hippocampal slice ATP 
levels were significantly decreased by treatment with either myxothiazol or 
another respiratory inhibitor, NaCN (3 mM), but were unaffected by 3 mM 
DETA/NO (Fig. 5.3). NaCN, like myxothiazol, caused complete cell death 
within 24 h (not shown).
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Figure 5.3 Whole slice ATP
Measurements (mean ± SEM; n = 8 slices) taken 1 to 6 h following treatments with 3 mM 
DETA/NO and 3 |jM myxothiazol; the effect of a 6 h exposure to NaCN (3 mM) is also 
shown. *P<0.05 versus control ATP at 1 h.
Since high DETA/NO concentrations failed to cause toxicity, a faster NO- 
releaser, NOC-12 (half-life = 160 min at 33°C), was used to generate higher 
NO concentrations. Slices were exposed to NOC-12 (0.3-3 mM) and ATP 
levels were measured at 4 h, and death at 24 h. At 3 mM, NOC-12 
significantly decreased ATP levels and caused a generalised 60-80 % death 
(Figs 5 .4A - C). In contrast, lower NOC-12 concentrations (0.3 and 1 mM) 
caused no obvious slice toxicity and little or no change in ATP levels. From 
measurements of the NO concentration generated by 0.3 mM NOC-12 (2.7 ± 
0.2 pM after 5 min at 33°C; n = 3), it can be calculated (Schmidt et ai, 1997) 
that 1 and 3 mM NOC-12 would produce peak NO concentrations of 6 and 10 
pM respectively.
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Figure 5.4 NOC-12 induced cell death in hippocampal slice cultures
(A) Representative photomicrographs of slices 24 h after exposure to 1 or 3 mM NOC-12 
(labelled 1 and 2 respectively) and stained with PI. (B) Summary data for the toxicity of 3 mM 
NOC-12 (means ± SEM; n = 12 slices) expressed as percentage death in the three major 
hippocampal regions. (C) Whole slice ATP measurements (mean ± SEM; n = 8 - 16) taken 4 
h following the above exposures.
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NO consumption by hippocampal slices
Work in the lab has previously described the consumption of NO by both 
isolated cerebellar cells and whole rat brain homogenates (Griffiths & 
Garthwaite, 2001; Griffiths etal., 2002b). Furthermore, semi-purified 
homogenates retained activity when the pellet and supernatant fractions 
were recombined (see fig 6.1). We questioned if tissue from acutely isolated 
hippocampal slices can consume NO in a similar manner, and whether 
hippocampal slice cultures differed. Upon addition of 200 pM DETA/NO to 
buffer, NO levels rose sharply in accordance with earlier results (fig 3.3A), 
reaching 150 nM within 1 min (fig 5.5A.B). In contrast, all samples from 
acutely isolated hippocampal slices, and hippocampal slice cultures, 
consumed NO in a similar manner to before (see figure 6.1 and Griffiths et 
al., 2002b), such that NO remained below 25 nM for at least 10 min, before 
rising similarly to buffer. In these cases NO did not reach 150 nM until about 
14 min (fig 5.5A.B)
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Figure 5.5 NO consumption by hippocampal slices
(A) Representative traces of NO following DETA/NO (200 fiM) addition to 20 mM Tris buffer 
(open circles), acutely isolated hippocampus aged P8 and P19 (closed circles), or 
organotypic hippocampal slice cultures after 12 and 19 DIV (open boxes). (B) Summary data 
is shown as time to 150 nM NO (mean ± SEM, n = 4).
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5.4 DISCUSSION
Toxicity of exogenous NO
The question addressed in this chapter concerned the vulnerability of 
hippocampal slice culture neurones to exogenous NO. Surprisingly, exposure 
to high NO concentrations (up to 4.5 pM) caused no detectable damage 
during a 24 h exposure period, nor were any changes in tissue ATP levels 
recorded. Given the positive control showing that inhibition of mitochondrial 
respiration with myxothiazol or NaCN depressed ATP levels and caused 
maximal death over an equivalent time period, these results suggest that the 
high NO concentrations applied were unable to inhibit cellular respiration 
significantly. NO competes with O2 for binding to the terminal complex of the 
respiratory chain, known as complex IV or cytochrome c oxidase (Brown, 
2001; Cooper, 2002). At O2 concentrations found in vivo (20-30 pM), a 
steady-state NO concentration of 120 nM is required to inhibit the O2 
consumption of cerebellar cells by 50% (Bellamy ef a/., 2002); see also 
(Brown & Cooper, 1994). Because of the higher O2 concentration existing in 
the in vitro environment (about 180 pM), it would be predicted that about 0.4 
pM NO should have been enough for 50% respiratory inhibition (Koivisto et 
a!., 1997). Consistent with this presumption, in dispersed hippocampal 
neurones (Brorson etal., 1999), PC12 cells (Bal-Price & Brown, 2000), and 
mixed cortical cultures (Bal-Price & Brown, 2001) in vitro, 0.5-2 pM NO 
inhibited respiration and provoked neuronal cell death. In the slice cultures, 
however, 10 pM NO was required to have this effect.
The data show that neurones in hippocampal slice cultures are 
remarkably resilient to NO-induced damage, including through respiratory 
inhibition. The simplest explanation is that the NO concentrations within the 
slices are much lower than those applied in the culture medium. Supporting 
this interpretation was the finding that 30 pM DEA/NO was needed to 
maximally elevate slice cGMP levels (figure 4.4A) whereas, in dispersed 
cells, 30 nM DEA/NO suffices (Gibb et a\., 2003). A plausible reason for the 
poor access of exogenous NO to the slice tissue is the activity of the 
formidable NO inactivation mechanisms that have been found in brain and
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other tissues (Griffiths et al., 2002b; Liu et al., 1998c). Analogous to the effect 
of O2 utilization on the diffusion of 02into isolated tissues (Hill, 1929), and the 
effect of transporters on the diffusion of glutamate into brain slices 
(Garthwaite, 1985), avid consumption of NO by the cultured slices would 
result in steeply declining NO concentration gradients going from the outside 
to the inside of the tissue, and necessitate addition of high concentrations to 
the medium in order that regions near the centre be supplied. Analysis of the 
rate of NO inactivation by slice cultures in situ is technically problematic. 
Homogenised slice cultures, however, inactivated NO to the same extent as 
acute hippocampal tissue in the manner previously reported (Griffiths et al., 
2002b). Furthermore application of cGMP immunocytochemistry to acute 
cerebellar slices incubated with NO indicates that, as predicted, steep 
steady-state gradients of NO exist across the slice thickness as a result of 
NO consumption. This apparent maximal rate of consumption was 1 pM/sec 
(Hall et al., 2003). In dispersed cells, this rate would typically be about 100- 
fold lower because of the effect of dilution, which would help explain why NO 
is more toxic to these preparations. In addition, neurones in slice culture may 
be inherently more resistant than dispersed cultures to oxidative stress 
resulting, for example, from ONOO’ formation, because of the close proximity 
of astrocytes which can supply neurones with protective glutathione 
precursors (Gegg et al., 2003).
Providing NO inactivation is sustained, therefore, it is difficult to 
envisage how NO could rise in intact hippocampal tissue to concentrations 
that are directly toxic. In our experiments, NO concentrations lower than 10 
pM were able to cause cell death, but the concentrations still needed to be 
very high (about 4.5 pM) and the exposure time long (3 days for substantial 
cell death). In the absence of evidence that constitutive nNOS can produce 
global tissue increases in NO concentration of this magnitude the mechanism 
was not explored. Possibly, failure of NO inactivation (Griffiths & Garthwaite, 
2001) may have increased the tissue NO concentrations sufficiently to 
achieve respiratory inhibition and/or other reactions (e.g. cumulative 
nitrosation of tissue thiols by products of NO autoxidation, such as N2O3; 
Augusto et al., 2002; Grisham eta!., 1999) may have been responsible.
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5.5 CONCLUSION
Intact hippocampal tissue in culture is remarkably resilient to prolonged 
exposure to high exogenous NO concentrations, presumably because NO 
consumption prevents cellular concentrations rising to those in the 
surrounding medium and/or because of protective cell-cell interactions. It will 
be important to determine if the findings are generally applicable in the brain, 
or if some regions are potentially more at risk, for example because of 
reduced NO inactivation.
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CHAPTER 6: LIPID PEROXIDATION IS A COMPONENT OF NO 
CONSUMPTION IN VITRO
6.1 INTRODUCTION
Although our knowledge of NO synthesis by the nitric oxide synthase (NOS) 
enzyme family has advanced considerably (Alderton et al., 2001), the 
mechanism by which NO is inactivated remains poorly understood. This is 
surprising, given that tissue NO concentrations (which reflect the balance 
between synthesis and breakdown) may directly influence the resultant 
behaviour of NO, be it as a physiological signal or toxic molecule. In aqueous 
solutions the major decomposition product of NO is N02 '(see chapter 3.1), 
however, in the presence of biological tissue NO3' is formed (Ignarro eta!.,
1993). In tissue, various NO half-lives have been reported, ranging from a 
few seconds in the original cascade perfusion experiments (Palmer et al., 
1987) to <100 ms in perfused heart (Kelm & Schrader, 1990). Recent work, 
based upon the consumption of NO by isolated rat hepatocytes estimates 
that extravascularly the NO half-life is between 0.09 - 2 s depending upon 
the O2 concentration (Thomas etal., 2001). Many potential NO inactivation 
pathways have been examined, some of which are described below.
Accelerated autoxidation
The simple reaction of NO with O2 (autoxidation), as described in chapter 
3.1, is too slow to have much physiological relevance as an NO sink. Due to 
the hydrophobic nature of NO, autoxidation is accelerated in the hydrophobic 
interior of rat hepatocyte membranes or detergent micelles, where the 
reaction speed may increase up to 300 fold (Liu etal., 1998c). Similarly, NO 
partitions into, and is consumed by, mitochondrial membranes in a non­
saturable oxygen-dependent manner (Shiva etal., 2001). Hydrophobic 
protein domains have also been proposed to accelerate NO breakdown 
(Nedospasov et al., 2000) though their relevance is difficult to gauge.
107
Reaction with O2*'
A major physiological source of 02*' in vivo is due to leakage from the 
electron transport chain, and it has been estimated that almost 1-2% of all 
electrons passing through end up as O2*' ions (Boveris & Cadenas, 2000). 
Alternatively it has been reported that under certain conditions, namely 
arginine or BH4 depletion, the various NOS isoforms may produce O2*', at 
least in vitro (Xia etal., 1996; Xia etal., 1998a; Xia etal., 1998b). Other 
enzymatic routes of synthesis include generation by xanthine oxidase (XO), 
which has been found co-localised with NOS in rabbit synaptosomes 
(Deliconstantinos & Villiotou, 1996), as follows.
xanthine + O2 xo -> H2O2 + O2 ' + uric acid
Non-enzymatically O2*' may be formed by the simple one-electron reduction 
of O2 by free ferrous iron, thus.
Fe2* + 0 2 -» Fe3* + 0 2’-
Most iron in the brain is tightly bound to proteins such as transferrin or ferritin 
and is unlikely to catalyse O2*' production, however a chelatable ‘transit pool’ 
of non-protein bound iron may exist with the potential to generate O2*" 
(Halliwell & Gutteridge, 1986).
Three endogenous superoxide dismutase (SOD) enzymes have been 
described. O2*' will not cross biological membranes and must therefore be 
detoxified in the compartment in which it is produced. Accordingly the 
enzymes have different locations. MnSOD is mitochondrial, whereas Cu,Zn- 
SOD is found either in the cytosolic and lysosomal fraction, or extracellularly 
where it is heavily glycosylated (Fridovich, 1995). SOD converts O2*' into 
H202, which is then converted to water by glutathione peroxidase and 
catalase. Since ~0.5% of total soluble protein in the brain is Cu,Zn-SOD, 
tissues have an excellent defence mechanism. NO reacts with O2*' with an 
almost diffusion-controlled rate constant of 0.7-1.9 x 1010 M'1 s'1 to form the 
strong oxidant ONOO’ (Koppenol, 2001a). However, SOD consumes O2*'
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almost as quickly, at 2 x 109 M'1 s'1 and, being present in micromolar 
concentrations, is generally the major drain for removing O2*'. Nevertheless 
the reaction of NO with 02*' may partially account for NO breakdown in 
various systems (Garthwaite etal., 1988; Palmer etal., 1987) including 
biological buffers (Beckman and Koppenol., 1996).
Lipid oxidation enzymes
The lipoxygenases (LOX) are a family of non-haem iron-containing enzymes 
that catalyse oxidation of arachidonate or linoleate to bioactive lipid 
hydroperoxides. 15-lipoxygenase is expressed in reticulocytes during 
maturation into erythrocytes, while 12/15-LOX is expressed in monocytes. 
Both may play a central pathogenic role in atheroscelerosis. 15 and 12/15- 
LOX catalytically consume NO and thereby decrease NOcgR activity in vitro. 
Such NO consumption may be the result of reaction between the enzyme- 
bound lipid peroxyl radical EredLOO* with NO to form an alkyl peroxynitrite 
(LOONO) which will undergo hydrolysis to ultimately form lipid hydroperoxide 
(LOOH) (Coffey etal., 2001; O'Donnell etal., 1999). Often overlooked, this 
reactivity of NO with lipid peroxyl radicals (LOO*) is extremely rapid, and both 
enzymatic and radical catalysed lipid peroxidation will be terminated with the 
consumption of 2 molecules of NO per molecule of LOO* (O'Donnell et al.,
1997).
Similarly to LOX’s prostaglandin H synthase (PGHS) catalyses the 
initial steps of arachidonate oxidation. NO may interact with this haem 
enzyme in many ways, and, by acting as a reducing peroxidase substrate,
NO is consumed rapidly by purified PGHS-1 plus arachidonate, or by 
thrombin-activated platelets. In these experiments NO consumption was fast 
enough to potently prevent NO-dependent activation of NOgcR (O'Donnell et 
al., 2000).
Mammalian Peroxidases
NO may be catalytically consumed by multiple peroxidases including 
myeloperoxidase (MPO), the most abundant protein in neutrophils. MPO is 
present in large amounts at sites of inflammation where NO and H2O2 are
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also likely to be present. In the presence of H2O2 NO serves as a substrate 
for MPO and the presumed intermediate, NO\ is extremely labile and is 
rapidly hydrolysed to N02"(Abu-Soud & Hazen, 2000).
Haemoglobin
Oxyhaemoglobin (Hb02) and deoxyhaemoglobin scavenge NO to give either 
methaemoglobin and N03 ', or iron-nitrosyl [Hb(Fe2+)-NO] respectively. Both 
reaction rates are rapid (~107 M'1 S’1), indeed Hb02 is regularly used to 
scavenge endogenous NO in vitro (Palmer etal., 1987). The concentration of 
Hb02 in circulating blood is -10  mM, hence NO produced by endothelial cells 
should have a half-life of -1 ps and be almost entirely inactivated, preventing 
NO-mediated vascular relaxation. Several mechanisms have been proposed 
to account for the obvious discrepancy. Firstly there exists an ‘erythrocyte 
free zone’ next to the endothelium, which is created as blood flows through 
the vessels (Liao etal., 1999), the size of the ‘zone’ being dependent upon 
the vessel diameter. Secondly, NO reacts with Hb02 encapsulated in 
erythrocytes nearly three orders of magnitude slower than with free HbO^ 
probably due to limited diffusion arising from the existence of an unstirred 
layer surrounding each cell (Liu et al., 1998a; Liu etal., 2002; Vaughn etal.,
2000). In this case the half-life of NO in the lumen is expected to be -2  ms 
(Liu et al., 1998a). Notably it has been suggested that Hb might not scavenge 
NO, but be involved in the transport and delivery of NO to tissues following S- 
nitrosation of a critical cysteine residue at position 93 on the p globin chain, 
forming SNO-Hb. The physiological relevance of such a mechanism is 
difficult to gauge, however, particularly since in humans basal SNO-Hb 
concentrations are very low (Hobbs et al., 2002).
Myoglobin
Myoglobin functions as a short term O2 reservoir in exercising skeletal 
muscle and in the beating heart. NO induces conversion of oxymyoglobin 
(Mb02) to metmyoglobin and is converted into NO3'. The recent development 
of myoglobin knockout mice has aided the investigation of the relevance of 
this reaction. Hearts lacking myoglobin reacted more sensitively to both 
exogenous and endogenous NO (vasodilation and cardiodepressant actions
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were more pronounced), while wild types were less sensitive (Flogel et al.,
2001). In acting like an NO oxidase the reaction of myoglobin and NO may in 
fact act to shield the heart from excessive NO produced from iNOS (Godecke 
etal., 2003). The relevance of this mechanism at physiological NO 
concentrations has, however, been questioned (Pearce etal., 2002).
Flavohaemoglobins
The bacteria Escherichia Coli (E.Coli) expresses an inducible, NADH- 
dependent, flavohaemoglobin with NO dioxygenase activity that is extremely 
efficient at converting toxic NO into NO3' under physiological conditions. The 
reaction rate is only -2  times slower than that of NO with 02*' (Gardner et al., 
2000; Hausladen etal., 1998). This activity is likely to be a defensive 
mechanism to protect bacteria from toxic levels of NO and has also been 
reported in other bacteria, yeast, fungi, and more recently in mammalian cell 
lines, most notably human colon cells (Gardner etal., 2001). NO 
consumption by flavohaemoglobins may be inhibited by CN' and the 
flavoenzyme inhibitor diphenylene iodonium (DPI), but unfortunately attempts 
to measure the activity in mammalian cell extracts were unsuccessful, so its 
functional role in vivo remains unknown.
Other mechanisms
Other potential mechanisms for NO inactivation include binding of NO to the 
protein haemopexin, which may act as a haem storage and transport system 
(Shipulina etal., 1998) and has been identified in multiple tissues including 
neurones and glia (Morris et al., 1993). NO also binds to the haem 
degradation enzyme haem oxygenase-2 (Ding etal., 1999) which cleaves 
haem into biliverdin, iron and CO. Despite no investigation of the NO half-life 
being made, HO-2 has been proposed to be a potential intracellular NO sink. 
Accelerated NO decay has also been postulated to occur upon reaction with 
cytochrome c oxidase (Brudvig et al., 1980; Torres et al., 1998), and may 
contribute to cellular and mitochondrial NO consumption (Borutaite & Brown, 
1996; Clarkson etal., 1995). However, another study found no such activity 
(Stubauer et al., 1998), and the recent observation that NO oxidation is
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accelerated in phopsholipid membranes casts further doubt on the 
significance of this mechanism as previously described in intact cells. Finally, 
NO may also bind to non-haem iron proteins such as metallothionin. 
Metallothioneins are small, sulphur-rich metal-binding polypeptides induced 
in response to cytokines. Following reaction with endogenous NO, the metal 
moiety may be released (Pearce et al., 2000), and a recent study has 
reported that metallothionein-lll may prevent exogenous NO toxicity in 
cerebellar granule cell cultures (Montoliu et al., 2000).
Aims
The rapid consumption of NO by suspensions of cells from rat 
cerebellum, an area of the brain rich in the NO-cGMP signalling pathway, has 
been previously described (Griffiths & Garthwaite, 2001). Functionally this 
sink converts constant rates of NO formation into low steady-state NO 
concentrations. When confronted by higher NO release rates for several 
minutes however, the consumption mechanism fails. Further investigation 
(Griffiths etal., 2002b) revealed that NO inactivation is preserved in rat brain 
homogenates, and that NO inactivation requires O2 and generates NO3" as 
the principal end product, as in vivo. NO inactivating activity in homogenate 
was found to be proteinase K sensitive and heat labile, strongly suggesting 
the involvement of a protein. Having ruled out any contribution of O2*' an 
array of candidate enzymes were tested including cytochrome c oxidase 
(Borutaite & Brown, 1996), lipoxygenases (Coffey etal., 2001; O'Donnell et 
al., 1999), peroxidases (Abu-Soud & Hazen, 2000), prostaglandin H synthase 
(O'Donnell et al., 2000) and a flavohaemoglobin-like NO dioxygenase 
(Gardner etal., 2001), all to no avail. This chapter continues to examine the 
mechanism by which NO is inactivated by acutely prepared cerebellar 
suspensions and whole brain homogenates.
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6.2 METHODS
General methods
Unless otherwise stated, all experiments contained SOD, (1000 U/ml). Stock 
solutions were; ascorbate oxidase (AO, 1000 U/ml) prepared in dH20, DTPA 
(10 mM) in equimolar NaOH, and Trolox (100 mM) in DMSO. The final 
DMSO concentration did not exceed 0.1 % in any experiment. Stock 
solutions of DETA/NO were made in 10 mM NaOH and kept on ice until use. 
Protein concentrations were measured by the bicinchoninic acid method. 
Measurements of NO and O2 concentrations, used ISO-NOP and Clark type 
electrodes respectively (see chapter 2.2). Data are presented as means ± 
S.E.M., each determination (n) being an individually prepared and treated 
sample. Statistical differences were analysed using one-way ANOVA with 
Dunnett’s post hoc test; P values of < 0.05 were regarded as significant
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Cerebellar cell suspension
Cell suspensions (20 x 106 cells/ml; 1.25 mg protein/ml) were prepared 
according to published procedures (Garthwaite & Garthwaite, 1987) except 
that the pups were not pre-treated with hydroxyurea. The following solutions 
(Table 6.1) were based upon artificial cerebral spinal fluid (aCSF) which was 
composed in (mM): NaCI (120), KCI (2), CaCI2 (2), NaHC03 (26), MgS04 
(1.19) and glucose (11).
Solution Composition
1 Ca^+ free aCSF
2 Solution (1) + 3 mg/ml BSA
3 Solution (2) + 0.5 mg/ml trypsin
4 Solution (2) + 0.8 mg/ml DNase, 0.52 mg/ml soybean 
trypsin inhibitor, 1.55 mM MgS04, 0.1 mM D-AP5
5 84 % solution (2): 16 % solution (4) (v/v)
6 Solution (2) + 1 mM CaCI2, 1.24 mM MgS04
7 (Incubation 
buffer)
15 mM Tris-HCI, 130 mM NaCI, 5 mM KCI, 2 mM CaCI2, 
1.2 mM Na2HP04 and 11 mM glucose at pH 7.4
8 Solution (7) -  Ca^+
9 Solution (8) + 40 mg/ml BSA (filtered, 0.6 pm)
Table 6.1 Solutions for cerebellar granule cell preparation
Prior to use solutions (1)-(6) were gassed with 95% 0 2, 5% C02 at room 
temperature. Cerebella from 8 day old Sprague-Dawley rats were removed 
and chopped into 0.4 mm blocks on a Mcllwain tissue chopper. The blocks 
were triturated gently in 10 ml (2) at 10-15°C and, once they had settled, 
supernatant was removed and the blocks were incubated in 10 ml of (3) for 
15 min at 37°C, shaking and under 95% 0 2, 5% C02. 10 ml (5) was added 
and the suspension was centrifuged at 150 g for 5 secs. The resultant 
supernatant was discarded while the pellet was resuspended in 2 ml of (4) 
and triturated gently 20 times with a pasteur pipette. After the remaining 
blocks had settled the milky isolated cell supernatant was removed and 
added to 2 ml of (6). A further 2 ml of (4) was added to the remaining pellet
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and the process repeated until no significant pellet remained (at least three 
times). The cell suspension was carefully underlayed with 1 ml of (9) and 
centrifuged at 150 g for 5 min. Supernatant and BSA were aspirated and the 
pellet resuspended in 5 ml (8), and spun at 150 g for 4 min. The resultant 
pellet was resuspended in 2 ml (7). Cell numbers were counted in a 1:1 
suspension with trypan blue using a Fuchs Rosenthal counting chamber and 
the concentration adjusted to 20 x 106 cells/ml. The cell suspension was 
allowed to recover at 37°C, shaking for 1 h before use.
Preparing semi-purified homogenate
Homogenate of whole rat brain tissue (8 day-old Sprague-Dawley rats, ~20 
mg protein/ml) was semi-purified at 4°C. Initial centrifugation was 10,000 g 
for 30 min, and then the supernatant was further spun at 100,000 g for 1 hr. 
The resultant pellet was re-suspended in Tris buffer (20 mM) at 10 mg 
protein/ml while the supernatant was spun overnight at 2000 g through 
10,000 kD cut-off filters (CENTRIPLUS®, Millipore UK Ltd, Watford,
England). Homogenate (0.3 or 1 mg protein/ml), supernatant (10-20 % final 
concentration) and pellet (0.1 mg protein/ml) components were tested for NO 
consumption with an ISO-NOP probe, alone or in combination (pellet + 
supernatant), by addition of DETA/NO (100 pM).
Haemoglobin bead assay
Haemoglobin beads (12-16 mg/ml) were triple washed in Tris buffer (20 mM) 
before reduction by exposure to freshly prepared sodium dithionate (10 mM) 
for 20 min in air. Following 2 washes in Tris, the beads were kept as a 
working stock at 1.2 mg/ml on ice until used. Pellet (0.1 mg/ml), supernatant 
(10 %) and SOD (1000 U/ml) were incubated with Tris buffer and 
haemoglobin beads (100 pi), in a final volume of 1 ml on a rotator at 37°C for 
up to 25 min. Test compounds EGTA (100 pM) and CaCb (60-110 pM) were 
added where appropriate. After incubation the bead mix was pelleted by 
centrifugation at 10,000 g for 5 min and resuspended in 300 pi Tris. The 
degree of bead oxidation was determined by reading the absorbance ratio in 
nm (401-410/410).
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6.3 RESULTS
NO consumption in the presence of brain tissue
Work in our lab has previously reported that the breakdown of NO is 
accelerated in the presence of brain tissue (Griffiths & Garthwaite, 2001; 
Griffiths etal., 2002b). To elucidate the mechanism(s) underlying this activity 
at a physiological rate of NO production the NO donor DETA/NO was used. 
The long half-life of DETA/NO (20 h at 37°C) means that at any concentration 
used, the rate of NO release will effectively be constant for several hours. 
Following DETA/NO (100 pM) addition to Tris buffer, the NO concentration 
rose to a steady value of -  450 nM after 10 min (Fig. 6.1 A). In agreement 
with previous studies (Griffiths & Garthwaite, 2001; Griffiths etal., 2002b), 
following the application of DETA/NO to either cells or homogenate, a 
different profile was observed. Within seconds, a steady low plateau or 
‘clamp’ was formed (~24 ± 4 and 8 ± 1 nM NO in cells and homogenate 
respectively). Once this mechanism became saturated a secondary rise in 
the NO concentration was observed (Fig. 6.1 A). The clamp duration was 
quantified as the time taken for the NO concentration to reach 100 nM, which 
was 0.3 ± 0.2 min in Tris buffer, compared to 49 ± 0.4 and 13 ± 0.4 min in 
homogenate and cells respectively (Fig. 6.1B).
The preservation of accelerated NO inactivation in whole brain 
homogenate facilitated further investigation of the underlying mechanism. 
Previous studies had indicated the requirement of a protein, since incubation 
of homogenate for 1 hr with proteinase K (pK) immobilised on acrylic beads 
resulted in a complete loss of homogenate-accelerated NO inactivation 
(Griffiths et al., 2002b). In order to isolate the protein species responsible 
classic purification methodology was undertaken (Dr C. Griffiths, unpublished 
data). Initially this comprised of centrifugation and filtration steps to leave 
crude pellet and supernatant fractions. When DETA/NO (100 pM) was 
applied to the pellet fraction the NO concentration was indistinguishable from 
that seen in buffer, rising to a steady plateau at -  450 nM NO. DETA/NO 
application to supernatant caused NO to rise to -  350 nM, indicating a slight 
retention of NO consuming activity in this fraction. In contrast, when
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DETA/NO was added to recombined pellet and supernatant fractions a 
steady low NO plateau (6 ± 2 nM) was attained within seconds and, similarly 
to cells or homogenate, a secondary rise in NO concentration occurred upon 
this clamp exhausting (Fig. 6.1C). Clamp duration was quantified as the time 
taken for the NO concentration to reach 100 nM, which was 0.9 ± 0.3 min in 
Tris buffer compared to 0.6 ± 0.2 min in pellet, 1.6 ± 0.4 min in supernatant 
and 16.4 ± 2 min upon combination of pellet and supernatant (Fig. 6.1 D).
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Figure 6.1 Inactivation of NO by brain tissue
(A) Representative traces following DETA/NO (100 nM) addition to either Tris buffer (20 
mM), cerebellar cells (20 x 106 cells/ml; 1.25 mg protein/ml), or whole brain homogenate (0.3 
mg protein/ml) in the presence of 1000 U/ml SOD. (B) The NO clamp duration was 
quantified as the time taken for the NO concentration to achieve 100 nM. The data are 
means ± S.E.M. (n = 3-4). (C) Representative traces of NO accumulation following DETA/NO 
addition to either Tris buffer, pellet (0.1 mg protein/ml), supernatant (10 %), or recombined 
pellet + supernatant. (D) Clamp duration (time to 100 nM NO) is summarised as mean ± 
S.E.M. n = 3-4.
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Recombined fractions consume NO in an EGTA / Ca2+ sensitive manner
To determine whether NO consumption was dependent upon Ca2+ ions, the 
chelator EGTA (100 pM) had previously been tested on homogenate or 
recombined pellet + supernatant (Dr C. Griffiths, unpublished data). While 
having no effect upon NO accumulation in buffer (not shown), the addition of 
EGTA (arrow, Fig 6.2) clearly inhibited the NO ‘clamp’ by both homogenate 
(not shown) and recombined pellet + supernatant such that NO immediately 
rose with a similar profile to that seen in buffer. Subsequent addition of CaCh 
(1 mM, arrow, Fig 6.2) restored the NO clamp within seconds.
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Figure 6.2 NO consumption by pellet + supernatant is EGTA / Ca2+ sensitive 
Representative traces of NO accumulation upon the addition of DETA/NO (100 fJVI) to buffer, 
or pellet + supernatant. EGTA (100 fiM) and CaCI2 (1 mM) were added as indicated (arrows) 
but had no effect on buffer traces (not shown).
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Using a haemoglobin bead assay to detect NO consumption
Although the NO electrode is a convenient and reliable means of detecting 
NO, it is time consuming and, therefore, not useful for high throughput 
experiments. To develop a means of quickly examining the effects of various 
compounds on NO consumption by pellet + supernatant we looked to other 
available methods. The use of haemoglobin to detect NO has been widely 
documented (Feelisch etal., 1996). NO oxidises haemoglobin in the following 
reaction;
Hb02 + NO -» metHb + N 03'
By measuring the absorbance spectrum, the NO mediated conversion of 
Hb02 to metHb may be followed. For the conversion of Hb02 to metHb the 
highest difference in absorbance is at 401 nm, with an isosbestic point 
(where no absorbance change is detected) seen at 410 nm. Calculation of 
the absorbance ratio (401-410 / 410) of each sample uses the isosbestic 
point as an internal reference for changes in volume.
As described above, the speed of NO consumption by reaction with 
Hb02  is likely to be such that the haemoglobin will preferentially react with 
NO, discounting other, slower, NO sinks from being detected. We have 
utilised haemoglobin immobilized on cross-linked 4% beaded agarose to 
detect NO. Similarly to the slowed reaction of NO with Hb02 in red blood 
cells, haemoglobin prepared in this way reacts with NO at a sufficiently 
slowed rate that other sinks may consume NO in competition.
Incubating haemoglobin beads with 100 pM DETA/NO for 25 min, 
caused the absorbance ratio to increase steadily from -0.12 to 0.13 as they 
became oxidised (Fig 6.3). In the presence of pellet (0.1 mg/ml) and 
supernatant (10%) this ratio increase was considerably lower (from -0.12 to 
-0.05) 25 min following DETA/NO application, indicating that NO was being 
consumed and prevented from reacting with the beads. In agreement with 
experiments on the NO probe (Fig 6.2), the addition of EGTA inhibited the 
NO ‘clamp’ by pellet + supernatant such that absorbance ratio increases 
were of similar magnitude to those in buffer. Likewise addition of 100 pM
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EGTA inhibited the NO ‘clamp’ even when applied 10 min after DETA/NO 
(arrow Fig 6.3).
0 .2 0 - 1  _ 0-B u ffe r  
^  0  1 5  Pellet + Supernatant + EGTA
Figure 6.3 NO consumption measured using haemoglobin coated beads
DETA/NO (100 |j.M) was incubated with haemoglobin coated beads in Tris buffer (O), pellet 
+ supernatant (□) or pellet + supernatant + EGTA (100 jiM) (•). Where indicated (arrow) the 
EGTA addition was made 10 min following DETA/NO addition. Bead oxidation was 
determined by measuring absorbance ratios. The data are means ± S.E.M. (n = 6)
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To determine the concentration of free calcium required for supernatant + 
pellet to resume NO consumption in the presence of EGTA, increasing 
concentrations of CaCh (60-110 pM) were incubated with pellet (0.1 mg/ml) + 
supernatant (10%) in the presence of 100 pM EGTA, haemoglobin beads 
and 100 pM DETA/NO. Absorbance ratios were determined after 25 min. In 
the absence of EGTA the ratio was -0.1, but in its presence it was almost 0.1 
(Fig 6.4), indicating that NO consumption had been inhibited by EGTA. As 
the concentration of CaCh was increased this inhibition was lessened, such 
that by 100 pM CaCh, EGTA was no longer an effective inhibitor (Fig 6.4).
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Figure 6.4 Determining Ca2+ requirement for NO consumption by pellet + supernatant
DETA/NO (100 pM) was incubated with haemoglobin coated beads and pellet + supernatant 
in the absence (•) or presence (O) of EGTA (100 pM) and increasing concentrations of 
CaCI2 (60-110 pM). Bead oxidation was determined by measuring absorbance ratios after 
25 min. The data are means ± S.E.M. (n = 6)
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Supernatant consumes NO in a 0 2* -dependent manner
Previous experiments investigating the NO consumption mechanism in brain 
tissue have contained SOD (1000 U/ml) to prevent the diffusion limited 
reaction of NO with 0 2*'. The NO probe was used to further study the 
supernatant component of NO consumption in the absence or presence of 
SOD. Following addition of 100 pM DETA/NO to supernatant in the presence 
of SOD, NO levels rose, reaching a steady-state of approximately 300 nM 
(Fig 6.5A). In the absence of SOD, the NO released from DETA/NO was held 
less than 50 nM, about 20 % of the response in buffer (Fig 6.5A,B), 
suggesting a rapid production of CV was occurring in supernatant. As 
discussed in chapter 3, a possible source of O2"  is via metal-catalysed 
reactions. In the absence of SOD, but in the presence of the metal chelator 
DTPA (100 pM), the NO steady-state in supernatant following DETA/NO 
addition was similar to that seen with SOD present (300 nM). Notably, 
compared to buffer, some NO consuming activity was retained in SOD or 
DTPA treated supernatant (about 20 %, Fig 6.5A,B). DTPA had no effect 
upon NO levels in buffer alone (not shown).
•  Buffer
O Supernatant + SOD 
▼ Supernatant + DTPA 
A  Supernatant
Figure 6.5 NO consumption by supernatant is 0 2*’ / metal-dependent
(A) Representative traces of NO accumulation upon the addition of DETA/NO (100 (o.M) to 
buffer, supernatant alone and supernatant with SOD (1000 U/ml) or DTPA (100 pM). (B)
Data is summarised as a percentage of the NO steady-state achieved in buffer. The data are 
means ± S.E.M. (n = 3)
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NO consumption by supernatant is EGTA / Ca2+-sensitive
In addition to chelating Ca2+, EGTA can bind metal ions including Fe2+ and 
Cu+ To test the possibility that EGTA could inhibit NO consumption in 
supernatant, 100 pM DETA/NO was added to supernatant in the absence of 
SOD but the presence of EGTA (100 pM). The resultant NO steady-state 
was similar to that seen in buffer, about 300 nM, (Fig 6.6A). Upon addition of 
1 mM CaCb to supernatant + EGTA (arrow, Fig 6.6A) the NO level 
immediately declined to rest at levels 20 % of those in buffer controls (Fig 
6.6B). In comparison, when DETA/NO was added to supernatant in the 
presence of DTPA, supplementary CaCh had no effect on NO levels, which 
remained -85 % of those in buffer (Fig 6.6B, and see Fig 6.5).
400
3 0 0 -
2 0 0 -
•  Buffer
o Supernatant + EGTA1 0 0 -
0 5 10 15
Tim e (min)
Figure 6.6 NO consumption by supernatant is EGTA / Ca2+ sensitive 
(A) Representative traces of NO accumulation upon the addition of DETA/NO (100 pM) to 
buffer, or supernatant and EGTA (100 pM) in the absence of SOD. CaCI2 (1 mM) was added 
as shown (arrow). (B) Data is summarised as a percentage of the NO steady-state achieved 
in buffer. The data are means ± S.E.M. (n = 3)
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Antioxidant treatment prevents NO consumption by recombined brain 
fractions
In the absence of antioxidant protection, transition metal-catalysed reactions 
may readily peroxidise lipids, generating LOO*. In this scenario NO may 
serve as an antioxidant, avidly binding LOO*, and consequently be consumed 
(O'Donnell et al,, 1997). The effects of metal chelation, or antioxidant 
addition, on pellet and supernatant NO consumption was tested. Pre­
incubation with the transition metal chelator DTPA (100 pM), or the synthetic 
vitamin E analogue Trolox (100 pM), almost completely abolished pellet + 
supernatant-dependent NO inactivation. Following either treatment,
DETA/NO addition resulted in a steady NO concentration of -200 nM (Fig. 
6.7A), only slightly lower than that attained in supernatant alone -250 nM. 
The addition of DTPA or Trolox to Tris buffer, or the supernatant or pellet 
fractions alone, had no effect (data not shown). When quantified as the time 
taken for the NO concentration to reach 100 nM only the untreated 
recombined pellet and supernatant combination (23.5 ± 0.9 min) was 
significantly different from buffer (0.8 ± 0.3 min; Fig. 6.7B).
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Figure 6.7 Antioxidant treatment or metal chelation inhibits NO consumption in 
recombined fractions
(A) 100 pM DETA/NO was added to supernatant (Sup, 20 %) or supernatant recombined 
with pellet (Pel, 0.1 mg protein/ml). The recombined samples were examined alone, or pre­
incubated with DTPA (100 pM) or Trolox (100 pM). (B) Clamp duration (time to 100 nM NO) 
is summarised as mean ± S.E.M. n = 3-5, * p<  0.05 vs supernatant control. Neither 
compound affected Tris buffer, supernatant or pellet traces alone, while the vehicle for Trolox 
(0.1 % DMSO) affected none of these conditions (data not shown; p < 0.05).
Supernatant contains ascorbate required for NO consumption
The formation of lipid peroxides by transition metal catalysed redox reactions 
is often enhanced by addition of ascorbate. At low concentrations ascorbate 
is widely used as a pro-oxidant because it is an excellent reducing agent and 
as such may serve to redox cycle catalytic metals, for example reducing Fe3+ 
to Fe2+ (Buettner & Jurkiewicz, 1996). To further elucidate how lipid 
peroxidation may be contributing to NO consumption, the ascorbate content 
of supernatant was determined. The enzyme, ascorbate oxidase (AO) 
converts ascorbate and O2 to water and dehydroascorbate. Thus by 
measuring [O2], ascorbate depletion can be monitored. AO (4 U/ml) was 
added to supernatant (10 % in Tris buffer) as indicated (Fig. 6.8A) and 
caused an immediate decline in [O2] (11.3 ± 0.8 piM) that was complete within 
2 min. Further addition of AO had no additional effect on the [02], and no 
decline was observed following addition of AO to Tris buffer (data not 
shown). To quantify the ascorbate concentration in supernatant, [O2] was
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measured during addition of ascorbate standards to buffer containing AO (4 
U/ml; Fig. 6.8B). The [O2] decline was proportional to the ascorbate 
concentration (Fig. 6.8B, inset) and indicated that at 10 % supernatant, the 
ascorbate concentration was 25-30 pM.
The functional impact of ascorbate depletion on NO consumption was 
then tested. Following pre-incubation with AO for 3-5 min, recombined pellet 
and supernatant failed to clamp NO (Fig. 6.8C), and the time taken for NO to 
rise to 100 nM (1.7 ± 0.5 min) was not significantly different from Tris buffer 
controls (0.8 ±0.1 min; Fig. 6.8D). AO addition had no effect upon NO 
concentration in Tris buffer controls (Fig. 6.8C and D). Finally the addition of 
ascorbate to the pellet fraction was assessed to see if it could substitute for 
supernatant. Increasing concentrations of ascorbate (1-30 pM) were 
incubated with pellet (0.1 mg protein/ml) and DETA/NO (100 pM) was added. 
As the ascorbate concentration was increased, the duration of the NO clamp 
increased, and was maximal at 10 pM ascorbate (Fig. 6.8E). The recorded 
NO profile was similar to that seen upon recombination of pellet and 
supernatant (low steady NO clamp followed by a secondary rise). As judged 
by the time taken to reach 100 nM NO (23.6 ± 2.8 min) the clamp maximum 
(10 pM ascorbate, Fig. 6.8F) is in close agreement with the above estimate 
of ascorbate concentration in supernatant.
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Figure 6.8 Supernatant contains ascorbate required for NO consumption
(A) Ascorbate depletion was monitored by measuring 0 2 consumption upon addition of 
ascorbate oxidase (AO, 4 U/ml; as indicated by an arrow) to supernatant (10 %). Each trace 
is representative of at least three experiments. Further additions had no effect on the [02] 
(not shown). (B) Ascorbate (1 0 -1 0 0  pM; as arrows) was added to Tris buffer containing AO 
(4 U/ml) and [0 2] monitored. The resulting linear standard curve (insef) allows estimation of 
the ascorbate concentration in pellet + supernatant. (C) Representative traces of NO 
accumulation upon addition of DETA/NO (100 pM) to Tris buffer, and pellet (0.1 mg 
protein/ml) + supernatant (10 %) in the presence or absence of AO (4 U/ml). (D) Clamp 
duration (time to 100 nM NO) is summarised as mean ± S.E.M., n = 3-4, * p < 0.05 vs buffer 
control. (E) Representative traces of NO accumulation upon addition of DETA/NO (100 pM) 
to Tris buffer, pellet (0.1 mg protein/ml) + supernatant (10 %), or pellet in the presence of 
ascorbate (1-30 pM). (F) Clamp duration (time to 100 nM NO) is summarised as mean ± 
S.E.M., n = 4-6.
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Lipid peroxidation accounts for NO consumption in homogenate
To test the contribution of lipid peroxidation to NO consumption homogenate 
(0.3 mg protein/ml) was pre-incubated (3-5 min) with DTPA (100 pM), Trolox 
(100 pM) or AO (4 U/ml). Upon the addition of DETA/NO (100 pM) to 
homogenate, NO consumption proceeded as before (Fig. 6.1). The addition 
of AO inhibited NO consumption by homogenate with the resultant NO profile 
reaching a plateau of ~ 300 nM, close to that seen in buffer (Fig. 6.9A). 
Similar profiles (akin to buffer) were seen in the presence of both Trolox and 
DTPA (not shown). Measured as the time taken to reach 100 nM NO, 
addition of any of the three compounds inhibited the NO clamp such that 
none was significantly different to buffer (0.3 ± 0.2 min, Fig 6.9B). Finally, 
using the same method as above the ascorbate content in 3 mg protein/ml 
homogenate was found to be 54.2 ± 1.4 pM.
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Figure 6.9 Lipid peroxidation accounts for NO consumption in homogenate
(A) Representative traces of NO accumulation upon addition of DETA/NO (100 pM) to Tris 
buffer, homogenate (0.3 mg protein/ml) or homogenate + AO (4 U/ml). Similar traces were 
recorded upon addition of DTPA (100 pM) or Trolox (100 pM), while no compounds affected 
Tris buffer traces (not shown). (B) Clamp duration (time to 100 nM NO) is summarised as 
mean ± S.E M. n = 3, * p < 0.05 vs buffer control.
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Lipid peroxidation in cerebellar cells
The efficacy of the various treatments that inhibited the homogenate NO 
clamp was then evaluated in the cerebellar cell suspension. In the presence 
of DTPA (100 pM) the ‘clamp’ height increased from 24 ± 4 to 44 ± 4 nM NO 
and the duration shortened from 13.1 ± 0.4 to 6.4 ± 0.2 min (Fig. 6.10A). 
Similar significant reductions in clamp duration were observed when the cells 
were pre-incubated (2-3 min) with either AO (4 U/ml) or Trolox (100 pM) (Fig. 
6.10B) indicating that the mechanism of NO inactivation by intact cells was at 
least partially attributable to lipid peroxidation.
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Figure 6.10 Lipid peroxidation partially accounts for cellular NO consumption
(A) Representative traces of NO accumulation upon addition of DETA/NO (100 |^M) to Tris 
buffer, cells (1.25 mg protein/ml) or cells incubated with DTPA (100 fiM). The NO profiles 
obtained in the cell suspension following pre-incubation with either Trolox (100 (iM) or AO (4 
U/ml) were indistinguishable from cells + DTPA (data not shown). (B) Clamp duration (time 
to 100 nM NO) is summarised as mean ± S.E.M., n = 3-4, * p < 0.05 versus cells. Controls 
(no cells or cells + vehicle) were not significantly different to Tris buffer or cells respectively 
(p < 0.05; not shown).
130
6.4 DISCUSSION
The initial observations described in this chapter, that NO consumption 
persists upon recombination of semi-purified pellet and supernatant fractions 
of brain, and that consumption was Ca2+/EGTA sensitive (Dr C. Griffiths, 
unpublished observations), led to further investigation of the individual 
components. To aid a high-throughput study of compounds affecting NO 
consumption, a modified haemoglobin assay was developed. Utilising the 
slowed rate of reaction of NO with haemoglobin beads (compared to free 
haemoglobin), this assay enabled clear detection of brain tissue NO 
consumption over time by simple absorbance measurement of the bead 
oxidation state. Using this method up to 240 individual experiments were 
possible per day, compared with less than 30 using an NO electrode.
Supernatant NO consumption
In the absence of SOD, supernatant consumed NO. Since a potential source 
of O2"  is metal autoxidation, the metal chelator DTPA was tested. DTPA was 
found to almost fully inhibit the SOD-sensitive NO consumption. The 
observation that supernatant NO consumption was also EGTA sensitive, but 
could be reversed by Ca2+ (unlike the effect of DTPA), may be explained by 
comparing the relative affinities of DTPA or EGTA for Ca2+ and Fe2+ (Table 
6 . 1).
EGTA DTPA
0 0) ¥ Kd = 4.5 E-08 M Kd = 3.7 E-08 M
Fe Kd = 4.3 E-09 M Kd = 1.5 E-13 M
Table 6.2 EGTA and DTPA equilibrium constants for Ca and Fe at 37 C 
pH 7.4. Source, MaxChelator v2.1 (http://www.stanford.edu/~cpatton/maxc.html)
In vitro trace catalytic metals are ubiquitous in salt and buffer solutions, with 
iron often reaching up to 10 pM and copper reaching 0.1 pM, or they may be 
introduced into solution, for example from Hamilton syringes (Buettner & 
Jurkiewicz, 1996). Using software designed to examine the relative affinities 
of chelators (MaxChelator v2.1; downloadable at
http://www.Stanford.edu/~cpatton/maxc.html) it was determined that in the
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presence of 100 pM EGTA, a contaminating concentration of 10 pM Fe2+ is 
chelated such that only 0.4 nM Fe2+ remains free. In the presence of 1 mM 
Ca2+, however, free iron levels are 5 pM. In comparison, DTPA chelates 10 
pM Fe2+ leaving only 0.02 pM free, the subsequent addition of 1 mM Ca2+ 
again increases free Fe2+, but only to 0.4 nM. Clearly the EGTA/Ca2+ 
sensitivity of NO consumption by supernatant may be explained by the 
inability of EGTA to adequately chelate metal ions in the presence of Ca2+.
EGTA/Ca2+ sensitivity of recombined supernatant and pellet
Similarly to the results seen in supernatant alone, both DTPA, and EGTA 
inhibited NO consumption by recombined supernatant and pellet. Using the 
haemoglobin bead assay, the exogenously applied CaCI2 concentration 
required to maximally reverse this (100 pM) EGTA inhibition was 100 pM 
CaCb. Under these conditions, again assuming Fe2+ contamination to be 10 
pM, it may be calculated that 770 nM free Fe2+ is available for radical 
reactions (taking into account that free Ca2+ present in tris buffer + 10%  
supernatant was measured at ~70 pM, Dr C.Griffiths, personal 
communication). Moreover, Fe2+ loosely bound to membranes in the pellet 
fraction may make a further contribution. Similarly to the results seen in 
supernatant alone, the EGTA/Ca2+ sensitivity of NO consumption by 
recombined pellet and supernatant may be explained by the inability of EGTA 
to adequately chelate metal ions in the presence of Ca2+.
NO consumption by lipid peroxidation
Since supernatant and recombined pellet and supernatant were found to 
consume NO in a manner dependent upon free metal ions, the nature of the 
NO consumption mechanism was reconsidered. Lipid peroxidation is initiated 
by radical species such as the hydroxyl radical (OH*), which can abstract a 
hydrogen atom from unsaturated lipid, thus generating a lipid radical (L*) and 
H20. The lipid radical can combine with 0 2, generating the lipid ‘peroxyl’ 
radical (LOO*), which can further react with unsaturated lipid. If allowed to 
progress unchecked, a damaging, self-propagating cascade of peroxidation 
results. Ultimately peroxidation alters membrane properties, including ion-
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channel activity and glucose transport, and can directly impair mitochondrial 
function to cause cell stress (Mattson, 1998). NO may either trigger 
peroxidation, following reaction with 02*' and formation of ONOO' (Hogg & 
Kalyanaraman, 1999), or may inhibit it, as has been shown in several in vitro 
systems including free fatty acids (Hiramoto etal., 2003), lipoproteins (Goss 
etal., 1997), and a cell line (Kelley etal., 1999). This inhibition may occur as 
NO interacts with LOO* at a near-diffusion limited rate, 1-3 x 109 M'1 s'1; 
(Padmaja & Huie, 1993), thereby preventing further propagation of the signal 
and consuming 2 molecules of NO per molecule of LOO* (O'Donnell et al.,
1997). Alternatively NO might inhibit peroxidation more directly by preventing 
OH* production (Sharpe et al., 2003).
The OH* usually thought to initiate lipid peroxidation can be formed by 
either the Haber-Weiss reaction (1), though this is probably too slow at 
neutral pH (Koppenol, 2001b), or more rapidly by the transition metal- 
catalysed Fenton reaction (2):
(1) 0 2*' + H20 2 -> 0 2 + OH" + OH*
(2) Fe27Cu+ + H20 2 -> Fe37Cu2* + OH' + OH*
Brain tissue has high iron levels, and though mainly bound to proteins such 
as ferritin, O2*" or ascorbate may aid mobilisation of this iron to participate in 
OH* formation (Halliwell & Gutteridge, 1986). As noted above, in vitro trace 
catalytic metals are ubiquitous in salt and buffer solutions. Addition of the 
transition metal chelator DTPA, or the chain breaking antioxidant Trolox to 
recombined pellet and supernatant fractions, or homogenate, abolished the 
low (nM) NO clamp in our experiments, indicating that NO consumption was 
indeed caused by metal catalysed lipid peroxidation reactions.
The contribution of ascorbate
Fenton / Haber-Weiss chemistry is substantially enhanced by redox cycling 
of the catalytic transition metal (reduction of Fe3+ to Fe2+ or Cu2+ to Cu+) 
particularly by ascorbate (Buettner & Jurkiewicz, 1996). Brain ascorbate is an
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important antioxidant, existing at an average concentration of several 
millimolar in vivo (Rice, 2000). However, lower (pM) concentrations are pro­
oxidant, and this “crossover” effect is dependent upon the concentration of 
catalytic metals present (Buettner & Jurkiewicz, 1996). Ascorbate 
concentrations were measured at -  30 pM in supernatant and ~ 50 pM in 
homogenate. Depletion of this ascorbate prevented NO consumption by 
recombined supernatant and pellet, or homogenate preparations. 
Alternatively, ascorbate substituted for supernatant in accelerating NO 
consumption when combined with pellet. These results further imply that lipid 
peroxidation was responsible for NO consumption.
Notably, ascorbate is readily oxidised, and simply increasing the 
temperature will accelerate its degradation (Meucci etal., 1985). In other 
experiments (Dr C.Griffiths, data not shown) it was found that following a 2 h 
incubation at 37°C a loss of NO consuming activity in homogenate was 
attributed to ascorbate depletion. This process was further accelerated in the 
presence of proteinase K, a misleading result that previously led to the 
conclusion that NO inactivation involves a novel protein (Griffiths etal., 
2002b). In addition, in the presence of ascorbate, a lipid mixture mimicking 
the fatty acid content of rat brain homogenate consumed NO identically to rat 
brain homogenate, and clearly underwent peroxidation as determined by the 
accumulation of TBARS (the major reaction product of lipid peroxidation). 
Moreover further purification of the pellet fraction by ion exchange and size 
exclusion chromatography successfully removed the majority of proteins, 
while NO consuming activity was always retained upon recombination with 
the supernatant fraction. Subsequent analysis of the purified pellet fraction by 
MALDI-TOF, however, revealed only the presence of a strong lipid profile (Dr 
C.Griffiths, data not shown). This data, combined with that presented in this 
chapter, provides evidence that no protein is required for the low NO clamp.
NO consumption by dispersed cells
In keeping with the results in recombined pellet and supernatant, or 
homogenate, NO consumption was significantly attenuated by the application 
of DTPA, AO or Trolox to intact cerebellar cells, thereby implicating lipid 
peroxidation as a consumption mechanism. Further experiments found a
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steady accumulation of TBARS in cells over time. This could be inhibited by 
Trolox, or 100 |jM DETA/NO (Dr C.Griffiths, data not shown), providing 
further evidence that cells are undergoing continuous lipid peroxidation in 
vitro. DTPA and AO are cell impermeable, though Trolox will access the cell 
membrane. Since all three compounds were similarly effective, lipid 
peroxidation is most likely being initiated by the metal catalysed Fenton 
reaction occurring extracellularly, and is enhanced by ascorbate leaking from 
the cells, as it can in vitro (Rice, 2000). To exclude the possibility that 
exogenous Cu,Zn-SOD was catalysing OH* generation and subsequent 
peroxidation (Yim et al., 1990) cellular TBARS accumulation was examined 
in the absence of SOD (Dr C.Griffiths, data not shown). A resultant increase 
in TBARS (~ 30%) demonstrated clearly that added SOD is not responsible 
for initiating peroxidation. Indeed allowing O2*' to accumulate enhances 
peroxidation, possibly through formation of ONOO" (Hogg & Kalyanaraman, 
1999).
In previous granule cell preparations, contaminating red blood cells 
(RBCs) comprised 0.85 % of the total cell number, and did not account for 
any significant proportion of the NO consumption seen upon addition of 250 
pM DETA/NO (Griffiths & Garthwaite, 2001). In the current experiments a 
higher level of RBC contamination (1.6 %) was found (C.Hall, personal 
communication) which, coupled with a lower concentration of NO donor (100 
pM DETA/NO), meant the resultant NO clamp by RBCs was enhanced. This 
RBC clamp fully accounted for the residual NO consumption that occurred 
when lipid peroxidation was inhibited (see figure 6.11).
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Figure 6.11 The contribution of contaminant red blood cells in the cellular NO clamp
In the presence of 1 % RBC NO reached 100 nM. Contaminant RBCs could fully account for 
the residual clamp activity in the cerebellar cell suspension following inhibition of lipid 
peroxidation (data from C.Hall).
Previously, it was reported that NO consumption was 02-dependent in 
homogenate and cells (Griffiths et al., 2002b), a finding in keeping with the 
current result, that (O2 requiring) lipid peroxidation is involved. It was also 
reported that NO was ultimately degraded to form NO3 ' in homogenate. 
Following reaction of NO with LOO* the resulting (transient) LOONO has 
been suggested to have two fates, rearrangement to a more stable L0N02) 
or cleavage to give LO’ and *N02 (O'Donnell et al., 1997). In the absence of 
any other targets ’ NO2 might further react with NO to generate N2 0 3 , which 
ultimately will hydrolyse to NO2 '. This does not exclude the generation of 
NO3 ' from lipid peroxidation reactions, since NO2 ' may be further converted 
to N03' by oxyhaemoproteins (Ignarro etal., 1993).
Another important characteristic of the NO consumption described 
previously is its saturability. Taking homogenate as an example, and 
assuming that NO is consumed primarily by reaction with LO* and LOO*, the
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time taken for the clamp to saturate will be governed by both the sink of 
(already available) LO* and LOO*, and their rate of formation. These 
parameters are, in turn, determined by the starting concentrations of metals 
and ascorbate. Once the sink is full, and the rate of NO production exceeds 
that of lipid peroxide formation, the clamp exhausts and NO levels rise. In 
cells the same process will occur, with the added contribution of RBCs, 
which, once their oxyhaemoglobin has been fully oxidised by NO, will also 
exhaust as an NO sink. Finally, it was previously reported that, once 
saturated, the cellular NO consumption mechanism regenerates over 2 hr. 
Lipid peroxidation in unstimulated cells was observed by measuring TBARS 
formation (Dr C. Griffiths, data not shown), which continued for at least 3 hr, 
only reaching 50 % of the maximum achievable upon stimulation with 
exogenous iron and ascorbate. Regeneration of the NO consumption 
mechanism in cells may therefore simply reflect the time taken for a sink of 
peroxidized lipid to be re-established. Alternatively, methaemoglobin 
reductase, present in RBCs, could replenish the pool of oxyhaemoglobin.
6.5 CONCLUSION
The data, together with the results discussed above (section 6.4), clearly 
demonstrate the ease with which freshly isolated neurones may become 
oxidatively stressed in vitro, and the profound effects this may have upon 
experiments with NO. Bearing this in mind it may be prudent to include a 
transition metal chelator or antioxidant compound during the preparation of 
primary neurones for work in vitro. Elevated lipid peroxidation is not solely a 
tissue preparation artefact, and is associated with cellular demise in diseases 
including Alzheimer’s or Parkinson’s disease (Moosmann & Behl, 2002). 
Agents that scavenge either the initiating radical or break the cycle of lipid 
peroxidation, by interacting with a lipid radical species, have been shown to 
protect brain tissue both in vitro and in vivo (Hall et al., 1997; Liu et al., 2003; 
Moosmann etal., 2001). Furthermore, NO itself can also inhibit lipid 
peroxidation in various in vitro scenarios (Goss etal., 1997; Hiramoto et al., 
2003; Kelley etal., 1999; Robb etal., 1999). With the exception of one (Robb 
etal., 1999), these studies have mainly used bolus addition of large
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quantities of authentic NO to demonstrate such antioxidant effects. Here it is 
demonstrated that physiological rates of NO production (Griffiths & 
Garthwaite, 2001) not only terminate lipid peroxidation, but that levels of NO 
itself are consequently restrained by the same process. It may be envisaged 
that in this way endogenous NO produced following cerebral ischaemia could 
limit the progression of damage via lipid peroxidation. NO itself would be 
restricted to concentrations capable of activating the NO receptor, NOgcR (< 
20 nM), but below that which might inhibit respiration (> 100 nM; (Griffiths et 
al., 2003)). Though no direct evidence exists for this at present, the protective 
effects of NO release from donors post-ischaemia correlate with a decrease 
in levels of reactive oxygen species (Mason et al., 2000; Pluta et al., 2001).
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CHAPTER 7: INHIBITION OF LIPID PEROXIDATION, WHAT LIES
BENEATH
7.1 INTRODUCTION
In dispersed cerebellar granule cell preparations NO is consumed by a 
combination of lipid peroxidation and red blood cell contamination (chapter 
6). Acutely prepared cerebellar slices also consume NO avidly. However, 
when slice cGMP accumulation was measured in the presence of lipid- 
peroxidation inhibitors, or in tissue taken from perfused brains, no difference 
was found compared to controls. This indicates that other mechanisms may 
be responsible for NO consumption in slices (Catherine Hall, personal 
communication).
One difference between preparing in vitro slices and dispersed cells is 
the O2 concentration required in the bathing solution. To enable all cells to 
respire across the thickness of a slice (400 pm), the slices are incubated in 1 
mM O2. Conversely dispersed cells are able to respire adequately in air- 
equilibrated solutions (~185 pM O2).
A complication when examining NO consumption in cerebellar 
suspensions is that the cells consume O2 at -  5 pM / min (Griffiths & 
Garthwaite, 2001), a rate that may cause O2 levels to fall significantly while 
the experiment is performed in a sealed experimental chamber. Since NO 
consumption mechanisms are likely to require O2, the existence of a further 
(02-dependent) cellular NO consumption mechanism was questioned.
Aims
The profile of NO consumption by dispersed cultures was re-examined under 
conditions in which lipid peroxidation was inhibited but the O2 concentration 
was not limiting.
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7.2 METHODS
NO consumption by cerebellar granule cells
Following addition of DETA/NO (100 and 250 pM) to a cerebellar granule cell 
suspension (see chapter 6.2) NO was measured in either a sealed or air- 
equilibrated chamber using an ISO-NOP probe (see chapter 2.2).
Cerebellar glial cultures
Large dishes (600 cm2, Nalge Europe Limited, Hereford, UK) were coated by 
addition of poly-D-lysine (final concentration 2 pg/cm2 in dH20) overnight, 
followed by 2 washes (15 min each) in dH2 0 , and allowed to air dry.
Digestion enzymes were prepared on the day of culture in Ca2+/Mg2+ free 
HBSS supplemented with 10 mM Hepes, 1 mM Na pyruvate, 0.35 % Na 
bicarbonate and P/S (100 U/ml: 100 pg/ml). Stock concentrations were: 
trypsin (5 mg/ml), soybean trypsin inhibitor (6.65 mg/ml), DNase (0.88 mg/ml) 
and MgCh (110 mM).
Cerebella were removed from Sprague-Dawley rats, post-natal day 7 
and placed in a petri-dish containing HBSS. Using a sterile double-edged 
blade not more than 10 cerebella were triple chopped into 4 mm cubes. 10 ml 
HBSS was used to remove the cubes, which were placed into a 100 ml pot 
with an equal volume of trypsin (final activity 2500 U/ml) and mixed.
Digestion continued for 15 min at 37°C with shaking. DNase (1 ml) and 
trypsin inhibitor (1 ml) were added and cells mixed before a further 10 min 
incubation at 37°C with shaking. Cells were transferred to a 50 ml tube, 5 ml 
growth media (as for hippocampal slices, chapter 4.2) was added, and a 25 
ml pipette used to triturate the suspension against the bottom of the tube until 
no large aggregates remained. The suspension was briefly centrifuged (120 
g, 90 sec) and the supernatant collected and maintained at 37°C. The cell 
pellet was washed and triturated in 10 ml growth media a further 3 times, 
collecting the supernatants only after the remaining blocks had settled.
Cells were counted in a 1:1 suspension with trypan blue using a Fuchs 
Rosenthal counting chamber, seeded at a density of 25 x 106 cells / plate in 
60 ml growth media and maintained in a humidified incubator at 37°C. Media
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was changed the following day and then every 2-3 days. Cultures were used 
after 6-7 days in vitro.
NO consumption by cerebellar glial cultures.
Glial cultures were washed twice in 50 ml calcium-free incubation buffer 
(chapter 6.2) before application of 25 ml trypsin/EDTA for 10 min at 37°C. To 
ensure the maximum number of cells detached, the plate was hit several 
times on the bench. Cells were collected in 20 ml incubation buffer, pelleted 
(120 g, 5 min) and resuspended in 0.5 ml incubation buffer. After counting 
(as above) cells were diluted and assayed for their ability to consume NO 
(released by DETA/NO 100 pM) at concentrations between 0.5 and 2 x 
106/ml (2 x 106/ml cells was equivalent to 0.6 mg protein/ml) in an air- 
equilibrated chamber using the ISO-NOP probe (chapter 2.2). Glial cells (2 x 
106/ml) were also assayed for NO consumption in the presence of DTPA, 
Trolox and deferoxamine (all 100 pM).
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7.3 RESULTS
Lipid peroxidation-independent NO consumption
The existence of a further (02-dependent) cellular NO consumption 
mechanism was questioned by examining the effect of adding DETA/NO 
(100 or 250 pM) to buffer or cells in a sealed, or air-equilibrated chamber, in 
the presence of 100 pM Trolox (Fig. 7.1). In buffer NO rose to a steady-state 
level (~ 400 nM from 100 pM DETA/NO and -  750 nM from 250 pM 
DETA/NO) in the sealed chamber. These values were not significantly 
different when the chamber was air equilibrated (not shown). Cells exposed 
to 100 pM DETA/NO in the sealed chamber behaved as before (Fig. 6.1), 
with RBC’s keeping NO clamped at a low steady-state (~ 20 nM) before 
exhausting after 7 min, allowing NO to rise. When the chamber was air- 
equilibrated, however, NO consumption continued, at least over the 20 min 
duration of the experiment. Upon application of 250 pM DETA/NO, the RBC 
clamp was shortened to about 3 min, and NO steady-state levels reached 
almost 100 nM. Again exhaustion of the RBC clamp allowed NO levels to rise 
steadily in the sealed chamber, however, in the air-equilibrated chamber a 
second NO steady-state was formed at about 150 nM, and remained 
constant for the duration of the experiment. When RBC’s alone were 
incubated with Trolox in an air-equilibrated chamber, such 02-dependent NO 
consumption was not observed (C. Hall, personal communication).
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Figure 7.1 lipid peroxidation-independent NO consumption in cerebellar granule cells
Traces of NO accumulation (mean ± SEM n=  3) following addition of 100 or 250 pM 
DETA/NO to buffer in a sealed chamber, or cerebellar granule cells in either a sealed or air- 
equilibrated chamber. All conditions contained 100 pM Trolox.
Lipid peroxidation-independent NO consumption was then examined using 
cerebellar glial cultures, which have the benefit of being free from 
contaminating blood cells. Cultured glia close to confluence (Fig 7.2A), were 
suspended in an air-equilibrated chamber at differing concentrations (0.5 -  
2x106/ml) and challenged with 100 pM DETA/NO. Cellular NO consumption 
was concentration-dependent, with steady-state NO reduced to 160 ± 5 nM 
in 2x106/ml cells compared to 360 ± 14 nM in buffer (Fig 7.2B.C). Metal 
chelation with DTPA, or the more cell permeable deferoxamine (both 100 
pM), or antioxidant treatment (100 pM Trolox) had no significant effect upon 
NO consumption by 2x106/ml cells (Fig 7.2D).
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Figure 7.2 Lipid peroxidation-independent NO consumption in cerebellar glial cells
(A) Representative photomicrograph of cerebellar glial cultures after 6 days in vitro. (B) 
Traces represent NO accumulation following addition of 100 pM DETA/NO to increasing 
concentrations of glia in air-equilibrated suspensions. (C) NO steady-state concentration is 
summarised as mean ± S.E.M. n = 3. (D) Summary of NO steady-state (mean ± S.E.M. n = 
3) following addition of 100 pM DETA/NO to glia (2x106/ml) in the presence or absence of 
DTPA, Trolox or deferoxamine (all 100 pM), ns = no significant difference versus glia.
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7.4 DISCUSSION
NO consumption persists following inhibition of lipid peroxidation
The use of compounds to prevent lipid peroxidation has unveiled another, 
similarly powerful, 02-dependent, NO consumption mechanism in cerebellar 
cells. Further investigation of this mechanism was beyond the scope of the 
current study, however, its persistence (albeit 10 fold weakened) in 
homogenates (C.Hall, personal communication) affords good opportunity for 
its identification. A similar NO consumption mechanism (DTPA, Trolox and 
AO insensitive) also persists in mixed cerebellar glial cultures, which will 
allow kinetic and other investigations to be undertaken in the absence of 
contaminating RBCs. Initially important will be to discount the mechanisms 
discussed in chapter 6.1, and to this end, work has already begun.
7.5 CONCLUSIONS
The resistance of hippocampal slice cultures to high concentrations of 
exogenous NO (chapter 5) may involve NO consumption mechanisms, and in 
brain cells and homogenates a significant route for such consumption is by 
reaction with peroxidising tissue (chapter 6). Though this mechanism does 
not necessarily contribute to NO consumption by slices, the use of 
antioxidant compounds has uncovered another, as yet unidentified, 
mechanism by which NO may be consumed by cells.
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SUMMARY
This study set out to question the controversial question of the role that 
endogenous NO plays in excitotoxic neuronal cell death. Following careful 
characterisation of the NO-cGMP pathway in hippocampal slice cultures, and 
elimination of a serious potential artifact (reaction with media components), 
no experimental evidence was found in support of the generation of lethal 
concentrations of NO during glutamate-dependent excitotoxicity. Subsequent 
investigation of the toxicity of exogenous NO to slice cultures suggests that a 
powerful inactivation mechanism exists to prevent excessive NO reaching the 
concentration required to inhibit neuronal respiration.
Accelerated NO consumption has been reported to occur by differing 
mechanisms in various experimental scenarios. In cerebellar cell 
suspensions and rat brain homogenates it is now evident that NO 
concentrations are ‘clamped’ by avid reaction with tissue undergoing 
iron/ascorbate induced lipid peroxidation, a mechanism that is of 
considerable significance during many disease states. The use of lipid 
peroxidation inhibitors has unveiled a novel, 02-dependent NO consumption 
mechanism in suspensions of cerebellar granule cells and glia, the future 
characterisation of which may be vitally important in understanding NO 
physiology and pathology.
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